Lymphatic mapping and the axilla in primary breast cancer by Lambah, P. A.
LYMPHATIC MAPPING AND
THE AXILLA IN PRIMARY
BREAST CANCER
MR P A LAMBAH
MD
The University Of Edinburgh
2003
To my parents Paul and Sheila Lambah
for their unconditional love and support
throughout my life and years ofstudy
2
-WWfSS-
Halsted's original drawing showing the excision of the pectoral muscles along with
the breast before the axillary contents are removed during a radical mastectomy,
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Abstract of Thesis
Assessment of axillary lymph node status in breast cancer is a collaborative exercise
between surgeons and pathologists that continues to provoke debate. A positive
result for lymph node metastases is the primary determinant for subsequent therapy
decisions.
At present wide variation exists in the surgical approach to the axilla ranging from a
complete level III clearance of all axillary nodes to no treatment in some centres. The
technique of sentinel node biopsy has recently been suggested as a less invasive
method of staging the axilla sparing the morbidity associated with an axillary
clearance.
Despite existing guidelines for the histological processing and reporting of lymph
nodes in the UK, practices continue to demonstrate considerable variation within and
out with these guidelines. New ways of staining lymph nodes, such as
immunohistochemistry are reported to improve on the sensitivity of conventional
haematoxylin and eosin in the detection of lymph node metastases but are not
considered standard practice in most pathology laboratories. The optimal surgical
and histopathological management of the axilla needs clarifying to allow correct
selection of patients for adjuvant treatments.
The chapters of this thesis present the results of a group of related studies examining
existing and new methods of surgical and histopathological assessment of axillary
lymph nodes in breast cancer patients.
The long-term results of randomised trials of 866 patients comparing a level III
axillary node clearance to a non-targeted four-node axillary sample reveal no
difference in long-term survival between the two procedures after a median follow
up of 8.2 years. Axillary recurrence appears to be more frequent following an
axillary node sample than after an axillary clearance.
A two-phase, randomised Multicentre trial (the ALMANAC trial) is currently aiming
to validate the role of sentinel node biopsy in breast cancer patients in the United
Kingdom. The early results of 153 patients recruited into the ALMANAC trial by
Edinburgh Breast Unit suggest that sentinel node biopsy is an accurate and reliable
method of staging the axilla in T1-2 node-negative breast cancer with minimal
morbidity.
Accurate intraoperative assessment of sampled lymph nodes allows a surgeon to
decide whether or not to proceed immediately to a full axillary clearance in node-
positive patients without the need for a second operation. Imprint cytology is
reported to improve upon frozen section histology in the intraoperative detection of
lymph node metastases. Imprint cytology of 238 freshly examined lymph nodes from
53 patients with and without immunohistochemistry suggests the technique is at least
as accurate as frozen section histology and can be useful in the intraoperative
assessment of axillary lymph nodes.
The prognostic significance of occult lymph node metastases (or micrometastases) is
uncertain. Lymph nodes from 26 node-negative patients who developed axillary
recurrence and from 26 patients who developed no axillary recurrence found no




1. To collect and report results of conventional surgical techniques currently
practised to stage and treat the axilla. A retrospective review is made of the
long-term results of two randomised clinical trials comparing axillary node
sample with axillary node clearance.
2. To introduce the technique of lymphatic mapping and sentinel node biopsy as
a new method of staging the axilla in clinically node-negative stage Tl-2
breast cancer.
3. To compare the results of sentinel node biopsy with conventional axillary
staging techniques as a means of staging the axilla in a randomised clinical
trial of clinically node-negative patients with stage Tl-2 breast cancer.
4. To study the technique of imprint cytology of axillary lymph nodes as a rapid
method of identifying lymph node metastases intraoperatively. To compare
two methods of staining lymph node imprints and discover a suitable staining
agent.
5. To study the significance of occult axillary lymph node micrometastases on
breast cancer disease progression.
6. To provide important information for breast surgeons and pathologists on the
optimal management of the axilla in clinically node-negative breast cancer






A full understanding of modern surgical management of breast cancer requires a
knowledge of its history, which dates back to the latter half of the nineteenth century.
The commonest of female malignancies was certain to cause death in women
suffering from it prior to 1867 when simple local excision was the only surgical
procedure performed. In 1863 Sir James Paget wrote, "I am not aware of a single
instance of recovery, that is that the patient should live more than ten years free of
the disease In deciding for or against the removal of a cancerous breast we may, I
think, dismiss all hope that the operation will be the final remedy for the disease.".
Charles H. Moore, surgeon to the Middlesex hospital published a revolutionary paper
in 1867 advocating the wider excision of the tumour along with involved skin and
lymphatics if necessary so that "the various undetected prolongations of the tumour
and outlying nodules be included in the operation." Mitchell Banks of Liverpool
supported his ideas and published two papers in 1878 and 1882 in which he wrote
"the axillary glands as well as the breast in all cases should be removed". Thus, the
first operations of axillary dissection were performed for breast cancer over a
hundred years ago.
Richard von Volkmann, the leading German surgeon ofhis time took things a step
further and recommended excision of the pectoral fascia " because microscopical
examination showed repeatedly what I had not expected that the fascia was already
carcinomatous, whilst the muscle was certainly not involved." Many surgeons
adopted this technique for a time and these included Billroth in Vienna. However,
this technique was later found to have abysmal results including an 18.5% operative
mortality, 82% 3-year local recurrence rate and only 4.7% 3-year survival when an
up-and-coming American surgeon reviewed Billroth's results. It was this man who
was the principal pioneer of modern surgical management ofbreast cancer and his
name was William S. Halsted.
He was born in 1852 into a prosperous New York mercantile family and entered
Yale University in 1870. It was here that he became interested in medicine and he
entered the college of physicians and surgeons in 1874. He graduated in 1877 and
12
soon afterwards sailed for Europe where he spent more than a year in Vienna
observing Billroth, the dean of European surgery. Halsted returned to New York in
1880 and became eminently successful performing the famous "radical mastectomy"
for the first time in 1882 at the Roosevelt hospital. In this operation, the entire breast,
skin and subcutaneous tissue over the breast are removed in continuity with the
pectoralis major and minor muscles plus the axillary lymph nodes. Halsted would
then cover the defect with a skin graft.
By 1894, Halsted had performed 50 radical mastectomies and reported the 3-year
results: there were no operative deaths, the local recurrence rate was 6% and 50% of
the 8 patients operated on more than three years previously were well. It must be
noted that there were no specific selection criteria for these patients, many of whom
had advanced disease and that all 50 had axillary metastases. He followed this series
with a second paper in 1898, reporting the results of the first 133 radical
mastectomies. In it he wrote that the local recurrence rate was 9% and 52% were
alive and well [1]. In the last paper which he wrote reporting on his results of 232
patients published in 1907, the operative mortality was 1.7 % and 42.3 % were alive
and well after 3 years [2], These results clearly reflect a significant improvement on
those of the earlier surgeons performing von Volkmann's technique. The radical
mastectomy was the most important and successful of the pioneering surgical
techniques for cancer of the breast and its practice was continued throughout the first
half of the twentieth century helping thousands of women to recovery from this
dreadful disease.
Halsted's operation was practised on both sides of the Atlantic almost
unquestionably until David Patey published his results in 1948 suggesting that it may
not be necessary to remove the Pectoralis major muscle in all cases of radical
mastectomy. Patey argued that more modern studies on lymphatic anatomy had
shown that firstly, the dermis was a plane rich in lymphatics and hence a rich
potential plane of spread particularly in the case of more superficial cancers and
secondly that the deep fascia was a plane devoid of or very poor in lymphatics and
consequently less important in its potential to spread cancer cells. He theorised that
this would suggest more aggressive excision of skin and less excision of muscle
would be a more logical strategy in ensuring adequate excision.
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His results compared 45 cases of Halsted's radical mastectomy with 46 similar
patients having a "modified" radical mastectomy in which more skin was excised but
only the Pectoralis minor muscle was removed with the Pectoral major muscle being
preserved.
There was no significant difference in 3-year survival or local recurrence rates
between the two groups. Patey therefore concluded that there was no evidence to
support the view that the addition of the removal of the Pectoralis major muscle
brings any increase in the survival figures[3].
At around the same time, Dr Robert McWhirter from Edinburgh published his results
from the 5-year follow up of 2809 cases ofbreast cancer referred to the Royal
Infirmary of Edinburgh between 1930 and 1945. He introduced the technique of
simple mastectomy followed by radical post-operative radiotherapy to the chest wall
and regional lymph nodes, and locoregional recurrence rates fell using this regime.
Within 5 years, the rates of locoregional recurrence fell from 40% to 14% and 5-year
survival rose from 37% to 51% (43.2% if those with distant metastases included) in
those treated with adjuvant radiotherapy [4],
These key, pioneering publications provided the foundations for the modern
management of breast cancer.
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1.1.2 Surgery to the axilla (post 1950s)
Both Halsted and Patey practised radical axillary clearance and in the majority of
Halsted's 1907 series, he also went on to include a supraclavicular neck dissection if
apical axillary glands were involved [2], McWhirter's practice differed from theirs
by his use of simple mastectomy to remove the primary tumour plus axillary node
irradiation to treat the lymph nodes instead of axillary clearance [5]. Radical
radiotherapy was thus practised but was not without serious morbidity and in 1968
Forrest and Kunkler suggested extension of the operation of mastectomy to include
the lower axillary lymph nodes lying close to the axillary tail of the breast [6]. It was
suggested that were these free of tumour, treatment might safely be limited to
mastectomy alone, immediate radiotherapy only being given to those patients whose
nodes were histologically proven to be involved by tumour.
During the late 1960s and early 1970s randomised trials were carried out in Cardiff
and St Mary's Hospital, London comparing the regime of lower axillary node
sampling as a determinant for radiotherapy following simple mastectomy with
radical mastectomy [7, 8]. These studies used a conservative policy of selective
radiotherapy to the axillary lymph nodes if histological examination of the axillary
nodes showed involvement. Patients with no disease in the axillary nodes received no
further treatment of the axilla. In the conservative group treated by simple
mastectomy, lymph nodes were taken from the axillary tail of the breast and
described as pectoral lymph nodes. These nodes are palpated on the medial aspect of
the axillary tail of the breast at the junction with the axillary fat and just behind the
outer border of Pectoralis major muscle. The results revealed significant reductions
in arm morbidity particularly a reduction in arm swelling and shoulder stiffness in
patients spared radical radiotherapy and radical surgery. This was at the expense of
more axillary recurrences in the conservative group although this was not statistically
significant. These trials set the stage for the move towards a more conservative and
selective approach to the management of breast cancer. This trend has continued to





The adult female breast lies in the superficial fascia of the anterior thoracic wall.
The base of the breast lies over a fairly constant area from the sternal edge medially
to near the mid-axillary line laterally and from the second to sixth ribs
craniocaudally. It overlies Pectoralis major and overlaps onto Serratus anterior and a
small part of the rectus sheath and external oblique aponeurosis inferiorly. The
axillary tail is an extension of the upper outer quadrant towards the axilla and usually
lies in the subcutaneous fat but rarely penetrates the deep fascia of the axillary floor
to lie adjacent to axillary lymph nodes.
Structurally, the breast is composed of three parts:
1. glandular tissue
2. fibrous tissue connecting its lobes
3. interlobar adipose tissue.
The breast has fifteen to twenty lobes containing many lobules supported by loose
connective tissue, which supports blood vessels and ducts. The smallest lobules
(terminal duct lobular units) are the functional component of the breast and drain into
ductules which unite to form larger tributaries of the terminal lactiferous ducts which
in turn drain a single lobe centrally to open onto the nipple. Each lactiferous duct has
a dilated sinus at its terminal portion behind the nipple.
Behind the breast, the superficial fascia, which extends superiorly as the continuation
of the superficial abdominal (Scarpa's) fascia, is condensed to form a posterior
capsule. The breast is suspended by strands of fibrous tissue or stroma (the
suspensory ligaments of Cooper) extending from the dermis of the skin to this fascia.
This helps to lift the breast in young women but ageing causes them to atrophy
leading to pendulous breasts. These ligaments become contracted when tugged on by
carcinomas and this leads to pitting (or tethering) of the skin. Between the posterior
capsule and the pectoralis fascia is the relatively avascular retromammary space
which contains lymphatics and a few blood vessels.
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Blood supply
1. the lateral thoracic artery (a branch of the 2nd part of the axillary
artery) is the main provider to the lateral half of the breast
2. the internal thoracic artery sends branches through the intercostal
spaces close to the sternum to the medial half of the breast
3. similar branches perforate from the intercostal vessels themselves
4. pectoral branches of the thoracoacromial artery (a branch of the
second part of the subclavian artery) supply the upper part of the
breast and also supply Pectoralis major and minor.
Venous drainage is mainly by deep veins that run with the arteries to the internal
thoracic and axillary veins. Some drainage to posterior intercostal veins presents a
link to the vertebral veins, which hence can allow metastatic spread to bone.
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1.2.3 Lymphatic Drainage
i. Background lymphatic anatomy
The lymphatic system comprises plexuses of minute vessels (lymph capillaries) that
commence blindly in the tissue spaces of the body and ultimately drain into the
brachiocephalic veins via the thoracic duct and right lymphatic trunk. Lymph nodes,
epitheliolymphoid tissue of the alimentary canal, respiratory tract, spleen and thymus
together with circulating lymphocytes make up the rest of the lymphatic system.
Lymph capillaries commence with a dilated, bulbous, blind-ended extremity in the
interstitial space. The wall of a lymph capillary consists of a single layer of
endothelial cells similar to a blood capillary although the basement membrane is
often lacking and specialised attachments between cells are few. This allows the
endothelial wall of a lymph capillary to be permeable to substances of much greater
molecular size than those, which can pass through the walls of a blood capillary. This
forms a pathway for absorption of colloidal material, particulate matter, cell debris
and microorganisms. Thus, if the lymph vessels become obstructed, the tissues
draining them become distended and oedematous with a fluid containing much
protein. Experimental evidence suggests that absorption ofmacromolecular and
particulate substances takes place through intercellular fenestrations between the
endothelial cells or by micropinocytosis across the cells.
Several factors are responsible for propelling lymph along the capillaries including
the filtration pressure in the interstitial fluid, contraction of surrounding muscle
causing compression of lymphatics, respiratory movements creating a negative
pressure in the brachiocephalic veins, and arterial pulsation compressing lymphatics,
which lie close to arteries. Lymphatic vessels also contain valves similar to veins,
which prevent retrograde flow of lymph ensuring its continuous flow towards the
regional drainage basins. If there is an obstruction in a lymphatic such as may occur
from a malignant tumour, the valves become incompetent and then lymph must
travel in a retrograde fashion to find an abnormal pathway out of the tissues to the
regional lymph nodes.
Lymphatic channels permeate the lymph nodes after lymph has entered through the
afferent lymphatic at the cortex of the node. These channels allow lymph to percolate
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and ensure maximum exposure of lymph to the macrophages and lymphocytes,
which line them. The afferent lymphatics enter at different points on the periphery of
the node and after branching and forming a dense plexus in the substance of the
capsule, open into the subcapsular sinus, a cavity running around the periphery of the
cortex except in the region of the hilum (a slight depression on one side of the node
allowing blood vessels to enter and leave). From the subcapsular sinus, numerous
radial cortical sinuses lead towards the medulla of the lymph node eventually
coalescing to form the medullary sinuses, which are confluent at the hilum and drain
into the efferent lymphatic or lymphatics. Arteries and veins serving the interior of
the lymph node enter and leave at the hilum and give off straight branches, which
traverse the medulla in company with connective tissue trabeculae, giving off a few
minor vessels en route. On reaching the cortex, the arteries divide to give off a dense
plexus of arterioles and capillaries forming numerous anastamosing loops before
passing back to the highly branched venules and veins. This rich vascular network
allows extensive movement of lymphocytes from the blood stream into the lymph
node [9].
The lymph nodes of the axilla can be divided into five groups:
1. Anterior (pectoral) nodes lie medially at the lower border ofpectoralis
minor alongside the lateral thoracic artery. This important group receives
lymph from the major part of the breast and from the anterior thoracic wall.
2. Posterior (subscapular) nodes also lie medially but along the subscapular
artery posteriorly in the axilla. They receive lymph from the upper half of the
trunk posteriorly and from the axillary tail of the breast.
3. Lateral nodes lie along the medial border of the axillary vein. These receive
lymph from the upper limb.
4. Central nodes lie in the fat of the axilla centrally and receive lymph from the
above groups.
5. Apical nodes lie in the apex of the axilla and receive lymph from all the other
groups. From here lymph passes by the subclavian lymph trunk to the
supraclavicular nodes which then drain into the thoracic duct or the right
lymphatic trunk.
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There are often lymph nodes present in the axillary tail or upper outer quadrant of the
breast substance itself, the so-called intramammary lymph nodes and there are
several nodes lying between Pectoralis major and minor, the interpectoral nodes [9].
ii. Lymphatics of the breast
The lymphatics of the breast were first described in detail by Cruickshank in 1786
who described two main lymphatic pathways one draining externally to the axilla
and the other perforating the intercostals to drain into the internal mammary chain.
Mascagani published similar findings a year later in 1787 and found additional
lymphatics accompanying the epigastric and intercostals vessels. Approximately 100
years later in 1885 Sappey discovered a plexus of lymphatics in the subareolar area
of the breast to which he believed the entire breast parenchyma drained before
draining into the axilla. He specifically denied that any lymphatics left the posterior
surface of the breast or that any lymph vessels reached the internal mammary chain.
Numerous lymphatic capillaries exist in the breast substance and the overlying skin.
Turner-Warwick's excellent paper "The Lymphatics of the Breast" describes in
detail the many lymphatic pathways of the breast from his extensive studies of breast
lymphatics in 88 patients by injection of vital blue dyes and radioactive colloidal
gold into the breast parenchyma and observing the drainage patterns [10].
His observations were as follows:
The lymphatics of the breast like other areas of the body accompany the blood
vessels. The blood supply of the breast is mainly derived from the axillary and
subclavian arteries and the perforating branches of the internal mammary artery with
a minor contribution from the lateral perforating branches of the intercostals vessels.
The lymphatic drainage in these three directions is approximately proportional to the
blood supply with the majority of the lymph (75%) draining to the axilla, a
considerable proportion to the internal mammary nodes (or parasternals) and only
occasional drainage into the posterior intercostal nodes, which lie between the necks
of their corresponding ribs, close to the vertebrae.
The lymphatics of the main axillary pathway arise in the breast lobules and were
observed by Turner-Warwick to drain directly to the lateral thoracic (pectoral) group
of lymph nodes through the breast substance and not via the subareolar plexus in
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contrast to Sappey's theory. These main lymphatic trunks were at no time observed
to run in the deep fascial plane.
The internal mammary lymph nodes lie along the internal mammary vessels
extending upwards from the 5th intercostal space to the supraclavicular nodes. They
usually lie between the costal cartilages but also lie behind them at times. These
nodes receive lymph not only from the perforating lymphatics that accompany the
blood vessels but also from lymphatics that accompany the lateral perforating
branches of the upper intercostal vessels thus constituting a further intercostal
pathway. The upper three or four intercostal spaces have large internal mammary
nodes with relatively smaller posterior intercostal nodes. Lymph tends to drain
anteriorly into these nodes from the lateral perforating branches of these upper
spaces while those entering lower spaces may drain into the posterior intercostal
nodes. Perforating branches also accompany the intercostobrachial nerves and such
branches in the upper intercostal spaces constitute at least a theoretical
communication between axillary and internal mammary pathways.
Most of the lymphatics which leave the posterior surface of the breast perforate the
pectoralis major muscle to reach the internal mammary chain and axilla creating an
interpectoral pathway. Those vessels following the thoraco-acromial vessels drain
into the interpectoral nodes on their way to the upper axilla. No lymphatics are
observed to perforate the pectoralis minor muscle although lymph nodes lie in front
of it (interpectoral), above it (infraclavicular) and behind it (lateral thoracic/pectoral
group).
Many studies have suggested that the breast drains centripetally into the subareolar
plexus (of Sappey) and from here to the axilla. The subareolar plexus is known to
exist and communicates with the lymphatics around the lactiferous ducts. Turner-
Warwick acknowledges this in his study but suggests that 10% of random injections
into the breast fill the lactiferous ducts causing this central drainage pattern
commonly observed and mistaken for lymphatic drainage. He concluded that the
subareolar plexus may be overemphasised in some studies.
The presence of a deep fascial plexus of lymphatics in the retromammary space is
not well demonstrated and it is believed that this area contains only a few lymphatics,
which drain the fascia itself but do not appear to be an important drainage pathway
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from the breast. As described above, several lymphatics pass across this space to
perforate the pectoralis major or intercostals but do not form a plexus of lymphatics.
Fascial spread of tumour is unusual in the early stages of breast cancer but is seen in
later stages probably as a result of direct mechanical infiltration of tumour.
The subcutaneous lymphatics of the breast form a coarse mesh network over the
breast similar to other areas of the body lying in the same plane as the superficial
venous plexus. They extend in the same plane across the midline, over the clavicles,
and down onto the anterior abdominal wall and they anastamoses with the deeper
lymphatics of the breast especially in the regions of the nipple. These lymphatics
drain only a small proportion of the breast's lymph but are of considerable
importance in the spread of carcinoma.
The supraclavicular lymph nodes receive lymph from the breast indirectly after it
has passed through the axillary and internal mammary drainage basins. There is little
significant direct drainage from the breast to the supraclavicular nodes.
Lymphatics from the breast rarely enter the para-xiphisternal area unless the main
pathways are obstructed but are not implicated as a pathway to the abdominal cavity.
In late stages of the disease, deposits in the internal mammary nodes may lead to
retrograde communication with the peritoneal lymphatics and similarly via the
intercostals to the pleural cavity.
There is no significant drainage of lymph to the contralateral axilla or internal
mammary chain under normal conditions. Contralateral deposits are occasionally
seen in late stages of the disease when the ipsilateral drainage pathways have been
obstructed by tumour or destroyed by surgery or radiotherapy.
In summary, the breast drains mainly to the ipsilateral axilla, which receives 75% of
the total lymph from the breast with the remainder draining into the internal
mammary chain. As there are no valves in the intramammary lymphatics, lymph can
pass freely across the breast from one half to another so both the internal mammary
nodes and the axillary nodes can freely receive lymph from both lateral and medial
halves of the breast. The posterior intercostal lymph nodes have been shown to
receive lymph from the breast in a small proportion of patients but the great majority
ofpatients have no drainage along this pathway at all unless the main pathways
become blocked. A rich subareolar plexus of lymphatics does exist but it may not be
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the main pathway of lymph drainage from the breast as some studies suggest and
other pathways clearly exist.
There is little evidence to suggest a significant deep fascial or retromammary plexus
of lymphatics so this is unlikely to be of importance in the early spread of breast
cancer. Superficial lymphatics can cross the midline and this can allow lymph to pass
to the opposite breast, to cervical nodes, to the peritoneal cavity and liver through the
diaphragm or rectus sheath or even to the inguinal nodes via the anterior abdominal
wall. This is unlikely to occur unless the usual pathways become blocked, as is
sometimes the case especially in the later stages of carcinomas of the breast.
Figures 1.1 & 1.2 anatomical diagrams of breast and axilla
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Figure 1.1 Lymphatic drainage ofthe breast (taken from Gray's Anatomy 37
edition, p848, illustration 6.207, Churchill-Livingston)
Infraclavicular











iii. Surgical lymphatic anatomy
For surgical purposes, the axillary nodes are often divided into three levels according
to their relation to the Pectoralis minor muscle:
Level I lymph nodes lie below and lateral to the lateral border of Pectoralis minor
Level II lymph nodes lie behind the Pectoralis minor muscle between its medial and
lateral borders
Level III lymph nodes lie above and medial to the medial border of Pectoralis minor
muscle usually up to the level of the 1st rib.
Figure 1.2 Levels ofaxillary lymph nodes (taken from the ABC ofBreast








During the reproductive years, cyclical changes occur in the breast in response to
oestrogen and progesterone levels.
Oestrogens cause proliferation ofmammary ducts and are largely responsible for the
breast enlargement seen at puberty in girls. They have been described as the growth
hormones of the breast.
Progesterone stimulates the growth of breast lobules and alveoli and supports the
secretory function of the breasts during lactation.
Prolactin is secreted by the anterior pituitary gland and has an important role in
lactation of the breast. Its levels rise steadily throughout pregnancy until parturition
when levels begin to fall again. It aids oestrogen and progesterone in the full lobulo-
alveolar development of the breasts during pregnancy [11].
During the menopause, which usually occurs around 52 years of age, the breast
substance undergoes involution in response to falling levels of oestrogen and
progesterone. Involution leads to the replacement of breast stroma by fat causing the
breast to become less dense, softer and ptotic. The glandular tissue of the breast also
changes and may develop small cysts, areas of fibrosis or an increase in the number
of glandular elements (adenosis) [12].
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1.4 PATHOPHYSIOLOGY OF BREAST CANCER
1.4.1 Aetiology
Breast cancers arise from the epithelial cells that line the terminal duct lobular unit
[12].





Genetic predisposition to breast cancer is only responsible for about 10% ofbreast
cancers. Two breast cancer susceptibility genes have been located on chromosome
17q21 known as BRCA1 gene and chromosome 13q known as BRCA2 gene, which
account for breast cancer in a substantial proportion of very high-risk families.
Mutations of the p53 tumour suppressor gene and PTEN gene are implicated less
frequently and are respectively associated with the Li-Fraumeni and Cowden's
familial syndromes. Amplification of the c-erb-B2 oncogene is thought to be related
to between 5-30% of cancers. In particular, its protein product pl85erb, is associated
with poor prognosis in node-positive breast cancer patients [12, 13].
A relative excess of the hormone oestrogen is clearly important in the development
of some breast cancers. This may be endogenous in the case of early menarche, late
menopause, nulliparity or late age at first pregnancy, which are all associated with an
increased risk of breast cancer. Exogenous oestrogen, as in the case ofhormone
replacement therapy (HRT) and the oestrogen-containing oral contraceptive pills, is
also a risk factor when prolonged exposure occurs. Normal breast epithelium
possesses both oestrogen and progesterone receptors and these receptors are found on
some but not all breast cancers in varying proportions. When present, they can be
stimulated by oestrogen to accelerate tumour growth. Human breast cancer cells
secrete a variety of growth promoters: transforming growth factor-alpha (TGF-a),
epithelial growth factor (EGF), platelet-derived growth factor (PDGF) and fibroblast
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growth factor (FGF). Studies suggest that they are involved in the autocrine
regulation of tumour growth.
Environmental factors are suggested by the considerable variation in the incidence of
breast cancer geographically. A high-fat diet and moderate to high alcohol
consumption have been implicated as possible risk factors but evidence for these is
neither strong nor consistent [14].
1.4.2 Histological type
Breast cancers are classified histologically under two main headings:
1. Invasive (infiltrating) ductal carcinoma of no special type (NST) or not
otherwise specified (NOS) - 65-80% of breast cancers
2. Invasive carcinoma of special type - lobular, medullary, tubular, mucinous,
apocrine, papillary - 20-35% of breast cancers
The invasive ductal carcinomas of no special type are graded I, II or III according to
the frequency of mitoses and degrees of nuclear pleomorphism and glandular
formation. These cancers tend to be of hard, 'scirrhous' consistency caused by the
marked increase in dense, fibrous stromal tissue with frequent invasion of
perivascular and perineural spaces as well as blood and lymphatic vessels.
Of the special types, invasive lobular carcinoma is the commonest accounting for 5-
10% of breast cancers and is characteristically rubbery and poorly circumscribed. It
is associated with a high percentage ofbilateral breast involvement (20%) and
multicentricity.
Some of the special type cancers are associated with a more favourable prognosis
than other invasive cancers. Tubular carcinoma, mucinous and medullary are
included in these.
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1.4.3 Metastasis to lymph nodes
The preferred route of breast cancer spread is through the lymphatics to the regional
lymph nodes. There are two methods by which this may occur and both are quite
possible. The favoured theory is that cancer cells breaking off from the primary
tumour are spread by embolism to the regional lymph nodes. The lymphatic
channels, which run between the primary breast cancer and the lymph nodes, are
usually free of carcinoma on histological examination giving weight to this
theory[l]. The opposing belief is that the cancer spreads by permeation of the
lymphatics as the tumour slowly grows along their walls. However, even some small,
very early cancers can have associated lymph node metastases making the embolic
theory far more likely in these patients when lymphatic permeation would not have
had time to occur. It is most likely that both patterns of spread do occur although
lymphatic permeation appears to be associated with advanced disease and emboli
probably occur earlier as well as later in the disease process. The difficulty lies in
predicting those patients who are most likely to metastasise
Several characteristics are associated with an increased risk of development of lymph
node metastases. These may be conveniently divided into patient and tumour
characteristics:
i. Patient characteristics and lymph node metastases
Age below 60yrs has a positive association with lymph node metastases in T1
tumours on univariate analysis[15]. Young age has also been found to be an
independent predictor of lymph node metastases in patients with Tla and Tib breast
cancer[16] on multivariate analysis. A Canadian study of 4,660 patients also reported
pre-menopausal status and clinical palpability of lymph nodes as well as young age
to be significantly associated with a higher incidence of positive lymph nodes [17].
The presence of overexpression of the oncogene c-erbB-2 has been reported to have
a significant association with the number of involved axillary lymph nodes and has
also been related to decreased overall patient survival [18]. Obesity is associated
with an increased risk of breast cancer in post-menopausal women [19, 20] and is
reportedly associated with poorer disease-free survival in breast cancer particularly
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when combined with an elevated serum cholesterol [21]. Some studies have also
reported an increase in the risk of lymph node metastases in obese women [22, 23].
ii. Tumour characteristics and lymph node metastases
Lymph node metastases are associated with increasing tumour size, presence of
lymphovascular invasion, moderate or high nuclear grade, high S-phase fraction and
multifocality or multicentricity on univariate analysis[15, 24]. Multivariate analysis
states palpable axillary lymph nodes, presence of lymphovascular invasion,
increasing tumour size and multifocality or multicentricity of the primary tumour as
independent predictors of lymph node metastases [15, 24], Oestrogen receptor status
does not appear to be an independent predictor of lymph node metastases from
reported studies [15, 17, 25-28]. The absence of oestrogen receptors (ER) does,
however, appear to be associated with aggressive disease in that more lymph node
metastases per patient are encountered and the rate of cell proliferation is higher
within these metastases than in those with ER-positive tumours. In addition, the
incidence of distant metastases is higher in ER-negative patients than in ER-positive
patients [29].
Axillary lymph node metastases are more commonly associated with tumours of the
upper outer quadrant (26%) than in other areas of the breast and similarly tumours of
the lateral half of the breast have a 28% prevalence of lymph node metastases
compared with 11.5% in the medial half of the breast [30]. The simple explanation
for this is that there is less distance for the cancer to travel than from the medial half
of the breast but this may also represent the different drainage patterns of the two
halves of the breast. Medial tumours are more likely to drain into the internal
mammary nodes (24.6% c.f 17.7% in lateral tumours) [31] making spread to the
axilla relatively less likely. Medial tumours are more likely to be understaged
because the internal mammary nodes are not routinely biopsied in the majority of
breast units because use of the procedure does not reportedly improve disease-free or
overall survival [31]. It has been suggested however, that a subgroup ofpatients with
Tl-2 tumours of the medial two quadrants and axillary node metastases may have a
survival benefit from internal mammary biopsy [32],
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Tumour angiogenesis has been proposed as an independent indicator of prognosis
and axillary lymph node metastases [33, 34]. The presence of a high microvessel
density within the primary breast tumour has also been reported to be strongly
associated with relapse-free survival and overall survival [35]. Additional reports
have also suggested neovascularisation and microvessel density within the lymph
node metastases could also be associated with disease-free and overall survival[36].
There may be a role for tumour microvessel density in helping to select patients who
would benefit from systemic adjuvant therapy[35, 37]. Evidence that tumour
angiogenesis is a predictor of lymph node metastases is inconsistent however, with
no firm evidence to confirm it as a useful marker of this [38-40].
There is little data reporting association ofhistological type of breast cancer with
lymph node metastases. It has been reported however, that the risk of lymph node
metastases is lower for tubular carcinoma than for other histological types [41, 42].
The presence of lymph node metastases in a breast cancer patient is internationally
recognised as the most serious adverse prognostic indicator of long-term survival and
is widely quoted in peer-reviewed journals [43-45]. Knowledge of lymph node
involvement is critical in making decisions on whether to give regional radiotherapy
and/or systemic adjuvant therapy.
1.4.4 Lymph node micrometastases
A lymph node micrometastasis (occult metastasis) is defined as a metastatic deposit
of less than 2mm in diameter detected in a single lymph node after extensive review
of the original histological material [46]. Such deposits are not normally appreciated
during initial routine assessment of lymph nodes by light microscopy.
Lymph node micrometastases can be detected by a variety of processing methods.
The simplest and most commonly used is to assess multiple levels of the same lymph
node by serial sectioning of the node every 2-3mm as opposed to bisection of the
node, which only examines it at two levels. Conventional haematoxylin and eosin
(H&E) staining is used on each level. Detection of micrometastases in node-negative
patients is reported as 7-17 per cent using this technique [47-49].
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The use of immunohistochemistry to detect micrometastases in axillary lymph nodes
has created much interest but currently is not used as a standard in the processing of
lymph nodes histologically in the United Kingdom. The anticytokeratins AE-1, AE-3
and CAM 5.2 are reported to give a greater yield of micrometastases (11-20%) when
compared with H&E staining methods [48, 50, 51]. This technique of processing
lymph nodes, in particular sentinel lymph nodes, has become popular in the United
States where some large cancer centres are now using immunohistochemistry
routinely. Polymerase chain reaction (PCR) of extracted RNA has been used to
detect micrometastases and has reported a yield of 28% in lymph node negative
patients[52]. Similarly, another study using mammaglobin B gene transcript with a
reverse transcription polymerase chain reaction (RT-PCR) assay revealed occult
metastases in 31% of node negative patients [53]. The use of PCR and RT-PCR in
detection of lymph node micrometastases is not yet validated, is still experimental
and is largely unavailable in the majority of hospital laboratories, however.
Specificity of these molecular biology techniques has also been questioned thus
increasing the risk of false positive results. These findings give rise to the fact that
detection of micrometastases is a function ofprobability in that the harder one looks,
the more likely one is to find additional information in the form ofmicrometastases
[54], For example in the Ludwig International Study ofmicrometastases [55], the
probability of detection of deposits between 100pm and 500pm was 6% if a single
section was examined rising to 36% if six evenly spaced sections were examined
[56].
The role of lymph node micrometastases in the natural progression of malignant
breast disease is unclear. Reports of a significant decrease in disease-free and overall
survival have been made from a relatively large, multicentre research group
suggesting that micrometastases have a negative prognostic effect on breast cancer
patients [57]. These findings are supported by a Japanese study of 129 node-negative
patients using CEA-specific RT-PCR analysis of lymph nodes, which reported a
significant difference in disease-free and overall survival in patients without
micrometastases compared to patients with micrometastases [58]. These reports have
been contested by other studies, which suggest no adverse prognostic association
with lymph node micrometastases [46] and no independent association of the
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presence of occult metastases with overall survival [59, 60]. There was, however a
significant association between the presence and increasing size of occult metastases
and poorer disease-free survival in one of the latter studies [59].
Closer examination of micrometastases suggests certain sub-groups of
micrometastases may be more important. Those measuring less than 0.2mm were not
associated with worse prognosis but micrometastases greater than 0.2mm were [47].
Similarly, in a study of 109 patients with micrometastases in sentinel lymph nodes
who subsequently had complete axillary dissection, the frequency of non-sentinel
lymph node metastases was significantly higher in patients with SLN
micrometastases measuring greater than 1mm than in those with SLN
micrometastases measuring 1mm or less [61]. Another study of micrometastases in
sentinel lymph nodes reported the risk of lymph node metastases in non-sentinel
lymph nodes following complete axillary dissection as being 15.2% [62]. This
information could be important in making an accurate choice ofpatients for further
axillary dissection after a staging sentinel node biopsy. A review paper of 8 studies
with at least 5 years' follow-up concluded that occult metastases were independently
predictive of survival in only one of these studies and that the size of the micro
metastasis was important in the clinical outcome stating those of less than 0.5mm as
small micrometastases with no proven prognostic relevance[63]. Another review of
large studies concluded that most studies did show a statistically significant, negative
effect of micrometastatic disease on disease-free and overall survival [64],
Histological type may also be important as two studies suggest with invasive lobular
carcinoma micrometastases showing no adverse effect on prognosis whereas invasive
ductal carcinoma (NOS) micrometastases was strongly associated with poorer
recurrence rates and to a lesser extent survival [65, 66].
The proliferation rate and angiogenesis of micrometastases has been shown to be
significantly lower than for macrometastases (those seen on routine light
microscopy) [67]. Although only a small number of patients were studied, these
results suggest that the two types of metastases are biologically different in their
behaviour and may explain their differential growth patterns.
Logic would say that the presence of cancer cells in the lymph nodes is a bad sign
and should create cause for concern. It is well known however, that breast cancer is
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not a homogeneous entity but consists of a broad spectrum of vastly differing
biological behavioural patterns. It would seem reasonable therefore, to accept the
view that micrometastases should be managed not with the indiscriminate use of
powerful adjuvant therapies and surgical procedures, but by following carefully
constructed guidelines according to other tumour and patient characteristics. For
example, patients with invasive ductal carcinoma (NOS) and with micrometastases
measuring greater than 0.5mm could be considered as a higher risk group and treated
more aggressively than those with invasive lobular carcinoma with small
micrometastases of less than 0.5mm. At present there is no general consensus as to
the optimum management of micrometastases but it appears that certain subgroups
may have more prognostic significance than others and further studies are needed to
increase our knowledge of this subject to produce surgico-pathological
recommendations. Guidelines so produced need to take into consideration the labour
involved and the corresponding patient benefit together with the resources available
to the majority of breast cancer units.
33
1.5 AXILLARY SURGERY AND STAGING
Breast cancer cells spreading along the lymphatic channels from the primary breast
tumour may affect axillary lymph nodes at any level in addition to the intramammary
and internal mammary lymph nodes. The commonest site of spread is to the level I
lymph nodes (lateral to the lateral border of Pectoralis minor muscle) which are
affected alone in 58.2% of node-positive patients. Levels I and II are affected in
21.7% and levels I, II, and III are affected together in 16.3% of node-positive
patients. In total this regular and progressive distribution occurs in 96.2% of node-
positive patients. Skip metastases, in which the first level is not involved by disease
but higher levels are involved, are found in 1.5% of cases. The first and second levels
are skipped in 0.4% and the second level is skipped in 2.6% when nodes are involved
in the first and third levels only [68]. Other studies report higher incidences of skip
metastases [69]. The level of involved axillary nodes is not an independent predictor
of overall and disease-free survival but the number of involved axillary lymph nodes
appears to be of greatest importance in prediction of survival[70].
The question thus arises ofwhich patients need axillary surgery and how much
axillary dissection is necessary to provide staging information and control of axillary
disease? Current practices vary extremely between centres and range from no
axillary surgery to a complete level three axillary clearance [71-75]. The advantages
of performing a full axillary node clearance are obvious, more accurate information
is provided on axillary node status leading to better selection of adjuvant therapies,
local control is excellent with failure rates of 0-2% and long-term disease-free
survival is improved[76]. It is only, however, the node-positive group ofpatients
who will benefit from such surgery and the remaining 60-70% of patients who are
node-negative following axillary clearance will achieve no benefit from the surgery
save the knowledge of a clear axilla. Haagensen showed that approximately 40% of
all breast cancers have metastasised to the axilla at the time of diagnosis [1] leaving
60% of women node negative at presentation. The difficulty lies in the identification
of node-negative and node-positive patients prior to surgical staging of the axilla. As
a result, many studies have tried to identify those patients likely to benefit most from
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axillary node clearance and those patients likely to be node-negative who may not
require this operation. Options available to the breast cancer surgeon are many and
include a level I axillary dissection[77], level I and II axillary dissection[78] and a
level I-III axillary clearance[79]. Accurate axillary staging information is vital to
enable the clinician to select appropriate patients for local and systemic adjuvant
therapy.
1.5.1 Level I axillary dissection
The number of axillary lymph nodes excised as part of an axillary dissection has
been related to disease-free survival. Removal of 10 or more lymph nodes is reported
to give better disease-free survival than removal of less than 10 nodes [71]. Five-year
survival increased from 75.7% to 86.2% in this study on patients with T1N0 breast
cancer. This finding was also reported in a large Danish study which, found
significantly better axillary recurrence-free survival, overall recurrence-free survival
and survival in patients in whom 10 or more negative lymph nodes were removed
[80]. Other studies have reported varying numbers of nodes as critical in conferring a
survival advantage and are discussed below in the section 'axillary node sampling'.
Excision of all axillary lymph nodes in level I is reported to provide reliable
information as regards axillary node status. A study examining the efficacy of a level
I axillary node dissection reported an average of 14 lymph nodes per patient at level I
with a 3.5% incidence of'skip' metastases to levels II and III without involvement of
level I [81]. This study reports an accuracy of 94.5% in correct identification of
node-negative patients and a false-negative rate of 8.7%. These figures are
comparable to those reported for axillary node sampling as discussed below.
Schwartz et al reported a mean of 27 nodes being excised per patient in a series of
level I axillary dissections[77]. Node-negative patients were subjected to a
complication rate of 13% with persistent axillary seroma formation occurring
frequently in this series of 154 patients and node-positive patients were noticed to
have a risk of late lymphoedema when treated by post-operative radiotherapy to treat
higher echelon lymph nodes left inside the axilla.
35
Lloyd et al reported that a level I axillary dissection could detect more than 98% of
patients with axillary metastases and the incidence of skip metastases was 3.2% [82].
This study also reported that there was a 45% probability of higher echelon lymph
node metastases ifmetastases existed at level I. This finding is significant as it leaves
50% of node positive patients with an under treated axilla post-operatively leaving
the unsatisfactory choice of a second axillary operation to clear the remaining
axillary lymph nodes or axillary radiotherapy together with the risk of lymphoedema.
1.5.2 Axillary Dissection/Clearance to levels II and III
Level I and II axillary dissection is the preferred technique for the staging and
treatment of the axilla in many breast cancer units. It is reported to have a low
recurrence rate and limited morbidity[78, 83]. Morbidity from axillary clearance, is
however, more frequent than in patients having axillary sampling or no axillary
surgery[84]. Similarly, a higher frequency of late arm complications was reported in
a series of over 800 patients receiving level III axillary clearance as opposed to level
I and II axillary clearance and there was no significant difference in survival between
the two groups of patients [85]. Arm morbidity thus appears to be more frequent (and
severe), the more extensive the surgery to the axilla.
Evidence from a large American cancer database has shown that fewer patients had
axillary node dissection in 1993 than in 1983 [86]. This suggests a trend towards
more conservative management of the axilla. An American review of axillary
dissection found that whilst randomised studies have shown improved loco-regional
control of breast cancer with axillary clearance procedures, there has been no impact
on overall survival and the main role of axillary dissection is limited to staging and
prognostication [87]. A meta-analysis of six randomised controlled trials comparing
standard treatment with axillary dissection to standard treatment without axillary
dissection conflicted with these results concluding that axillary node dissection did
confer a mean survival advantage of 5.4% [88], It was noted however; that few of the
patients in the six trials had T1 a breast cancer and no patients were treated with
adjuvant therapy unlike current practices suggesting the risk reduction may be less
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apparent if adjuvant therapy had been given. The large NSABP B-06 trial comparing
patients showed no difference in survival between node-positive patients treated by
either radical mastectomy including axillary clearance or simple mastectomy without
axillary dissection but with axillary radiotherapy [89]. Such contradictions have
resulted in more careful selection ofpatient groups in particular with regard to
tumour size in an attempt to rationalise these findings. In some centres there is a
selective process identifying high-risk patients for axillary clearance and low-risk
patients for an axilla-conserving operation such as axillary node sampling [90]. The
prevalence of axillary node metastases falls to 12.1% in stage Tla and Tib breast
cancer thus further questioning the need for complete nodal dissection in early breast
cancer [91]. The introduction of breast cancer screening along with the increase in
public awareness has led to earlier detection and hence more patients than ever
before now fall into these groups.
1.5.3 Axillary node sample
There is good evidence from randomised trials to suggest that axillary node sampling
is a reliable method ofproviding accurate information about the status of the axillary
lymph nodes[92]. In the Edinburgh series, all 135 node-positive patients undergoing
axillary node clearance had a positive axillary node sample in a 4-node procedure
performed immediately before a level III axillary clearance. Results from randomised
studies comparing a 4-node axillary node sample with a level III axillary clearance
have provisionally reported no significant difference in survival or axillary
recurrence between the two groups after median follow-up of 11 years and 4.1 years
in patients treated by mastectomy or breast conservation respectively [79, 84],
Another study from Sweden reported a sensitivity of 97.3% with a five-node biopsy
of the axilla in clinical stage T0-3,N0-1,M0 breast cancer suggesting an alternative
to full axillary clearance in operable breast cancer as a staging method[93].
Radical mastectomy plus axillary node clearance was compared with simple
mastectomy plus no axillary surgery if lymph nodes were not clinically palpable or
local excision of nodes if they were, in patients with Tl-2, N0-1, MO breast cancer in
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Capetown, South Africa. It was noted that there was an increase in axillary
recurrences in the simple mastectomy group at 40 months leading to the termination
of the trial. Long-term review of patients however, revealed no difference in
recurrence at other sites, time to recurrence or survival between the two groups at 10
and 25 years [94].
A Danish study of over 3,000 patients reported that false negative staging of the
axilla was related to the number of nodes examined histologically. The false negative
was modest at 2% when at least three axillary lymph nodes were removed and found
to be negative on histological examination. The false negative rate increased to 7% if
only two nodes were excised and 12% ifno lymph nodes were excised [95]. A
follow up study by the same group found that the estimated five-year probability of
developing axillary relapse was 3% whether 5-10 lymph nodes were removed or
whether greater than 10 lymph nodes were removed from the lower axilla. As
progressively fewer nodes were removed, there was a progressive increase in the
estimated axillary relapse rates up to 19% ifno nodes had been removed. Median
follow-up was 6.5 years in this study [96],
1.5.4 Omission of axillary surgery
It has been suggested that certain patients, in particular those older patients with
small, screen detected, impalpable breast cancers may not benefit from axillary
dissection as such patients are at low-risk of axillary disease and their nodal status
would not influence choice of adjuvant treatment[97, 98], This theory is
controversial and other research suggests that treating all patients with an axillary
node dissection will prevent axillary recurrences and does not adversely affect arm
morbidity in the absence of axillary radiotherapy [99]. Patients with small T1 breast
cancers are less likely to have axillary metastases. Lymph node metastases were
found in 3% of Tla cancers, 13% of Tib cancers and 25% of Tic cancers in an
American study that found no difference in survival between patients who had an
axillary node clearance compared with those who had no axillary surgery[73]. It was
suggested that patients with Tla tumours did not need axillary surgery but those with
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Tib and Tic should still receive axillary dissection because of the higher risk of
axillary disease. These findings were supported by a similar study in which it was
suggested that axillary dissection was only necessary in patients with a greater than
15% probability ofhaving lymph node metastases and supported its use in Tib and
Tic tumours as a staging procedure [100],
It is clear from the above amalgam of data that there is no clear consensus on how
best to manage the axilla inoperable breast cancer. It is clear however, that patients
with breast cancer, rather than a group suffering from the same illness, have become
a heterogeneous population inflicted with a diverse spectrum of clinical conditions
and who need compartmentalising into specific treatment groups.
1.5.5 alternative methods of staging the axilla
Clinical examination is not accurate in identification of axillary lymph node
involvement [101]. Ultrasound of the axillary nodes has not been helpful in detection
of metastases with a reported sensitivity similar to that for clinical examination in the
region of 56-72%[102-104], Even when used in combination clinical examination
with ultrasound still misses axillary metastases in one-third ofpatients [102], Colour
Doppler has also been studied as a possible technique to improve the sensitivity of
standard ultrasound in the detection of axillary nodal metastases but is only reported
to detect 70% of involved axillary nodes [105].Axillary mammography has been
unsuccessful in improving these figures and only has a reported sensitivity of 39%
[104], The use of magnetic resonance imaging (MRI) is reported to have a greater
accuracy than either ultrasound or clinical examination with a sensitivity of 83%
[106] but still compares unfavourably with lymph node biopsy whether by axillary
dissection or axillary node sample in staging the axilla[92]. The use of ultrasound-
guided fine needle aspiration of clinically non-palpable lymph nodes has also been
attempted but failed to detect positive nodes in 37% of cases [107].
A number of other methods of staging the axilla have been examined. CT scanning
of the axilla may have a role in defining the extent of disease in local and regional
recurrence when used in combination with chest CT[108]. It's role in axillary staging
, however, has been assessed as inadequate with a sensitivity of only 50% (similar to
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clinical examination) and a negative predictive value of only 20% [109]. More
recently, however, the use of thin section CT has reported improvement on these
results with a sensitivity of 93.8% for involved lymph nodes but with a specificity of
82.1% runs the risk of a false positive result [110]. Positron emission tomography
(PET) scanning of axillary nodes is a relatively new technique, undergoing
evaluation in detection of lymph node metastases but the results reported are not
favourable when compared with the accuracy of sentinel node biopsy either in cases
of breast cancer or malignant melanoma [111-114]. It has a sensitivity of about 79%
in detection of axillary lymph node metastases overall, which increases to 94% in
primary tumours of greater than 2cm in diameter but unfortunately drops to only
33% inTl tumours [115].
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1.6 AXILLARY RADIOTHERAPY
The use of radiotherapy as adjuvant treatment following a complete lymph node
clearance of the axilla is no longer considered appropriate in view of the high
incidence of lymphoedema (38.3%) in patients treated in this way [116]. Instead
axillary radiotherapy is commonly used in two clinical settings nowadays. Firstly to
treat node-positive patients who have had less than a complete axillary clearance and
in whom further positive axillary nodes possibly persist within the axilla. Secondly
as a complete treatment to the axilla in patients who do not undergo surgical staging
of the axilla.
The NSABP-06 study in America found no difference in the disease-free survival,
distant disease-free survival and overall survival after ten years' follow-up of a large
group of clinically node-negative patients with invasive breast carcinoma treated by
either radical mastectomy, simple mastectomy plus axillary radiotherapy or simple
mastectomy alone plus delayed axillary node clearance only if positive nodes were
subsequently found clinically [89]. Similarly, this same study observed no difference
in disease-free or overall survival in clinically node-positive patients whether treated
by radical mastectomy or simple mastectomy plus axillary radiotherapy. This study
suggested that complete axillary dissection was no longer the only method of treating
the axillary lymph nodes but that axillary radiotherapy was an acceptable alternative
with equal results and thus spared the patient more extensive surgery. Since this trial
was performed in the 1970s, there has been a gradual trend towards the more
conservative approaches to stage and treat the axilla. The technique of axillary node
sampling to avoid the morbidity associated with axillary clearance was introduced
[92]. In a randomised trial, patients with no disease in four sampled axillary nodes
received no further treatment to the axilla and those with positive nodes received
axillary radiotherapy. Outcomes were compared with those of standard level III
axillary clearance without axillary radiotherapy in patients treated by simple
mastectomy and no significant difference was observed in overall survival or loco-
regional recurrence [79]. A similar trial in patients treated by breast conservation
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came to the same conclusions and recommended a selective policy in approaching
the management of the axilla[84].
Subsequent trials have tried to identify patients who would most benefit from
axillary radiotherapy as opposed to an axillary clearance. Zurrida and Veronesi
recently reported results from a trial in Milan, which found no significant difference
in overall survival or axillary recurrence in clinically node-negative patients with
small cancers < 1.2cm randomised to receive no axillary treatment or axillary
radiotherapy after breast conservation [117]. Hoebers specifically targeted
postmenopausal women with node-negative breast cancer and treated them with
adjuvant breast, axillary and supraclavicular fossa radiotherapy after breast-
conserving surgery and reported no isolated axillary recurrences after 5 years'
follow-up although two patients developed synchronous axillary recurrence and
distant metastases [118]. These studies suggest the use of axillary radiotherapy in
selected patient groups may negate the need for axillary surgery.
Axillary radiotherapy is itself, not without risk. The potential long-term risks of its
use include lymphoedema, brachial plexopathy, radiation pneumonitis, rib fractures,
cardiac toxicity, and radiation-induced second neoplasms [119]. Most of these side-
effects are relatively infrequent with the exception of lymphoedema which occurs in
approximately 4% of patients after radiotherapy alone [41].
A study examining extracapsular extension of lymph node metastases as a cause for
axillary failure, found no benefit from giving axillary radiotherapy to patients with
node-positive breast cancer after a level I-II+/-III node clearance whether or not they
had extracapsular extension and concluded that extracapsular extension did not lead
to an increase in axillary failure rates but was probably associated with poorer overall
and disease-free survival [120], These patients appear adequately treated by axillary
clearance and may represent one group in whom radiotherapy is not necessary.
The American Society of Clinical Oncology has recently recommended not to use
axillary radiotherapy in patients having a complete (level I-III) axillary clearance or a
level I-II axillary dissection in view of the risk of lymphoedema and the adequacy of
the surgical procedure in treatment of the axilla[l 19].
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1.7 ARM MORBIDITY
Arm morbidity is commoner the more extensive the surgery and includes: cellulitis,
seroma, lymphoedema, shoulder joint stiffness, arm pain and altered sensation [121-
124] particularly of the axillary skin and the skin of the medial upper arm supplied
by the intercostobrachial nerve (the lateral cutaneous branch of the second intercostal
nerve[125]) which some surgeons sacrifice during a routine axillary node clearance.
In addition to these physical arm side-effects, patients suffer from psychosocial
maladjustment and increased psychological morbidity [126]. Consequently, if these
complications can be avoided or minimised then we should endeavour to find a safe
and reliable method of doing so.
1.7.1 Lymphoedema
Lymphoedema is the accumulation ofprotein-rich fluid in the interstitial spaces
resulting in an abnormal enlargement of the affected part [127]. There is little
literature defining the specific increase in arm volume necessary for lymphoedema to
be present with studies using lOOmls [122] and 200mls [116, 128] increase in
ipsilateral arm volume as well as percentage increase in ipsilateral arm volume
compared with the premorbid arm volume as cut-offs [84], It is important to
recognise that arm volume can have significant variation when compared with the
contralateral arm of up to 10% difference between the two arms in normal
individuals. This has been noted by the author from pre-operative arm assessments
made in phase 2 of the ALMANAC study (chapter 4) but is a well-recognised entity.
Assessment of arm swelling and lymphoedema must therefore allow for this by
documenting premorbid arm measurements. Several methods have been used to
objectively measure lymphoedema including arm circumference 15cm above and
10cm below the olecranon [84, 116, 121], arm volume by water displacement [84,
116, 128] and arm volume by circumferential measurements along the limb usually
every 4cm with subsequent volume calculation using equations for the volume of a
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cylinder or frustrum (truncated cone) [129]. Altered circumference of the arm
provides a crude measure and limb volume is now the accepted standard. The water
displacement method is highly reproducible but is messy and can be logistically
impractical and arm volumes from circumferential measurements show good
correlation with water displacement data in repeated series [129-132], In Edinburgh
Breast Unit the lymphoedema therapists request that any patient with a perceived
increase in arm volume, i.e. any subjective increase in volume, be referred for
assessment in addition to patients with a measured increase in ipsilateral arm volume
of 10-20% compared with the premorbid measurement.
The incidence of lymphoedema of the arm is reported at between 2 per cent and 62.5
per cent [129]. These figures represent data collected on patients over the last century
and whom varying combinations of surgery and radiotherapy to the breast and axilla
has treated. Kissin et al studied 200 patients and found that the objective incidence of
lymphoedema was 25.5 per cent in all groups. The incidence of subjective late
lymphoedema varied according to treatment received. After radiotherapy alone the
incidence was 8.3 per cent rising to 9.1 per cent following axillary sampling plus
radiotherapy. Axillary clearance alone revealed an incidence of 7.4 per cent but when
patients had axillary clearance followed by radiotherapy, the incidence rose to 38.3
per cent. He concluded that radiotherapy should be avoided in axillary clearance
patients [116]. A more recent series of 121 patients treated by breast conservation
compared the rates of lymphoedema and other arm morbidities between groups of
patients according to the extent of axillary surgery [128], Results showed that
increases in arm circumference were significantly greater in patients having more
extensive axillary surgery when comparing axillary dissection to levels II and III
with axillary sampling. The lymphoedema rate in this study was 32 per cent.
Findings also confirmed those of Kissin et al reporting substantially higher rates of
arm swelling in patients having axillary dissection to level II followed by
radiotherapy. Patients having an axillary node clearance to level III did not have
radiotherapy to the axilla in this study. Both of these studies used a figure of 200mls
increase in arm volume as their definition of lymphoedema.
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In another study, there was no difference in lymphoedema rates whether or not
patients had post-operative radiotherapy [133] but this conflicts with most other
reports [116, 123, 129, 134, 135] .
A number of other reasons have been given as contributors to lymphoedema and
these include positive axillary nodes, tumour size and grade, pre-operative arm
volume and body mass index
Lymphoedema causes considerable distress to the patient and is a common fear
amongst pre-operative patients who often ask "Will my arm swell up, doctor?"
during their pre-surgical consultation. It can significantly impair a patient's quality of
life with 37.5% complaining of pain in the affected limb whilst choice of clothing,
sleep, ability to perform household activities or sports and problems with
employment may also contribute [136],
The treatment of lymphoedema falls into three main groups: conservative measures,
drug treatments and surgery. Conservative measures include massage, scrupulous
attention to personal hygiene to avoid skin and subcutaneous infection, compression
bandaging and dynamic muscle exercises. These comprise the mainstay of treatment
for lymphoedema.
The use of drugs in lymphoedema focuses on attempts to encourage breakdown of
proteins deposited within a brawny limb. The benzopyrone group of agents,
including coumarin, is thought to activate proteolysis by macrophages and to induce
an increase in total macrophage numbers. Administration may be topical or orally in
tablet form. The topical form of the drug is of limited use as it penetrates to a
maximum depth of l-2cm.
There are concerns that long-term use may lead to hepatotoxicity and 2-5% of
patients experience mild gastrointestinal upset. Autologous lymphocyte infusion has
been used and stimulates cytokine release by lymphocytes, which subsequently
activate macrophage proteinases. Such pharmacological therapy should be limited to
those patients in which conservative measures have failed. There is no place for the
use of diuretics in lymphoedema.
Surgery for lymphoedema can be divided into two groups, debulking procedures and
those that aim to improve lymphatic flow. Debulking operations involving radical
excision of large portions of tissue have met with little success although a recent
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study using liposuction has given promising initial results with an average reduction
in limb volume of 106% after twelve months [137]. A variety ofprocedures have
been used in an attempt to improve the lymphatic drainage of the affected limb
including rubber tubes, nylon thread, tube pedicles to carry fluid to the chest wall,
buried dermis flaps to encourage lymphatic drainage via the deep channels and
microsurgical lymphaticovenous anastamoses. The results have been mixed although
there has been some success with the microsurgical techniques. However, as with
drug treatments surgery is really only used in extreme cases resistant to conservative
management [129].
Evidence suggests that lymphoedema rates are falling with less aggressive modern
approaches to treatment [138] and this supports the introduction of more
conservative surgical techniques in selected patients.
1.7.2 Arm pain and altered sensation (neuropathy)
Both axillary surgery and axillary radiotherapy run the risk of damage to nerves
located within or crossing the axilla. Whilst all surgeons will endeavour to avoid
damage to the important nerves of the brachial plexus and the long thoracic and
thoracodorsal motor nerves, there is occasional difficulty in the preservation of the
sensory intercostobrachial nerve and lower intercostobrachial nerves during axillary
operations. A study in Edinburgh showed that a significantly higher frequency of
numbness was seen in patients whose intercostobrachial nerve was divided during an
axillary clearance than in patients having an axillary sample or an axillary clearance
in which the intercostobrachial nerve was preserved [139], Patients having a node
sample had significantly less numbness than those having a clearance even when the
nerve was preserved. In addition, significantly fewer patients experienced moderate
or severe pain if their nerve was preserved rather than divided during an axillary
clearance. These findings suggest that careful preservation of the nerve limits the
morbidity of an axillary clearance procedure and that axillary sampling causes less
damage to the nerve than axillary clearance. Ivens confirmed the presence of
significant arm morbidity six months-2 years following an axillary clearance
reporting subjective numbness of the ipsilateral arm as the commonest complaint in
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70% ofpatients with pain 33%, weakness 25%, limb swelling 24% and arm stiffness
15% as the other side-effects in descending order of frequency. Objective assessment
confirmed decreased sensation in 81 %, weakness in 27% arm swelling in 10% and
arm stiffness in 10% [140]. Similar results are reported in a longer-term study 2-5
years post axillary dissection. Warmuth et al reported a prevalence of 35% for
numbness, 30% for pain, arm swelling in 15% and restricted arm movement in 8%
[141]. Younger age was associated with significantly higher incidence of numbness,
pain and arm swelling. Arm swelling was also commoner in patients with a greater
body surface area and numbness commoner in smokers in this latter study. These
studies reveal that a significant proportion of patients experience pain and numbness
following axillary node dissection. These symptoms whilst mostly considered mild,
may contribute to psychological distress[142]. Numbness and pain in the upper arm
and axilla are most likely related to nerve damage and to the extent of axillary
dissection. Performing a more conservative procedure may help to limit these side
effects.
1.7.3 Restricted arm movement (shoulder joint stiffness)
Both surgery and radiotherapy are associated with a reduction in the range of
movement of the shoulder and about 5% develop a frozen shoulder [143].
Radiotherapy following axillary surgery appears to increase the risk of shoulder
stiffness both subjectively and objectively[84, 121]. A significant reduction in
shoulder stiffness is seen when surgery is performed without post-operative
radiotherapy suggesting radiotherapy is responsible for the morbidity here. Other
studies have reported incidence of shoulder stiffness as 12-21% after an axillary node
dissection without radiotherapy [144, 145], suggesting significant morbidity from the
surgery alone. The incidence of shoulder stiffness after a trial using axillary
radiotherapy alone to treat node-negative postmenopausal patients was reported as
35% subjectively and 17% when objectively measured [118]. From these studies it is
clear that restricted arm movement can occur with either surgery or radiotherapy
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used independently and the use of the two treatment modalities in combination
appears to lead to a magnified risk compared with their independent use.
Thompson et al reported reduction in upper limb mobility in all four groups of
patients treated by breast conservation whether they received axillary node sample,
axillary node clearance, axillary sample plus radiotherapy or level II axillary node
dissection plus radiotherapy but it was most pronounced in patients treated by level II
axillary dissection plus radiotherapy [128]. It was concluded that the incidence of
shoulder stiffness is related to the extent of axillary surgery and radiotherapy with
significant reductions in mobility seen when surgery and radiotherapy are combined.
The author recommended that level II axillary dissection plus subsequent
radiotherapy should no longer be performed.
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1.8 SENTINEL NODE BIOPSY
1.8.1 Background
The technique of sentinel node biopsy as a means of staging the axilla in breast
cancer is a highly topical and exciting concept. The 'sentinel node' concept was
described as far back as 1960 when Ernest A. Gould published a series of 28 total
parotidectomies during which; a specific lymph node ('sentinel node') at the junction
between the anterior and posterior facial veins was excised and sent for frozen
section histology. If the node was shown to be positive, a radical neck dissection was
carried out. If the node was negative, no further surgery was performed. Follow-up
of five patients who had malignant parotid tumours and a negative sentinel node
revealed no evidence of recurrence or metastasis [146].
Ramon Cabanas described the sentinel node as a specific lymph node centre to which
cancer cells from a tumour would spread to first. He used the technique of lymphatic
mapping in penile carcinoma between 1965 and 1973 by injecting contrast material
into the dorsal lymphatics of the penis or the dorsum of the foot to follow the
drainage of contrast to the inguinal lymph nodes. It was observed that there was a
fairly constantly located node to which the tumour would always drain first. It was
located in the superficial epigastric group of nodes within the inguinal region close to
the superficial epigastric vein. There were lymph node metastases in 33% of patients
in whom sentinel node biopsy was performed and in 80 per cent of these the sentinel
node was the only node to contain metastatic disease. In no patients was the sentinel
node biopsy negative when other nodes were found to be positive. Cabanas
concluded that anatomically, clinically and pathologically the sentinel node was the
first site of metastasis and may be the only node involved. He recommended bilateral
sentinel lymph node biopsy followed by inguinal lymph node dissection for positive
cases. If the sentinel node is negative, he recommended no further surgery in the
initial management of the primary cancer [147]. Cabanas' study was criticised for its
small patient numbers and for the loss to follow-up of many of his patients.
Subsequent use of the technique in penile carcinoma as recommended above led to
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early regional recurrence in some cases [148] and the technique was not thought to
be reliable.
The next person to use the technique was Donald Morton from the John Wayne
Cancer Institute in Santa Monica, California. He presented a paper detailing the use
of patent blue V or isosulfan blue to identify the sentinel lymph node in 223 patients
with clinical stage I malignant melanoma. After induction of anaesthesia, 0.5-lml of
the dye was injected intradermally with a 25-gauge needle at the site of the
melanoma. The injections were repeated every 20 minutes during the procedure.
Repeated injections were thought to keep the blue dye flowing into the first echelon
sentinel node(s) and avoid errors in the identification of sentinel nodes. It was felt
that if sentinel nodes were not identified quickly then blue dye would pass into
higher echelon nodes leaving the lower ones only faintly stained as the dye filtered
through leaving higher nodes more deeply stained and mistaken for true sentinel
nodes. The injection site was gently massaged to promote the passage of dye along
the lymphatics. An incision was then made over the regional lymph node basin and
the lymphatic channel from the primary site was dissected carefully away from the
subcutaneous fatty tissue of the lymph node basin to the draining lymph node(s)
which stained blue. In this way the sentinel lymph node was distinguished from other
lymph nodes of the lymphatic basin. The surrounding area was then examined for
additional blue nodes. Sentinel nodes were sent separately for frozen section and
routine haematoxylin and eosin histological examination. Lymph nodes were also
stained using immunohistochemical techniques using antibodies to SI00 protein and
the melanoma-reactive monoclonal antibody NKI/C3. Patients went on to have
excision of their primary melanoma following this and completion of the regional
lymph node dissection. The incidence of metastases in the sentinel nodes and other
lymph nodes was measured. Morton identified a sentinel node in 82% of cases and
18% (47) of these contained metastases. He claimed a false negative rate of 1% with
2 positive cases identified from other nodes when the sentinel nodes were negative.
However, his results actually showed a false negative of 4%. He concluded that the
technique could accurately identify patients with nodal metastases and stage I
melanoma who would benefit from radical lymph node dissection [149].
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The technique was first used in breast cancer by Armando Giuliano also at the John
Wayne Cancer Institute with the help of his colleague Donald Morton. He used a
similar technique of injecting isosulfan blue dye in a volume of 3-5 mis directly into
the breast mass and surrounding breast parenchyma. Injection was performed after
induction of anaesthesia approximately five minutes before axillary incision. Sentinel
nodes were identified in 65.5% of procedures. Nodal status was accurately assessed
in 109 of 114 cases (95.6%) in which the sentinel node was identified. The false
negative rate was claimed to be 4.3% in this series. This percentage was actually the
failure rate of the technique's prediction of axillary status however, the false negative
rate (i.e no of false negatives/no of true positives plus false negatives) being 11.9%
(5/42).
The rate of axillary metastases detected in sentinel nodes was 32.4% (37/114)
compared with 35.6% of cases in total suggesting the techniques accuracy is close to
that of a complete axillary dissection. Giuliano performed an interesting analysis to
determine whether the uptake of blue dye by lymph nodes containing metastases was
random by examining all the nodes of 14 cases in which only one positive lymph
node and at least one sentinel node were identified. Of the 285 lymph nodes
examined, 18 were sentinel and 13 of these (72.2%) contained metastases. Only one
of 267 non-sentinel lymph nodes contained metastases making it highly statistically
unlikely that these findings were by chance alone. Giuliano demonstrated the
presence of a learning curve for the clinician performing this technique with
increasing identification of sentinel nodes as experience is gained. This is an
important consideration for new surgeons learning the technique. These findings
were supported by a similar study by Guenther et al [150],
In a follow-up study, Giuliano's identification rate of sentinel nodes increased to
93.5% with a 0% false negative rate [151]
Giuliano went on to perform another study this time looking at histological methods
of increasing the accuracy of axillary staging with SNB. He used serial sectioning of
lymph nodes and immunohistochemistry with antibodies to cytokeratin to examine
sentinel nodes and found a highly significant difference in the number of
micrometastases identified in sentinel nodes as opposed to non-sentinel nodes [152].
These results however, are significantly flawed in that Giuliano uses a completely
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different technique to examine the non-sentinel lymph nodes than he does to examine
sentinel nodes using only routine H&E staining of fewer levels of the lymph node as
opposed to immunohistochemistry and H&E staining in multiple sections of sentinel
nodes. He also fails to report his false negative SNB cases in this study excluding
them from his results.
Krag and Alex first studied the use of a radioisotope in cats to identify sentinel
lymph node locations pre-operatively with a gamma-detection probe and reported
results comparable to those using blue dye [153]. They went on to use the technique
in pilot studies in both malignant melanoma and breast cancer confirming its
potential for use as a mapping agent in humans[154, 155].
Reynolds et al studied the relationship ofpositive non-sentinel nodes to
clinicopathological features to identify which patients were most at risk of further
axillary node involvement following a positive sentinel node biopsy. Primary tumour
size and the size of sentinel node metastases were found to be significant predictors
of further axillary metastases in non-sentinel lymph nodes. From this information the
investigators proposed that completion axillary node dissection may not be necessary
in women with primary breast tumours 2cm or smaller and micrometastases rather
than macrometastases in the sentinel node [156].
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Another method of identifying sentinel nodes was introduced by van der Veen in
1994 using radioisotope and lymphoscintigraphy preoperatively to identify lymphatic
drainage patterns in stage I melanoma patients followed by blue dye injection after
induction of anaesthesia [158]. The use of isotope and patent blue V dye in
combination increased identification of sentinel nodes to 100% although only a small
number of patients were examined in this study. Pijpers used a similar technique and
achieved a SN identification rate of 100% in a series of 41 melanoma patients when
dynamic imaging was used following intracutaneous injection of technetium-99m-
labelled albumin. 93% of patients were blue dye-positive when identified. The
interesting feature of this paper was the use of dynamic lymphoscintigraphy. The
first draining lymph node was assumed to be the true sentinel node and 95% of
sentinel nodes were seen in the first 20 minutes of imaging. Dynamic imaging
allowed differentiation between spill and multiple sentinel nodes and also revealed
that the initial focus retained the highest fraction of radioactivity for at least 18
hours[159].
John Albertini from the Lee Moffitt cancer centre in Florida, first reported the
technique of combined lymphatic mapping in breast cancer. He suggested the
techniques were complementary and achieved a greater SN identification rate when
used together. He defined a sentinel node as any node staining blue and/or any node
with a radioactivity count greater than ten times that of a neighbouring non-sentinel
node (activity ratio greater than 10). The neighbouring non-sentinel lymph node was
removed as a control for background nodal radioactivity and radioactivity was
measured after excision (ex-vivo). Further lymph nodes were sought if the gamma
probe counted residual axillary radiation greater than 150% of the background count.
An estimate of the background count was made by taking measurements from four
areas in the axilla equidistant from the injection site and away from the SN [160].
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1.8.2 Injection technique in breast cancer
i. Site of injection
A variety of techniques have been employed for injection of lymphatic mapping
agents into the breast tissue including intra-tumoural, peritumoural and periareolar,
subdermal and intradermal.
The intra-tumoural method used by Giuliano in his early studies[157] has since fallen
out of favour. The puncture of tumour tissue percutaneously created concern that
seeding of metastases along the needle track was a possible risk with this technique.
Injection of dye into the tumour itself was also thought to lead to leakage of dye into
the peritumoural breast tissue because of the high interstitial and intercellular
pressures, which exist within tumours. This led to the development of the
peritumoural method of injection now commonly preferred. This method involves
injection of mapping substances at several points around the tumour in its immediate
vicinity in order to be absorbed by the lymphatics, which drain the tumour. Good
results are reported using this technique with consistent sentinel node detection rates
ofbetween 91-100% in the majority of studies [156, 160, 162-164, 168]
The presence of a rich layer of lymphatic vessels in the subdermal plexus of the skin
is well described in the literature and this is the rationale for using a subdermal
injection of mapping agent directly above the tumour. Veronesi et al who reported a
sentinel node identification rate of 98% using a single mapping agent successfully
employed this method of injection [161]. The periareolar injection follows a similar
principle to the subdermal injection by using the subdermal plexus of lymphatics as a
mapping pathway. This technique was compared to the peritumoural method in an
experiment using combined lymphatic mapping using blue dye and a technetium
99m-labelled colloid. Results showed a higher rate of identification of sentinel nodes
(100%) using the periareolar method compared with the peritumoural method [169].
Borgstein et al compared periareolar intradermal injection ofblue dye with
intradermal injection over the site of the primary tumour in patients having
peritumoural mapping with radiocolloid to verify whether the site of injection of blue
dye was related to the peritumoural localisation of sentinel nodes. They hypothesised
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that the skin envelope and the underlying glandular tissue of the breast share a
common lymphatic pathway to the same draining (i.e sentinel) axillary nodes.
Similarly, the circumareolar lymphatic plexus, on the external surface of the gland
substance, anastamoses with the subdermal lymphatic plexus of the overlying skin.
The results of the study showed that a sentinel node was identified in 96% ofpatients
and that 94% of sentinel nodes were localised simultaneously by both agents
regardless of the location of blue dye injection. The sentinel nodes were consistently
located in the same position in the lower axilla, almost without exception. They
reported that there was no concordance between site of tumour, injection site and
sentinel node targeting. They concluded that intradermal injection improves the
efficacy ofblue dye because transport by skin lymphatics is more rapid and reliable
than in the breast parenchyma.
Borgstein argues that parenchymal lymph vessels accompany the lactiferous ducts
centripetally to empty into the dense subareolar plexus of Sappey where pooling of
lymph from all parts of the breast occurs. Two enormous lymph trunks (vasa
lymphatica mammaria magna) leave the areolar region to course superficially
towards the lower axillary lymph nodes thus the subareolar plexus conveys lymph
produced by the whole breast towards the first lymph node filter of the axilla [170].
Van der Ent reported similar success using the intradermal technique following
relatively poorer blue dye mapping with the peritumoural technique [167].
Although there is rationale supporting each technique, there is no conclusive
evidence to support the use of one method over another in terms of success in
sentinel node identification. However, the periareolar and subdermal techniques
suggest a slight improvement in sentinel node identification rates possibly because of
the improved transit ofmapping agents along the subdermal plexus to the axillary
lymph nodes. The only method that appears to be limited is the intratumoural method
for the reasons described above and as such is probably best avoided.
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ii. Timing of injection
There have been a number of studies, which have included data regarding the timing
of injection ofmapping agents and timing of lymphoscintigraphy. These figures are
represented in table 1.2 below:
Table 1.2 Timing of injection relative to sentinel node identification
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Krag et al reported no relationship between method of injecting tracer, time interval
between injection of tracer and surgery and the success in identifying a sentinel node.
He did however, find an association between a prior excision biopsy, age 50yrs or
more, a primary tumour in a medial location and failure to identify a hot spot before
axillary incision [163]. The figures in table 2 above would tend to agree with Krag's
finding that sentinel node identification is not related to timing of injection of
tracer. Clearly a time interval is required to allow tracer materials to be absorbed into
the lymphatics and to pass to the lymph nodes, however. In the studies shown in
table 2, isotope was injected at least 2 hours and up to 24 hours pre-operatively.
From these results and from the finding of Pijper's study in melanoma patients
58
mentioned earlier in this chapter [159], there appears to exist a substantial time
interval during which successful lymphatic mapping is possible.
1.8.3 Injection volume
The role of injection volume in sentinel node identification is difficult to assess.
A wide range of volumes has been used in the various studies producing varying
success. For example, Krag [163]used a volume of 4mls technetium-labelled sulphur
colloid injected peritumourally and identified a sentinel node in 91.4% of patients.
Veronesi, on the other hand, injected only 0.2mls microcolloidal albumin
subdermally to obtain a 98% identification rate [161]. These figures may suggest that
the subdermal injection site rather than the injection volume has led to Veronesi's
greater success. The microcolloidal albumin tracer used by Veronesi however, has a
smaller particle size to the sulfur colloid used by Krag and this is another possible
explanation for the different rates of identification between the two investigators.
Giuliano used a volume of 3-5mls of isosulfan blue returning an identification rate of
93.5% [151]. Guenther used an identical technique with the same volume of
isosulfan blue and only returned a 71% identification rate of sentinel nodes [150].
Van der Ent obtained a 100% identification of sentinel nodes using 4mls Tc"m-
labelled colloidal albumin peritumourally and 0.5-0.8mls patent blue V intradermally
[167]. In this study he also included patients who had undergone previous excision
biopsy injecting tracer around the biopsy cavity rather than into it. A higher
radioactive dose of colloid (370MBq) was used in this study compared with the
majority of other studies in which doses of less than lOOMBq have generally been
used [156, 158, 159, 163].
It is impossible to make a definitive statement on the true role of injection volume
from these studies but results suggest that technique and site of injection may be
more important than actual volume of injection.
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1.8.4 Mapping agents
The various types of lymphatic mapping agents are considered in this section with
respect to past performance, particle size and lymphodynamics.
i. Aqueous dye agents
A number ofblue staining dyes are commercially available for use in lymphatic
mapping. Patent blue V (Laboratoires Guerbet, France), a triphenylmethane dye, is
commonly used in Europe for this purpose. It is available as a 2.5% solution
distributed in 2ml glass vials and is commonly diluted with a similar volume of 0.9%
sodium chloride solution or 1% lignocaine hydrochloride prior to injection although
it can be injected undiluted. It costs £4.80 per vial in the United Kingdom. Patent
blue V is also used as a food colour.
In America, isosulfan blue (Lymphazurin 1%, Hirsch Industries inc., Richmond, VA)
[151] is more widely used for lymphatic mapping and is administered as above.
Methylene blue has been used in the past but has been associated with fat necrosis of
the breast so is not recommended for lymphatic mapping in these circumstances.
All of the blue dye agents pass rapidly into the lymphatics and into the regional
lymph nodes so timing of injection is crucial in identification of the first echelon
lymph nodes in contrast to timing of radiopharmaceutical injection, which allows a
significant time interval in which to inject as described above in section 1.8.2ii. In
the case of breast cancer, it has been recommended that blue dye should be injected
into the breast parenchyma around the tumour 5 minutes before the axillary skin
incision [157].
ii. Radiopharmaceuticals
Numerous radiopharmaceuticles have been used for lymphoscintigraphy including
technetium<)9m-labelled dextran, "mTc hydroxy ethyl starch, "mTc human serum
albumin and several labelled colloids including gold-198-colloid, "mTc stannous
phytate, "mTc sulphur colloid (99mTc-SC), "mTc antimony trisulphide colloid and
"mTc colloidal albumin (99mTc-CA). Among these agents only "mTc-SC and "mTc-
CA are commercially available and licensed for use in Europe.
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Colloid particles are mixed with the radioactive isotope technetium under aseptic
conditions to allow parenteral administration into the patient.
Technetium 99m is an artificially produced element from the decay of Molybdenum
99 (Mo99). There are no stable isotopes of technetium and it has almost no beta
emission but emits gamma rays rendering it suitable for gamma camera scanning and
gamma-detector probes [171].
"Mo ► "Tcm + P" + y Half-life = 67 hours
"Tcm ► "Tc + y Half-life = 6 hours
Technetium 99m (99mTc) must be made on a daily basis, as its half-life is only 6
hours.
The importance ofparticle size in the dynamics of lymphoscintigraphy has been
stressed by Ege in his early study into internal mammary lymphoscintigraphy [172],
Too large a particle size will lead to poor uptake of tracer into the lymphatics leaving
most of it redundant within the breast interstitium. In contrast, particles of very small
size will migrate too easily into the lymphatics, flowing rapidly through first, second
and third level nodes leading to either complete passage of tracer into the circulation
or 'lighting up' of multiple lymph nodes rather than one or two sentinel nodes.
Ideally, intermediate-sized particles are needed to allow passage into the lymphatics
and subsequent trapping in the level 1 (first echelon) lymph nodes.
Particle size of technetium-labelled colloidal albumin (Nanocoll "mTc-CA,
Nicomed-Amersham, Soren, Italy) ranges from 5-80nm. More than 95% of the
particles are smaller than 80nm and only 1% are larger than lOOnm [173].
Antimony trisulphide colloid (99mTc-ATC) is a small tracer measuring 3-12nm and
runs the risk of sampling non-sentinel nodes [174], During the 1970s and 1980s,
antimony sulphide colloid was favoured for lymphoscintigraphy as it showed up the
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whole lymphatic basin better than other agents allowing clinicians to look for filling
defects to predict axillary and internal mammary metastases[175], This feature is no
longer desirable for the practice of sentinel node biopsy.
Sulphur colloid (99mTc-SC) has large particles in the 100-400nm range which carry
the opposing risk of failed migration of tracer material [173]. This
radiopharmaceutical is favoured in the USA over colloidal albumin, which is the
favoured radiopharmaceutical for lymphatic mapping in Europe.
Technetium-labelled dextran has also been used with good success in sentinel node
biopsy for operable breast cancer with a reported sentinel node detection rate of 98%,
a sensitivity of 100% and no false negative cases [176].
Animal studies have suggested that the optimal lymph-node uptake of colloids
should be achieved with particle sizes between 10 and 50nm [173] although accurate
localisation of sentinel nodes has been demonstrated with all three of the commonly
used radiopharmaceuticals: sulphur colloid (99mTc-SC), colloidal albumin ("mTc-
CA) and antimony trisulphide colloid (99mTc-ATC) despite their different particle
sizes [173],
Paganelli et al reported on the optimal size of radiocolloid in SNB for breast
carcinoma examining three particles of different sizes. He concluded that a larger
size ofparticle achieves the desired results of localising one or two sentinel nodes
whereas the smaller particles led to detection of four or five sentinel nodes [177,
178].
Optimal particle size thus appears to be an issue of some controversy with mixed
reports of the optimum radiopharmaceutical. It is logical to assume that there will be
a variation in migration time to sentinel nodes dependant upon the size of colloid
used. Clearly, the timing of surgery must also play a part in the optimisation of the
technique to allow accurate and repeatable identification of the true sentinel node(s).
1.8.5 Lymphoscintigraphy and the lymphatic system
The lymphatic system is an extremely dynamic and reactive system. The normal 24-
hour lymph flow is 2-4 litres. Lymph flow occurs by contraction in skeletal muscle,
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the negative intrathoracic pressure during inspiration, the suction effect of high
velocity flow in veins in which the lymphatics terminate and rhythmic contractions
of the walls of the large lymph ducts. Lymph vessels have valves similar to veins,
which prevent backflow of lymph and ensure flow is directed towards the heart. The
rate of contractions in the walls of the lymphatic ducts increases in direct proportion
to the volume of lymph contained within them. Lymphatic flow can increase with
exercise by a factor of 10-30 and lymphatic channels are seen to contract and relax
every 2-3 minutes. There is evidence that these contractions are the principal factor
in propelling lymph. The lymphatic walls are permeable to macromolecules such as
proteins. One of the functions of the lymphatic system is to return protein that
accumulates in the interstitial fluid in the liver, intestines and other tissues back into
the bloodstream from whence it came. This accounts for 25-50% of the circulating
plasma protein each 24 hours [11]. When particulate substances of an appropriate
size are delivered to the interstitial fluid they can cross the lymphatic capillary wall
and enter the lymphatic lumen to pass along the lymphatic vessel towards the first
draining lymph nodes [178], It is in this way that tracer materials are absorbed from
the interstitial fluid after injection into the breast parenchyma.
The role of lymphoscintigraphy in breast cancer was originally proposed in 1978 by
Agwunobi and Boak [171]. In this study, pre-operative lymphoscintigraphy of the
axillary lymph nodes was performed following subcutaneous, periareolar injection of
lml of technetium-labelled antimony sulphide colloid into both breasts.
Interpretation of the photoscan images led to a sensitivity of 93% in detection of
axillary metastases confirmed by histological examination. In a similar study in
Edinburgh, a sensitivity of 90% was achieved in detection ofpositive axillary lymph
nodes in breast cancer patients [179] and several other studies produced similar
results [180, 181]. These findings were however, contradicted by other studies [182,
183], which failed to reproduce these results. Ege reported a large series of patients
who underwent staging of the internal mammary nodes by lymphoscintigraphy and
preliminarily suggested it's use may help to predict those patients at risk of relapse,
reporting a treatment failure rate of 19% in patients with axillary metastases and a
positive internal mammary scan [172], He failed to compare these results with those
patients with negative axillary nodes and positive internal mammary scintiscans
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however, making his proposals fundamentally flawed. The use of internal mammary
lymphoscintigraphy has thus not become a routine part of breast cancer staging.
Lymphoscintigraphy of sentinel nodes is considered an essential component of the
sentinel node technique by some researchers as it potentially increases the sensitivity
for detection of nodes [150, 159, 160], In one report the addition of a static scintiscan
identified 10% more sentinel nodes than by using the probe alone
preoperatively[174]. Breast drainage patterns do not always follow the expected
pathways with 32% of cases reported to show paradoxical drainage across the centre
line of the breast (i.e. outer quadrant tumours draining to internal mammary nodes or
inner quadrant tumours draining to axillary nodes) [184]. Lymphoscintigraphy can be
used to demonstrate such drainage patterns more accurately.
A variety of methods have been studied to identify the optimal scanning practice.
Pijpers examined timing of scintiscans at 2 or 18 hours post-injection of the
radiocolloid. He reported that the site and number of sentinel node foci were
unchanged in all but one patient in whom the first nodal uptake appeared only during
the 18-hour scan. "mTc-colloidal albumin was used in this study and was reported to
give good nodal retention without overspill in over 95% ofpatients. He concluded
that imaging was possible within a considerable time window post-injection of tracer
allowing flexible timing of surgery [174], Another study reported similar results
claiming that images taken 2hrs and 24hrs post-injection were identical 185]. Pijpers
also investigated the benefits of dynamic together with late static lymphoscintigraphy
in melanoma patients. Dynamic imaging revealed at least one sentinel node in 95%
of patients within the first twenty minutes post-injection and in all cases the first
focal accumulation retained the highest fraction of radioactivity for at least 18 hours.
Dynamic lymphoscintigraphy also differentiated between true sentinel nodes and
'spill' nodes (those drawing tracer from lymphatic vessels leading off from lower
echelon lymph nodes) [159], In the Milan study, scintiscans were taken at 15
minutes, 30 minutes and 3 hours post-injection of radiocolloid and the majority of
patients revealed a sentinel node after the 30-minute scan [161]. In this study
microcolloidal albumin was used as the tracer which has a smaller particle size than
standard colloidal albumin and hence will probably reach the sentinel node more
rapidly. It thus may be said that the exact timing of the scan is not critical but should
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probably be performed at least 2 hours post injection in the case of colloidal albumin.
Certain mapping agents may pass more rapidly to the sentinel node and in these
cases dynamic imaging may help to illustrate more accurately the true sentinel
node(s) before 'spill' nodes are picked up.
1.8.6 Gamma probe
The use of a gamma-detection probe to detect gamma rays emitted as radioisotope
decays is the current method used to locate the position of sentinel nodes before
incision to guide the surgeon to the most appropriate incision site. The probe is
constructed using a lead and steel coating to protect the tip from surrounding
interfering radiation. The radiation detector itselfmay consist of one of two types of
detection material: a scintillation detector (usually a single crystal of thallium-doped
sodium iodide or caesium iodide) or a semiconductor detector consisting of a solid
crystal of cadmium telluride or cadmium-zinc telluride.
Scintillation detectors work by emission of a tiny burst of light created by gamma
rays hitting the crystal. The photons of light thus emitted are amplified by a
photomultiplier tube and converted into a measurable electronic pulse, which is also
amplified to produce a measurable energy signal. The total light energy generated is
directly proportional to the energy from the absorbed radiation.
When a gamma ray impacts with a semiconductor detector the crystal material
becomes ionised producing charged particles creating a current, which is displayed
as a voltage signal. These charged particles are produced in a quantity 10-20 times
that of the photons produced by scintillation detectors making the potential for
energy resolution much greater in these types of detector. The sensitivity of the
detector requires a suitable energy window through which it can operate. This will
keep detection of scatter radiation to a minimum whilst still allowing detection of
higher energy gamma rays from the true radiation source, in this case the sentinel
node(s). Typically unscattered radiation is detected at 140kev (kiloelectronvolts)
with the limiting energy being approximately 200-300kev for acceptable sensitivity
of a semiconductor detector in clinical practice [178]. In addition to the energy
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resolution, the spatial resolution of the detector device is important. This allows two-
point discrimination between two adjacent energy sources. As the probe is moved
closer to the energy source, the spatial resolution will increase and vice-versa. Spatial
resolution in detection of axillary sentinel nodes is obviously of great importance
with many nodes lying close together in the axilla. Similarly, sensitivity is crucial to
avoid failed detection of nodes containing small amounts of radiation, which could
potentially contain metastases if they have drained directly from the tumour site.
It is possible to select a lower energy threshold and energy window on the probe
monitor, which will alter the sensitivity and spatial resolution of the probe. Reducing
the lower energy threshold leads to an increase in sensitivity and a corresponding
reduction in spatial resolution and vice-versa within the finite limits of the machine.
In clinical practice the depth of lymph nodes varies within the axilla and internal
mammary chain of lymph nodes. This factor should be taken into account
particularly when searching for deeper sentinel nodes containing weak radioactivity
when it may be necessary to reduce the lower energy threshold of the gamma-
detector in order to increase sensitivity. A reduction in the low energy threshold from
100 keV to 40 keV for example, results in an increase in the acceptance volume by a
factor of 5 therefore increasing sensitivity but reducing spatial resolution [186].
A number of gamma-detector probes are commercially available for clinical use in
radio-guided surgery and have been evaluated in studies simulating clinical
environments.
Britten studied the performance of five intra-operative probes for sentinel lymph
node localisation ranking them in terms directly related to their ability to localise
lymph nodes in the presence of scatter background radiation from the injection site.
Measurements were made of basic physical performance and clinical simulation with
Neoprobe 1500 (Neoprobe Corporation, Ohio, USA) and Europrobe (Eurorad,
Sevres, France) each with two probes and one probe with the Navigator GGS system
(US Surgical Corporation, Norwalk, USA). It was concluded that the Neoprobe
system with a cadmium-zinc telluride probe of 14mm outperformed the other probes
with the Europrobe system with 16mm caesium-iodide scintillator probe second
followed by the Navigator cadmium telluride probe, the Neoprobe system plus
19mm probe and lastly the Europrobe system with 11mm cadmium telluride probe.
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One criticism of this study would be that different energy windows were set for each
probe making the comparison non-uniform.
Tiourina studied the C-trak 19mm probe (Care Wise, USA), The Gammed II system
(Eurorad, France), the Neoprobe 19mm probe and the CTC-4 10mm probe (RMD,
USA). In her study the energy window standardised for each operating system and
was also examined using two different energy windows for each probe in addition to
simulation studies to more accurately measure the overall performance of each
probe.
It was concluded that the Neoprobe and C-Trak systems were superior to the other
two. A minimal analysis of absolute sensitivity and angular (spatial) resolution was
also performed on three additional probes confirming the Neoprobe to have superior
physical characteristics compared with the Europrobe 16mm and 11mm probes and
the Navigator 14mm probe. This side-study also noted that there was no facility to
set the upper energy threshold of the Navigator consul.
It may be concluded that a surgical gamma probe should meet the following
requirements:
a. High absolute sensitivity
Allows detection of low-uptake or deep-seated nodes
b. Side shielding
To absorb scatter radiation from injection points
c. High spectral (energy) resolution
Allows detection of sentinel nodes close to injection sites
d. High angular (spatial) resolution
To discriminate between two points (nodes) closely located
e. Ergonomic characteristics
Probe must be easy to use with optional audio signals to guide
surgeon during search procedures.
Radiation counts should be easy to measure and to read
In general when choosing a surgical gamma probe the surgeon and nuclear physicist
should work closely together taking into accounts the specific operational
requirements and budget of the department.
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Interference from electrocautery equipment can cause the radiation detector to pick
up unwanted signals so it is essential not to use diathermy whilst measuring
radioactivity counts. The radiation detector device should undergo a regular
sensitivity test to guard against gradual deterioration in performance over time.
1.8.7 Radiation exposure
It is important to realise correct safety procedures when handling radioisotopes. The
correct method of handling and administration of the radiocolloid will be covered in
the chapters on sentinel node biopsy in the results section of this thesis.
The department of medical physics at University of Wales College of Medicine,
Cardiff has estimated the following measurements of radiation exposure to patients
and personnel during a sentinel node biopsy procedure, see table 1.3 below.
Table1.3 Typical radiation doses per procedure when 20mbq Tc-labelled
















Using the above figures, if a surgeon performs 2 operations per week for 1 year then
his/her total exposure will be 4160microSv (4.16mSv) to the hands or 728microSv
(0.728mSv) to the whole body.
The legal limit for radiation exposure over 12 month period is 50milliSieverts i.e.
50,000microSv and a standard bone scan exposes the patient to 5000microSv (5mSv)
dose of radiation. The figures in table 3 obviously stay well within these limits.
The radiation intensity rapidly diminishes with increasing distance from the source
and follows the inverse square law. In other words, as the distance from the source is
doubled, the radiation intensity is reduced by a factor of four.
A workshop conducted in Adelaide in 1998 came up with slightly different figures to
those provided by The University of Wales College ofMedicine depending on
whether the surgeon handled the tissues manually or using forceps. The dose rates at
various distances from a 40MBq point source of "mTc using an equivalent dose rate
constant for soft tissue are shown in table 1.4.
Table 1.4
Equivalent dose-rate to soft tissue versus distancefor a 40MBq "mTc point source










(taken from Sentinel node biopsy in breast cancer: recommendations for surgeons,
pathologists, nuclear physicians and radiologists in Australia and New Zealand:
Kollias, J et al; Aust NZJ Surg 70 (2); 132-6)
It was calculated using the figures above that the dose to the surgeon's hands and
torso respectively during a 15-minute procedure using forceps to handle the tumour
would be 1.7pSv and 63pSv. If forceps were not used to handle the injected tumour
site, the radiation dose to the surgeon's hands would be approximately 1850pSv.
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This would allow a surgeon to perform up to 270 sentinel node biopsies per year
before the annual occupational dose limit of 500,000pSv (averaged over any 1cm2)
for the hands or skin is exceeded. The calculated doses to the pathologist's hands and
torso during a 30-minute examination of the tumour without using forceps would be
1850pSv and 1.7pSv respectively if the examination is performed at 30cm form the
pathologist's torso and 6 hours (one half-life) following the isotope injection. The
dose from the sentinel nodes would be of the order of 2-5% of the dose from the
tumour. Storage of specimens overnight to allow further decay of the radioisotope
can further reduce these doses.
Doses to the torsos of ancillary staff in theatre would be approximately 0.16pSv and
0.04pSv for a 15-minute exposure at 1 metre and 2 metres respectively[187].
These figures should help to reassure patients and personnel that radiation exposure
is minimal, conforms to legal requirements and does not place them at risk of
damaging doses of radiation.
A study performed in America evaluated radiation exposure to operating room
personnel, pathologist and equipment, from specimens during breast sentinel node
biopsy. Twenty patients having sentinel node biopsy 1.5-3 hours following injection
of 0.7-1.lmCi of "mTc were studied. Exposure rates to the surgeon's hands and
torso, scrub nurse, pathologist's hands and torso and to the operating instruments,
clinical waste containers, suction canisters and pathology slides were measured using
a calibrated Geiger counter. Results revealed maximum exposure was to the
surgeon's hands from the breast injection site before skin incision followed by the
pathologist's hands, surgeon's torso, scrub nurses torso and pathologist's torso. All
operating instruments and pathology slides had radiation equal to the background
rate along with 85% of clinical waste containers and 33% of suction canisters.
It was concluded that a primary surgeon could perform 2,190 hours, a scrub nurse
33,333 hours and a pathologist 14,705 hours of procedural work before surpassing
Occupational Safety and Health Administration limits [188].
A review article gives similar reassurance that personnel involved in sentinel node
biopsy are exposed to low levels of radiation and that these levels are not high
enough to justify designated radiation workers in theatre or in the pathology
laboratory [189],
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Whenever exposure to radiation is occurring, it is important however, to minimise
exposure by minimal time exposure to, maximum distance and ifpossible lead
shielding from the radiation source. Protective clothing such as theatre gloves and
gowns will help protect personnel from direct contact with radioactive agents. Good
practice must also be followed to correctly dispose of contaminated waste and to
follow local decontamination procedures in the event of spillages. The advice of the
local radiation protection adviser (RPA) should be sought at the outset prior to any
new plans to perform sentinel node biopsy using radiopharmaceuticles.
If administering radioactive substances, it is a legal requirement to possess or be
given written permission following training by someone in possession of a certificate
from the Department of Health according to MARS (Medical Administration of
Radioactive Substances) regulations.
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1.8.8 Pitfalls of SNB
i. Reasons for failed sentinel node identification
Guenther et al identified the presence of multiple nodal metastases as a risk factor for
a failed SN identification 150]. He noted a median of nine positive lymph nodes in
the axillae of a third of patients in whom a sentinel node could not be found. The
reason for this is likely to be caused by the blockage of lymphatics by tumour
deposits in more advanced disease thus blocking the normal pathway of tracers.
A higher percentage of failed detection (36%) in SN procedures is seen in patients if
previous excision biopsy of the primary tumour has been performed for example in
the case of diagnostic breast biopsy[190]. This is most likely caused by disruption to
the lymphatic vessels during breast biopsy leading to poor uptake of tracer from the
biopsy cavity. Hill et al found success in identifying a sentinel node was not related
to tumour size, type, location or multicentricity; the presence of lymphovascular
invasion; histological or nuclear grade or a previous excision biopsy [165]. This is in
contradiction to the findings by Krag as described above.
Multifocality of breast tumours was associated with a 50% false negative rate in
cases of sentinel node biopsy in the Milan study, most likely caused by multiple
lymphatic drainage pathways leading to skip metastases. It was suggested that such
patients should be excluded from sentinel node biopsy procedures [161]. This theory
conflicts with the theory of Borgstein that lymphatic drainage of the breast follows a
common pathway to the axilla along the two vasa lymphatica mammaria magna
lymphatics [170] which would suggest that multifocal tumours should not pose a
problem for sentinal node biopsy.
Reduced functional capacity of the sentinel node by tumour or fatty degeneration, as
occurs in older or obese patients can lead to poor uptake of tracer materials and
failure to locate a sentinel node [191]. This is a recognised entity based on surgical
and histological observation. If the sentinel node is replaced by fat, its localisation is
difficult due to decreased capacity of the node to retain the tracer. Increasing the dose
of radiopharmaceutical injected may help overcome this problem in elderly patients.
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The presence of a learning curve associated with successful performance of sentinel
node biopsy is well documented in some of the earlier studies [150, 157]. The false
negative rate and number of failures in identifications of a sentinel node fell with
each successive 100 cases performed in a study of 500 cases in America [192]. These
issues must be considered when selecting patients for a sentinel node biopsy. Whilst
the presence of clinically involved nodes and multifocality are absolute
contraindications to sentinel node biopsy and a previous excision biopsy a relative
contraindication, none of the other problems above should prevent a patient from
having a sentinel node biopsy if otherwise suitable.
ii. Side effects
A transient decrease in pulse-oximetry readings is frequently noticed with the use of
blue dye as a mapping agent as it causes blue discolouration of the skin and mucous
membranes [150, 193] and anaesthetists need to be warned of this as it is unlikely to
be a true drop in Pa02.
Hypersensitivity to patent blue V dye is occasionally encountered and has a reported
incidence of 2.2%. The commonest presentations of a hypersensitivity reaction are
local oedema or generalised urticaria but there have also been reports of
mucocutaneous oedema, bronchospasm and even cardiovascular collapse [194],
A study of over 600 patients undergoing sentinel node biopsy in the USA reported
severe anaphylactic reactions to isosulfan blue dye in 1.1% of patients subsequently
requiring vigorous resuscitation [195], There were no deaths or permanent
disabilities. It was concluded that lymphatic mapping with blue dye should be carried
out in an environment where staff are trained to recognise and treat anaphylaxis.
Patent blue V is excreted through the kidneys and discolours the urine for up to 24
hours post-surgery so patients need to be warned of this before they are injected with
blue dye.
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1.9 INTRAOPERATIVE ASSESSMENT OF LYMPH NODES
1.9.1 Frozen Section
The performance of accurate intraoperative histopathological assessment of surgical
specimens allows surgeons to make vital judgments regarding the most appropriate
operation to perform on a given patient under anaesthesia. This facility renders the
need for re-operation (a second procedure) redundant. Application of this principle to
the dilemma experienced by breast surgeons in deciding whether to sample or clear
the axillary lymph nodes could remove this uncertainty. Currently available
techniques for the intraoperative assessment of surgically excised tissue have so far
however, failed to match the accuracy of routine histological examination specimens.
The intraoperative histological assessment of axillary lymph nodes has been
performed using frozen section techniques[196]. The results of frozen section
analysis are somewhat variable in accuracy. The Edinburgh study of axillary lymph
nodes ofbreast cancer patients by frozen section reported a sensitivity of only 73%
for the detection of involved nodes with a false negative rate of 27%[ 197], The
specificity of frozen section analysis in this study was however 100%, as was the
positive predictive value but the negative predictive value was only 90%, leaving
10% of patients to face a second operation. Similar results are reported elsewhere
[198, 199]. Other studies have reported slightly higher sensitivities of 83% and 87%
and the same specificity of 100% [200, 201] An American study examined the
benefit of frozen section in lymph nodes according to tumour size and found that its
sensitivity ranged from 40% in Tla breast cancers to 76% in T2 breast cancers. It
was also found that frozen section was much better at detecting macrometastatic
disease (sensitivity 92%) than micrometastatic (sensitivity 17%) and it was
concluded that the benefit of intraoperative frozen section increases with tumour size
[202]. This finding was also found in a second American study[203]. A third
American study found the opposite result however, reporting false negative rates of
5.6% and 19% for T1 tumours and T2-3 tumours respectively [204]. Serial
sectioning of lymph nodes for intraoperative frozen section presents more of the
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lymph node for histological assessment and this has been reported to increase the
negative predictive value of the test to 95.4% with a false negative rate of 2.7%[205],
an improvement on conventional frozen section, which usually only samples the
node at two levels.
Despite the pitfalls of frozen section with its considerable proportion of false
negative results, it has been uniformly reported as having good specificity with no
false positive results. This is a reassuring characteristic if relying on the technique in
deciding to proceed to full axillary clearance on the basis of a positive result. With
more centres now introducing more detailed analyses such as immunohistochemistry
into their routine examination of lymph nodes however, a new problem is created in
that frozen section is once again made less sensitive in comparison, a finding
highlighted by Turner el al[204]. The finding of Veronesi et al that the sensitivity of
the technique improves with serial sectioning is certainly worth further study until
more sensitive techniques become available[205]. Unfortunately, performing serial
sections requires significant time and is labour intensive making it impractical in
many UK laboratories where staffing levels would not allow this.
1.9.2 Imprint Cytology
The technique of imprint cytology provides an alternative to frozen section for the
intraoperative examination of lymph nodes. It has been reported to have a sensitivity
of 100% in some studies [206, 207]. A study from Northwick Park Hospital by
Fisher et al, compared its sensitivity favourably with frozen section reporting a
sensitivity of 98% for imprint cytology and only 90% for frozen section in the
detection ofpositive lymph nodes from axillary node samples ofpatients with Tl-2
breast cancer [208]. This finding has also been repeated by another study using the
technique in patients having sentinel node biopsy for Tl-2 breast cancer reporting
sensitivities of 96% and 52% for imprint cytology and frozen section respectively
[209]. Other studies report similar positive results with over 99% accuracy[210,
211],Other studies have reported lower sensitivities [200, 212] similar to those with
frozen section.
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Imprint cytology has some advantages over frozen section. Firstly, it does not distort
or damage the lymph node leaving the entire specimen available for further analysis
by haematoxylin and eosin histology or immunohistochemistry if necessary.
Secondly, laboratory staff performing the technique have subjectively reported that
good quality imprints are quicker and easier to prepare than frozen sections of lymph
nodes[208]. Finally, imprint cytology does not require expensive equipment or
experienced technical staff to perform it [207] although it does require the expertise
of an experienced cytopathologist. One potential problem with imprint cytology lies
in the examination of small lymph nodes of less than 2-3mm in diameter when
slicing of the nodes to produce a cut "imprint" surface is technically difficult or
impossible. In such cases nodal material may need to be examined and sliced using a
fine tool under magnification to produce an imprint or simply processed for routine
paraffin section thus removing the possibility of an intraoperative cytological
diagnosis.
Imprint cytology has been used in the past as an adjunct to frozen section for
intraoperative diagnosis of malignancy in solid tumours with a reported accuracy of
93.7%[213]. Turner et al used the combined techniques of frozen section and imprint
cytology to examine sentinel lymph nodes from Tl-3 breast cancer patients reporting
an accuracy of 93.2% overall, detecting 98% ofmacrometastases but only 28% of
micrometastases[204]. This finding of poor detection ofmicrometastases is
unsurprising given that two further levels of the node were examined by routine
histology in this study following the imprint cytology and frozen sections of two
initial levels. As the clinical significance of lymph node micrometastases is still in
doubt as described in an earlier section of this thesis it is impossible to make surgical
decisions on the basis of these results. However, the finding of 98% of
macrometastases using this technique may have some use in avoidance of a second
axillary procedure if the decision to clear the remaining axillary nodes is made
intraoperatively.
Certainly the published reports suggest imprint cytology is at least as good as frozen
section with a number of studies reporting better results with imprints than with
frozen section. These findings together with the possible benefits of a quicker,
cheaper procedure justify more study into further improvement of this technique.
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SUMMARY
The currently widespread use of axillary levels I, II and III to describe the stepwise
progression of disease are no longer valid. These levels have been provided to give
surgeons a landmark to use when performing axillary dissections, the Pectoralis
minor muscle. This has been used as an easily located anatomical landmark but it has
no biological foundation. The lymphatic vessels and lymph nodes of the axilla follow
a more complex course as defined by lymphatic mapping. This can help to explain
why the reported 'skip metastases' have come about [160]. The following chapters
will attempt to provide useful information on the management of the axilla in breast
cancer.
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2. LONG-TERM RESULTS OF RANDOMISED
STUDIES OF AXILLARY CLEARANCE AND NON-
TARGETED AXILLARY SAMPLE
£_yriPH nod£S
Diagram of the axilla during an axillary clearance. The dotted line
marks the line ofdivision ofthe pectoralis minor muscle. This gives
access to the level II and III lymph nodes which are subsequently
cleared awayfrom the axillary vein.
Diagram of the lower axillary lymph nodes andpectoral nodes




Axillary surgery is the only reliable method to stage the axilla in operable breast
cancer. Most women having axillary surgery for breast cancer will have no disease in
their axilla. Randomised trials comparing sentinel node biopsy with conventional
axillary surgery will not provide information on its safety for many years. This
chapter presents long-term results for axillary recurrence and mortality from two
randomised trials comparing level III axillary node clearance with a four node
axillary sample.
Patients and Methods
870 women with clinically staged T1-3,N0-1,M0 breast cancer were prospectively
enrolled into two consecutive studies. In the mastectomy trial patients were
randomised to receive a four-node axillary sample or level III axillary clearance after
mastectomy (n=404) between 1980 and 1993. In the conservation trial patients were
randomised to receive a four-node axillary sample or level III axillary clearance after
breast conservation surgery (n=466) between 1987 and 1995. Patients who were
node-positive after an axillary sample received axillary radiotherapy. Data were
collected to compare axillary recurrence rates and survival between the two axillary
procedures. Node negative and node positive patients were also compared separately
for the two procedures.
Results
There was no difference in 5, 10 or 15 year survival between the groups treated by
sample or clearance in either overall (p=0.38) or survival in node negative (p=0.33)
or node positive (p=0.99) patients. There was a significant difference in axillary
recurrence at 10 years in favour of axillary clearance in both the node negative
(p=0.023) and the node positive (p=0.033) groups ofpatients. Patients having
axillary sampling with 4 or more positive nodes were more likely to develop axillary
recurrence than patients with 3 or fewer positive nodes (p=0.016). There was a clear
association between increasing number of involved lymph nodes and decreased
patient survival (p<0.0001).
Conclusions
Axillary sampling is a safe method of staging the axilla in operable breast cancer and
does not place patients at risk of decreased long-term survival but it is associated
with more axillary recurrences than complete axillary clearance. Patients with four or
more positive nodes after axillary sampling are best treated by axillary clearance
rather than axillary radiotherapy. Axillary recurrence developing after a node
negative sample can be treated by axillary clearance combined with systemic therapy
without affecting patient survival.
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2.2 PATIENTS AND METHODS
870 women with clinically staged T1-3,N0-1,M0 breast cancer were prospectively
enrolled into two consecutive studies on Edinburgh Breast Unit during the 1980s.
The aims of this study were to amalgamate data from both of these trials (originally
begun by Professor A.P. Forrest and continued by Mr U. Chetty and many other
surgeons working on the breast unit at that time), obtain up to date follow-up
information on patients enrolled in these trials and analyse the specific end points of
survival and axillary recurrence comparing outcomes of axillary node clearance to
levels I-III with a four-node axillary sample.
The mastectomy trial ran between January 1980 and October 1983; patients
undergoing mastectomy (Mx) were randomised to receive a four-node axillary
sample or level I-III axillary clearance. There was no age restriction as long as
patients were fit for both surgery and radiotherapy and had clinically operable breast
cancer (Tl-2, operable T3, N0-1, MO).
All patients in the mastectomy trial underwent bilateral mammography,
haematological and liver function testing, radiography of the chest and pelvis, liver
ultrasonography and skeletal scintigraphy. Any abnormal results led to further
investigation for metastases.
Exclusions were in-situ disease, Paget's disease of the nipple, multiple ipsilateral or
contralateral breast cancer and patients unlikely to participate in continuous follow-
up[214].
The conservation trial ran between 1987 and 1995; patients undergoing a breast
conserving wide local excision (WLE) were randomised to receive a four-node
axillary sample or level I-III axillary clearance. Patients were all under seventy years
of age and had unilateral invasive breast cancer measuring 4cm or less and no
evidence of metastatic disease.
All patients in the conservation trial underwent bilateral mammography,
haematological and liver function testing and radiography of the chest and pelvis.
Any abnormal results led to further investigation for metastases.
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Exclusions were multicentric disease, locally advanced disease (T4), previous history
of invasive cancer ofany site (excluding basal cell carcinoma) and fixed axillary
nodes (N2).
Records were searched by the author for data on survival and regional recurrence




1. Women undergoing mastectomy (Mx), n=404
















Systemic adjuvant therapy after surgery was based on node status and was identical
in both randomised groups
Axillary radiotherapy was given to all node-positive sampled patients apart from 5
patients who were randomised to the 'no radiotherapy' arm of the Scottish
Conservation Trial which was designed to determine whether or not radiotherapy








For mastectomy and axillary node sampling the breast was dissected from the
underlying chest wall from medial to lateral and the axillary tail mobilized from
serratus anterior between the pectoralis major and latissimus dorsi muscles up to the
point where it merged with the lower axillary fat. Nodes were sought by inspection
and palpation of the axillary tail and contiguous fat. Ifnecessary the dissection was
extended up above the intercostobrachial nerve, which was preserved. The surgeon
was asked to identify and submit four separate lymph nodes for histological
examination.
Mastectomy with axillary node clearance was performed by the Patey technique,
with division and/or resection ofpectoralis minor to facilitate access to levels II and
III of the axilla. The neurovascular pedicle to latissimus dorsi was preserved. Fat and
nodal tissue was removed to the level of the first rib.
With breast conservation, the axillary sampling technique was performed through a
transverse incision between the latissimus dorsi and the pectoralis major muscles.
The axillary tail was mobilized away from the serratus anterior muscle and nodes
were identified by palpation in the lower axilla. If no lower axillary nodes were
palpated, palpable nodes from level II or interpectoral regions were removed.
Axillary clearance to level III was performed through a transverse axillary incision
with division of the pectoralis minor muscle. The thoracodorsal and long thoracic
nerves and vessels were preserved. The intercostobrachial nerve and lower
intercostobrachial nerves were divided in the majority of cases.
2.2.2 Radiotherapy
Patients in the mastectomy trial were given radical postoperative radiotherapy with
6MV X-rays to the axilla if they were node-positive following a sample. During the
course of the trial there were three modifications to the axillary radiotherapy
regimen. These were to reduce the dose from 42.5Gy to 40Gy and to increase the
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number of fractions from 10 to 20 in 4 weeks and to protect the shoulder joint with
lead blocks.
Patients in the breast conservation trial with a node-positive sample were given
axillary radiotherapy as a direct anterior field covering the axilla and supraclavicular
fossa with a posterior axillary boost bringing the mid-axillary dose to 45Gy.
No patient in the axillary clearance group received radiotherapy.
Five patients who were node positive after axillary sampling did not receive
radiotherapy as they were randomised to the 'no radiotherapy' arm of the Scottish
Conservation trial.
Thirty-nine patients who were node negative after axillary sampling did receive
radiotherapy to the regional lymphatics. These patients were entered into the
conservation trial pre-1990 at which time all patients having axillary sampling were
irradiated as a routine.
2.2.3 Follow up
Patients were followed up by clinical examination in surgical and radiotherapy
clinics at 3-monthly intervals for 2 years, 6-monthly intervals from 2-5 years and
then annually thereafter. Patients were also screened by annual mammography.
Minimum follow-up was 4 years, apart from 4 patients lost at 26, 36, 37 and 46
months.
2.2.4 Analysis
Kaplan-Meier survival curves were plotted for survival and axillary recurrence based
on 'treatment received' . Survival curves were compared using the log-rank test.
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2.3 RESULTS
There were 404 patients in the mastectomy trial; there were 3 protocol violations in
patients with in-situ carcinoma so 401 patients remained for analysis. There were 233
node negative and 168 node positive patients. At the time of analysis, 199 patients
had died, 28 from non-breast cancer causes.
There were 466 patients in the breast conservation trial; there were 12 protocol
violations, four patients had benign disease, seven patients had in-situ carcinoma and
one patient had distant metastases when randomised. Thus, 454 patients remained for
analysis. There were 310 node negative patients and 144 were node positive. At the
time of analysis 65 patients had died, 11 of these from non-breast cancer causes.
Five node-positive sampled patients did not receive axillary radiotherapy. One of
these patients developed regional recurrence in the ipsilateral axilla and
supraclavicular fossa and unfortunately died 58 months after presentation. Of the
other four, 3 were alive at follow up in 1999 and one was known to be alive in 1996.
None of these 4 has developed any recurrence at a mean follow up of 107 months
(8.9 years).
The mean follow-up was 4484 days (12.3 yrs) for women undergoing mastectomy,
2586 days (7.1 yrs) for women undergoing wide local excision and 3476 days (9.5
yrs) for the two groups combined.
The median follow-up was 5503 days (15yrs) for women undergoing mastectomy,
2650 days (7.3yrs) for women undergoing wide local excision and 3009 days
(8.2yrs) for the combined groups.
Results were analysed as four specific groups according to node status and axillary
procedure:
ANC -ve negative axillary nodes after level III axillary clearance
ANS -ve negative axillary nodes after 4-node axillary sample
ANC +ve positive axillary nodes after level III axillary clearance
ANS +ve positive axillary nodes after 4-node axillary sample.
The numbers of patients in the 4 groups for the mastectomy and conservation trials
respectively and the patient survival, numbers of deaths and axillary recurrences with
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percentages in each group are shown in tables 2.1 and 2.2. The same data combined


























ANC -ve 121 2(1.7%) 53 (35.5) 10 56.2%
ANS -ve 112 6 (5.4%) 44 (35.8) 6 60.7%
ANC+ve 81 2 (2.5%) 52 (61.8) 5 35.8%






















ANC -ve 139 3 (2.2%) 15 (7.9) 4 89.2%
ANS -ve 171 10 (5.8%) 16(8.2) 2 90.6%
ANC +ve 83 4 (4.8%) 18(21.7) 0 78.3%
ANS +ve 61 8(13.1%) 16(19.6) 5 73.7%

























ANC -ve 260 5(1.9%) 68 (21.1) 14 73.8%
ANS-ve 283 16(5.7%) 60 (19.5) 8 78.8%
ANC+ve 164 6(3.7%) 70 (40.9) 5 57.3%
ANS+ve 148 15(10.1%) 66 (39.7) 12 55.4%
Median follow-up 3009 days (8.2 yrs)
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There was a significantly higher rate of axillary recurrence in node-negative patients
who had an axillary node sample compared with those having a level III axillary
clearance (P=0.023). There was a significant difference in axillary recurrence in
favour of axillary node clearance in patients who were node-positive (P=0.033). The
results for axillary recurrence and survival from both trials combined were analysed
statistically with 5 and 10-year estimates for axillary recurrence and 5, 10 and 15-
year projections for survival and these are shown in table 2.4.
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value




NS-ve 283 3.3 7.0 89.6 82.0 67.1




NS+ve 148 7.5 10.7 74.1 57.4 46.9
The Kaplan Meier survival curves for axillary recurrence subdivided into node-
negative and node-positive patients are shown in figure 2.2.
There was no significant difference in survival between the groups treated by sample
or clearance either overall (P=0.38) or subdivided into node-positive (P=0.99) or
node-negative patients (P=0.33) as shown in table 2.4. These figures are displayed
graphically in figures 2.3 and 2.4
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All patients with axillary recurrence were also analysed as a separate group. The
mean time to axillary recurrence was 1627 days (4.5 years) for the combined group
with a range of 131-6505 days (0.4-17.8 years). Two patients with node-positive
samples recurred after nearly 18 years of follow-up. Patients having an axillary
clearance recurred slightly earlier with a mean time to recurrence of 1452 days (4
years) compared with 1689 days (4.6 years) in patients having an axillary sample.
Comparing sample with clearance recurrences, 45% of sample recurrences were alive
compared with 36% of clearance recurrences after a mean follow-up of 1349 days
(3.7 years) from time of axillary recurrence.
Synchronous distant metastases were present in 16% (5/31) ofpatients who had
axillary recurrence after node sample and in 36% (4/11) of patients who had axillary
recurrence after node clearance. The survival figures for axillary recurrence patients



























ANC -ve 260 5 1.9% 2 40%
ANS -ve 283 16 5.7% 8 50%
ANC +ve 164 6 3.7% 2 33.33%
ANS +ve 148 15 10.1% 6 40%
Mean follow up 1349 days (3.7 years) from time of axillary recurrence
There was a significant difference in axillary recurrence in node-sampled patients
with four or more positive nodes compared with those having three or fewer nodes
91
positive (P=0.016) suggesting axillary radiotherapy is under treating this group.
There was no such difference in the axillary clearance group (P=0.258). These results
are displayed in figures 2.5 and 2.6.
There was an overall negative association between survival and the number of






























Axillary recurrence after node sample subdivided by
























Axillary recurrence after node clearance subdivided





i i i i i i








With no reliable non-invasive method of staging the axilla, it is still necessary to
surgically excise axillary nodes to stage the axilla in operable breast cancer. Sentinel
node biopsy is currently under trial as a minimally invasive technique for axillary
staging. Long-term results will not be available for many years to prove the safety of
this technique. Our results demonstrate that performing an axillary staging procedure
such as a four-node sample rather than a full axillary dissection does not place the
patient at risk of increased mortality over a 15-year period.
Axillary recurrence rates were higher in patients who were node-negative after an
axillary sample. This suggests that some patients are understaged by this method.
There are a number of reasons to explain this increased rate of axillary recurrence.
Four of the sixteen patients who developed axillary recurrence after node-negative
axillary sample had fewer than four lymph nodes removed on histology. Three of
these had only three nodes removed and one had only two nodes removed.
Understaging of the axilla in these four patients is probably due to poor surgical
technique in the early years of the trial when axillary sampling was relatively new.
This suggests there is a learning curve for this technique as has been demonstrated
for sentinel node biopsy.
Two further patients with a node-negative sample were shown to have axillary
metastases when their histology was reviewed by another pathologist as part of a
recent study[216]. This represents failure of the first pathologist to detect metastases
in these two patients.
The importance of lymph node micrometastases (those measuring less than 2mm in a
single lymph node) is not clear. Studies have reported a negative effect of axillary
micrometastases on overall patient survival[55, 217] and other reports have shown
that closer examination of lymph nodes by the pathologist either by haematoxylin
and eosin serial sectioning or immunohistochemistry leads to up to 20% more
metastases being discovered[48]. Another study looked at the importance of
micrometastases detected by serial sectioning and immunohistochemistry (IHC)
according to tumour histology and concluded that micrometastases detected using
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IHC in cases of lobular carcinoma was prognostically unimportant but that serial
sectioning and examination using H&E was prognostically significant in 120 patients
in whom recurrence and survival were adversely affected[66]. These findings
suggest that some node negative patients will have micrometastatic deposits present
in lymph nodes, which are missed by routine histological examination. As fewer
nodes are examined in a node sample, the potential to miss such deposits may be
greater than with a node clearance in which larger numbers of nodes are examined
thus increasing the potential metastatic yield.
Another reason for axillary sampling missing involved nodes is the presence of
'skip' metastases. The incidence of skip metastases is reported at between 1% [218]
and 25% [101] although most reports give an incidence between 1 and 5%[41, 219,
220]. Even with axillary clearance involved nodes may be missed [221] and the most
frequently missed areas reported in this study were the interpectoral area and the area
lateral to the subscapular vessels in level I. Interpectoral nodes are involved in up to
14% of patients with operable breast cancer and in a small number ofpatients no
other disease exists in the other axillary nodes[222]. When sampling the lower axilla
it is worth examining these areas paying particular attention to the axillary tail of the
breast for very low intra-mammary nodes which are sometimes overlooked and may
be the first location for axillary spread.
Overall mortality was not affected by axillary sampling and salvage surgery
combined with systemic therapy appears to be an effective treatment for patients who
relapse with axillary recurrence. It may be suggested that because more patients in
the sample group had axillary recurrence than in the clearance group and hence
received systemic therapy, that this may unfairly boost the sample group's survival.
Looking at the data for node negative recurrences first; six more node-negative
sample patients (2.1%) survive after axillary recurrence than node-negative clearance
patients. If this affected survival then one would expect a rise of no more than 2.1%
in overall survival for the node-negative sample group. However, table 2.3 reveals a
non-significant 5% greater overall survival in the node-negative sample group
compared with the node-negative clearance group suggesting that other factors are
involved and that systemic therapy is not alone responsible for this. Even if this 2.1%
of patients surviving recurrence were subtracted from the overall survival then the
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figures would not be significantly altered. Similarly adjusted figures for node-
positive patients do not significantly affect overall survival.
Survival after axillary recurrence was worse in patients who underwent axillary
clearance than in those having an axillary sample. Reasons for this are unclear but
over twice as many clearance patients had synchronous metastases and axillary
recurrence than sample patients. The absence of any lymphatic filtering in the axilla
may explain any apparent easier seeding ofblood-borne metastases in the clearance
group. A sampling procedure may thus preserve this route of spread for cancer cells
by conserving the axillary lymphatic filtration system.
Patients who were node-positive after an axillary sample were treated by
radiotherapy to the axilla and supraclavicular fossa. There was a significantly higher
rate of axillary recurrence in the sample group ofpatients compared with those
having axillary clearance. The addition of simulation of radiotherapy in the
conservation trial together with the more accurate placement of the posterior axillary
field and a higher overall dose of radiation (45Gy) did not reduce axillary
recurrences in this group ofpatients. This suggests that axillary clearance gives better
regional control than radiotherapy as treatment for node-positive disease although
overall survival is not affected. This conflicts with results from the Institute Curie in
Paris [223] who compared axillary recurrence in patients having complete axillary
dissection with those having complete regional nodal radiotherapy after lumpectomy
and breast radiotherapy. However there was a significant difference in distant
disease-free survival in favour of the surgically treated group compared with the
radiotherapy group in this study. An American trial comparing axillary dissection
with axillary radiotherapy after mastectomy between 1971-1974 also showed no
difference in regional recurrence rates over ten years [89] conflicting with our data
although this latter trial also reported no difference in survival between the two
groups in keeping with our study. Table 2.1 actually shows a small non-significant
(p~0.5) survival advantage in favour of axillary node sample in node-positive
patients treated by mastectomy. A more recent (as yet unpublished) analysis by
Edinburgh Breast Unit with a median follow up of 17 years for patients in the
mastectomy trial showed a non-significant (p=0.66) 6% survival advantage for node-
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positive sampled patients (46% overall survival) compared with node-positive
clearance patients (40% overall survival) but reasons for this are unclear.
Our survival figures show a small, non-significant difference in node negative
patients in favour of axillary sampling. This is interesting given that these women in
the node-sampled group had a significantly higher number of axillary recurrences.
One possible explanation for this is the higher rate of metastatic recurrence in the
node-negative clearance group. Patients with an axillary recurrence following
clearance fared slightly worse then those following a sample suggesting that axillary
recurrence is more often salvageable when occurring after an axillary sample.
Our figures support the association between increasing node positivity and decreased
survival [143], In the node-positive sample group, patients with 4 or more involved
nodes had a significantly higher incidence of regional recurrence than those with 3 or
fewer nodes positive. This subgroup of patients is probably best treated by axillary
clearance as a secondary axillary procedure whilst those with 3 or fewer nodes
positive do appear to be adequately treated with axillary radiotherapy. Radiotherapy
after axillary sampling does carry an increased risk of restricted shoulder movement
compared with axillary clearance which increases arm swelling and is associated
with more frequent development of lymphoedema[84]. Nowadays, axillary clearance
has become our standard secondary treatment in all node-positive sampled patients
with 4 or more involved nodes.
In this analysis, five node-positive sampled patients did not receive adjuvant axillary
radiotherapy and thirty-nine patients who were node-negative after axillary sampling
did receive radiotherapy to the axilla. It may be fairly suggested that these patients do
not fulfil the trial guidelines. In view of this, a subsequent analysis excluding all of
these patients was performed in 2003 by the staff of Edinburgh Breast Unit to clarify
this point and it was found that there were no differences in terms of the statistically
significant findings reported in this chapter i.e. all of the significant findings
presented here remain relevant.
Patients who are clinically node negative are unlikely to have multiple involved
nodes and are now being offered sentinel node biopsy alone as primary axillary
staging as part of large randomised, multicentre trials comparing sentinel node
biopsy with standard axillary surgery such as the ALMANAC trial[224]. Initial
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results from randomised trials of sentinel node biopsy are encouraging but until long-
term figures are available, the technique is not recommended for use out with trials.
Our figures demonstrate the safety of a non-targeted 4-node axillary sample in
patients with stage Tl-3 breast cancer. Axillary sampling correctly predicted node
status in over 96% of patients and was associated with a false-negative rate of 9.75%,
similar to figures reported for sentinel node biopsy[150, 163, 165]. In Edinburgh, it is
our practice to perform axillary sampling in T1,N0 breast cancer with selective use in
T2,N0 breast cancer according to patient age, menopausal and ER status along with
patients' general health. The in-patient hospital stay for sample is shorter and post¬
operative arm morbidity is lower than for clearance[84]. In particular the incidence
of lymphoedema is significantly reduced[84]. Returning home early with fewer side
effects removes the anxiety associated with more prolonged hospitalization and
delayed recovery.
This study has demonstrated that axillary sampling is a safe method of staging the
axilla in operable breast cancer. Patients with 4 or more positive axillary nodes after
sampling are best managed by axillary clearance rather than axillary radiotherapy.
Axillary recurrence after node-negative sample is higher than after a node-negative
clearance but can be treated by axillary clearance and systemic therapy without
affecting patient survival.
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Notes on Trial Violations and Patient Recruitment
To address the problem of the trial violations, clearly it is less than desirable for
patients with benign disease and in-situ disease to have had axillary surgery. These
violations may perhaps be explained by the fact that at the time of recruitment,
cytological techniques were less well developed than they are nowadays and also
because patients were operated on based on frozen section histology of the primary
tumour on occasion. Both of these methods are associated with a false positive rate
leading to the inevitable inclusion of a small number of patients with benign disease
and in-situ disease. It is now the unit policy to reserve axillary surgery for patients
who have a clear diagnosis of malignancy based on triple assessment of clinical,
radiological and cytological or histological examination. Although only 466 patients
were recruited into the conservation trial over an eight-year period, many patients
were not included in the trial as they had impalpable, screen-detected cancers, which
were very small and had a low risk of lymph node metastases. It was thought that
these patients would be best treated by axillary sample rather than axillary clearance
to limit their morbidity based on previous results [121]. Similarly, other patients
were ineligible for the trial, as they required mastectomy to adequately treat their
primary disease. Only two consultant breast surgeons were working in Edinburgh
Breast Unit for the main period of recruitment and as such, the unit was treating far
fewer cancers than are being treated today on the unit providing another explanation
for seemingly low recruitment. It is hoped that these points adequately address any
possible suggestions of selection bias.
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Legends to Graphs and Tables
Table 2.1 Mastectomy trial patients subdivided into axillaryprocedure received
and node status. Numbers andpercentages for axillary recurrence
andpatient deaths including deaths from non-breast cancer causes
are shown along with a percentagefor overall survival.
Table 2.2 Conservation trial patients subdivided into axillary procedure
received and node status. Numbers andpercentages for axillary
recurrence andpatient deaths including deaths from non-breast
cancer causes are shown along with a percentagefor overall survival.
Table 2.3 Patients from both the mastectomy and conservation trials combined
subdivided into axillary procedure received and node status. Numbers
andpercentagesfor axillary recurrence andpatient deaths including
deaths from non-breast cancer causes are shown along with a
percentagefor overall survival.
Table 2.4 Combined trial data showing axillary recurrence and overall survival
analysed statistically with 5 and 10-year projections for axillary
recurrence and 5-year, 10-year and 15-yearprojections for overall
survival.
Table 2.5 Patients with axillary recurrence subdivided according to axillary
procedure received and node status. Numbers andpercentages of
axillary recurrences andfor survival after axillary recurrence are
shown.
Kaplan Meier curves are shown in figures 2.2-2.7 as follows:
Figure 2.2 Axillary recurrence rates comparing axillary clearance with sample
subdivided into node-negative and node-positive cases.
Figure 2.3 Overall survival comparing axillary clearance with sample.
Figure 2.4 The effect of node status on survival comparing axillary clearance
with sample
Figure 2.5 Axillary recurrence in node-sample patients subdivided by number of
positive nodes.
Figure 2.6 Axillary recurrence in node-clearance patients subdivided by number
ofpositive nodes
Figure 2.7 Survival according to the number ofpositive axillary nodes
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3. ALMANAC STUDY PHASE 1 - AUDIT PHASE
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INTRODUCTION
The ALMANAC study (Axillary Lymphatic Mapping Against Nodal Axillary
Clearance) is a two-phase multicentre trial to evaluate sentinel node biopsy in breast
cancer in the United Kingdom. The trial's principal investigator is Professor R E
Mansel of the University Department of Surgery, University College of Wales
College of Medicine, Heath Park, Cardiff CF14 4XN. Edinburgh Breast Unit is one
of the main centre's taking part in the trial.
Phase 1 will be an audit phase and Phase 2 a randomised trial comparing
conventional treatment of the axilla with sentinel node guided treatment of the axilla.
Mr U Chetty and Mr J M Dixon were the two consultant breast surgeons chosen to
perform sentinel node biopsy in Edinburgh during the two phases of the trial.
i. Audit phase - Phase 1
The primary objective of the audit phase is to validate each surgeon's ability to
localise the sentinel node in breast cancer. All surgeons who take part will perform
sentinel node biopsy in a minimum of 40 patients with invasive breast cancer using
the combined mapping technique of radiocolloid and blue dye followed by axillary
sampling or clearance according to the unit's routine policy. A localisation rate of
90% and a false negative rate of 5% or less in the last 40 consecutive cases is
required before a surgeon can proceed to the randomised phase (phase 2) of the trial.
A secondary objective of the audit phase is to follow-up patients for arm and axillary
morbidity. Health service resource use and quality of life after treatment of the axilla
will also form part of the national study and will not be covered in this thesis.
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ii. Randomised Phase - Phase 2
The primary objective of phase 2 is to compare sentinel node biopsy with
conventional axillary surgery. Three main outcome measures will be studied:
a) arm and axillary morbidity
b) resource costs
c) quality of life
Resource costs and quality of life are part of the national study and will not be
covered in this thesis.
The secondary objective is to record the incidence of local recurrence in the axilla for
the different axillary procedures.
In phase 2 patients will be randomised to either the control group who will have a
wide local excision or mastectomy plus axillary sampling or clearance according to
routine policy or the sentinel node biopsy group (study group) who will have a
wide local excision or mastectomy plus a sentinel node biopsy. Sentinel node
positive patients on routine histology will go on to have delayed treatment of the
axilla by surgery (axillary clearance) or radiotherapy. Sentinel node negative patients
will have no further axillary treatment. Patients who are node-positive after
conventional axillary surgery will go on to have adjuvant treatment according to unit
policies.
108
3.1 PATIENTS AND METHODS
3.1.1 Patients
83 patients with stage T1-2,N0,M0 invasive breast cancer were enrolled into phase
one of the trial.
Two patients had DCIS alone with no invasive cancer found in the operative
specimens histologically and were excluded from the results. Both of these patients
had clinical, radiological and cytological features of malignancy and it is the policy
of Edinburgh Breast Unit to perform surgery on the basis of such findings. These
cases represent the small group of patients in whom falsely positive triple assessment
can occur. Even if histological diagnosis is obtained using core biopsy, false positive
results occasionally still occur. Both of these patients had axillary samples and wide
local excisions of their disease and suffered no complication as a result of their
surgery.
Of the remaining patients 70 were T1N0M0 and 11 were T2 N0M0.
75 patients had axillary sampling following SNB
6 patients had level III axillary clearance following SNB
Patient age ranged from 31-80 years.
Tumour size ranged from 5-40mm radiologically and from 7-40mm histologically.
3.1.2 Methods
Inclusion criteria were: age 18-80 years, presence of invasive breast cancer proven
by cytology or histology, having an axillary procedure as part of the routine
treatment of the patient's disease, patient's informed consent in writing.
Exclusion criteria were in-situ breast cancer, clinically involved lymph nodes,
previous breast cancer in the same breast, multifocal disease, locally advanced
disease, pregnancy, previous axillary surgery, previous or existing limb swelling or
lymphoedema of the ipsilateral arm and history of allergy to human serum albumin
or patent blue V dye.
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i. Patient recruitment
Patients were chosen by consultants at the multidisciplinary meeting. Patients were
listed for a standard axillary procedure of either axillary node sample or axillary node
clearance according to the existing unit protocols plus sentinel node biopsy according
to the entry and exclusion criteria above.
Suitable patients were counselled during a 20-30 minute consultation, which
included a thorough explanation of the standard surgical procedure in addition to the
technique of sentinel node biopsy. Patients were given ample opportunity to ask
questions during and at the end of the consultation. A patient information sheet was
given to any patients who were interested in taking part following the consultation.
Patients were asked to return the signed consent form by mail if they agreed to take
part in the trial. Once consent was obtained isotope was ordered from the nuclear
medicine department for preoperative injection.
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ii. Preoperative assessment
A preoperative assessment of all patients was made and the following features were
documented:
Patient's height and weight
Side and site of the primary tumour
Clinical and radiological size of the tumour
Palpable or impalpable lesion
Screen detected or self-referred breast cancer
Mammographic abnormality ifpresent
3.2 ARM MORBIDITY
All patients had preoperative arm measurements documented as a reference point for
post-operative arm morbidity. The following measurements were made:
3.2.1 Arm volume
Right and left arm volume in mis.
Measurements for arm circumference were taken using a tape measure at 4cm
intervals along the length of the arm starting at the wrist 20cm from the nail fold of
the middle finger and ending at the junction of the arm and the axilla or as close to
this point as possible. All values were entered into the programmable calculator
®Lymcalc 1.0 supplied by Colibri Software Systems UK which uses a mathematical
equation to calculate the limb volume from your circumferential measurements. This
calculator is designed specifically for use by healthcare personnel in calculation of
lymphoedema.
Arm volume measurements are illustrated in figs 3.1 and 3.2.
Ill
Figure 3.1 Assessment of arm volume. Serial arm circumferences are recorded
starting 20cm proximal to the nailfold of the middle finger and then
every 4cm up to the axilla
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Figure 3.2 Measurement of arm circumference
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3.2.2 Shoulder joint mobility
Shoulder movements of flexion, abduction, and internal and external rotation.
Measurements were taken using a standard large-joint orthopaedic goniometer.
The table below and figures 3.3-3.6 describe and illustrate the methods used.
Movement Plane Axis Range





















Rotation at 90° abduction
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Figure 3.4 Measurement of shoulder flexion
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Figure 3.5 Measurement of shoulder abduction
3.2.3 Arm sensation
Arm and axilla sensation to pin-prick (fig 3.7) and light touch.
A 23 gauge needle and a piece of cotton wool were used to test pin-prick and light
touch respectively. All dermatomes of the upper limb were tested and any defect
carefully mapped and recorded as area in square centimetres.
Figure 3.7 Assessment of arm sensation to pin-prick
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3.3 QUALITY OF LIFE ASSESSMENT
Patients were asked to fill in a baseline quality of life questionnaire as part of a side
study carried out by the CRC Psychosocial Oncology Group, Department of
Oncology, University College London Medical School. Further questionnaires were
mailed to patients at one and three months post-operatively and returned to
University College London.
This study is not part of this thesis and its results will not be be discussed here.
3.4 SENTINEL NODE BIOPSY TECHNIQUE
A combined lymphatic mapping technique is performed using human colloidal
albumin radiolabeled with the isotope Technetium 99m (® Nanocoll) and Patent
Blue V dye (Laboratoire Guerbet, 16-24 rue Jean-Chaptal, 93600 Aulnay-sous-Bois,
France).
Both agents are injected peritumorally at the 3, 6, 9 and 12 o'clock positions around
the primary breast cancer in equal proportions.
3.4.1 Injection of Isotope
The nanocoll (£35 per dose) is injected in the nuclear medicine department usually
on the morning of surgery for afternoon operations or in the afternoon the day before
surgery for morning operations. A dose of 20MBq is used for same day injections or
40MBq for previous day injections. A volume of 2mls is used in each case, 0.5mls of
the isotope is injected in each area as described above. The time of injection is
recorded and the patient returned to the ward.
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3.4.2 Scintiscan
Two scintiscans of 10 minutes duration each are performed approximately 3 hours
after injection of isotope (fig 3.8). A straight anteroposterior (AP) scan is performed
and an oblique lateral at 30-60° from vertical. Two images are thus obtained showing
the injection site and in the majority of cases the sentinel node or nodes (fig 3.9). The
location of the sentinel node is marked on the axillary skin in the nuclear medicine
department to help guide the surgeon to the best site for the axillary skin incision (fig
3.10). Following scintiscan the patient is sent to the operating theatre.
3.8 Scintiscanner in the nuclear medicine department
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Figure 3.9 Scintiscan showing a single sentinel node in the axilla of a breast
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Figure 3.10 X-marking a sentinel node identified at lymphoscintigraphy
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3.4.3 Injection of Blue dye
A single vial containing 2mls Patent blue V dye (fig 3.11) is drawn up into a 5ml
syringe using a green (21 gauge) needle. A further 3mls of sterile normal saline
solution is also drawn up into the same syringe to dilute the dye to 5mls (fig 3.12). A
quarter volume (1.25mls) of this fluid is injected using a blue (23 gauge) needle into
each of the four locations peritumorally as described above approximately five
minutes before the skin incision is made (fig 3.13). The area of injection is gently
massaged concentrically towards the ipsilateral axilla to disperse the dye into the
lymphatic vessels (fig 3.14).
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Figure 3.11 Vials of Patent Blue V (Laboratoires Guerbet, Aulnay-sous-Bois,
Figure 3.12 Patent blue V diluted from 2mls to 5mls using 0.9% sodium chloride
Solution
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Figure 3.13 Peritumoural injection of Patent Blue V dye




Prior to incision a 10-second background radiation count is taken from the ipsilateral
upper arm using the gamma (©Navigator) probe (Navigator Gamma Guidance
System, by RMD for the United States Surgical Corporation, 44 Hunt Street,
Watertown, MA, USA.); figs 3.15-3.16. The gamma probe is also used to locate the
maximal radioactivity in the axilla representing the sentinel node location (fig 3.17).
The surgeon can then decide on the best incision site for retrieval of the sentinel
node. The time of the axillary skin incision is noted.
The preferred technique is to make the axillary incision first. A standard curvilinear
skin incision is made in an oblique/transverse orientation just below the hair-bearing
skin of the axilla. The wound is carefully opened through the fat layer and
clavipectoral fascia to expose the axillary fat and axillary lymph nodes. As soon as a
blue lymphatic is seen, it is followed using careful sharp and blunt dissection to its
draining lymph node, which is stained blue by the dye. The lymph node is mobilised
either digitally or using tissue forceps to retract it forwards on its pedicle taking care
not to crush the node itself. A 10 second count is taken using the gamma
(©navigator) probe and this is recorded. The node is excised by careful diathermy of
its blood and lymphatic supply or by using artery forceps and hand tied vicryl
ligatures to secure its blood supply prior to excision. A further 10-second count is
made outside the patient at a distance from the injection site to prevent contamination
of the recording.
The lymph node is then labelled separately, fixed in formalin and sent for
histopathology.
If there is no visible blue lymphatic, then radioactivity is sought using the gamma
probe. When an area of increased activity is found, the surgeon explores the area to
identify separate lymph nodes, which are then counted individually for 10 seconds as
above to confirm the presence of a sentinel node or nodes. Any nodes with a ten
second count greater than ten times the previously measured background count
qualify as a sentinel node whether or not they contain blue dye and they are
described as being 'hot'. They are removed, counted again for ten seconds outside
the patient and sent separately for histopathology. A sentinel node must contain blue
124
dye alone, radioactivity of greater than ten times background count alone or both
blue dye and radioactivity to qualify as a sentinel node. The process is repeated until
all 'hot' and/or blue sentinel nodes are removed.
If the primary breast cancer is sited very close to the axilla in the upper outer
quadrant of the breast or in its axillary tail, an alternative method is used excising the
primary tumour first followed by sentinel node biopsy. This removes the
radioactivity contained around the primary tumour and allows accurate readings to be
taken of sentinel node counts that would otherwise be contaminated by the close
proximity of the tumour.
Following sentinel node biopsy, the remaining axillary procedure is completed i.e
axillary node sample or axillary node clearance and the primary tumour is then
excised. Wound closure is performed according to the standard practice of the
surgeon but usually involves a two-layer closure with an absorbable monofilament
suture such as Dexon®, Monocryl® or PDS®. Two consultant breast surgeons
performed all operations in phase one of the trial. A 90% sentinel node identification
rate and a false negative rate of less than 10% were required to progress to phase
two.
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Figure 3.15 Navigator Gamma Guidance System, by RMD for the United States
Surgical Corporation
126
Figure 3.17 Search for sentinel node(s) using the gamma probe prior to axillary
Incision
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3.4.5 Post operative care
Patients were informed of the risk that their urine may be discoloured by the blue dye
for 24 hours post-operatively.
Patients were seen on the ward and educated on arm exercises to reduce shoulder
stiffness following discharge.
Any immediate post-operative complications were documented recording in
particular haematoma, seroma or infection of the breast or axilla, pneumothorax or
dye sensitivity.
3.4.6 Pathology
Pathology results from the surgical specimens were followed up and recorded for
each patient including histological type, presence or absence of associated DCIS,
special features, grade, lymphovascular invasion, oestrogen receptor status and
presence or absence ofmetastatic disease in each lymph node specimen.
3.4.7 Follow up
Patients were seen at 1 month and 3 months when their breast and axilla was
examined and further measurements were taken to assess arm morbidity.
Any further complications, surgical procedures or extra visits to their GP, practice




At least one sentinel node was identified in 79 (97.5%) of 81 patients (fig 3.18).
An average of 2.76 sentinel nodes were identified for each patient in whom a sentinel
node was identified
In 2 patients (2.5%), a sentinel node could not be found.
Of these, one patient had macroscopic tumour in the axillary lymph nodes visible at
surgery. The other patient was node negative but a sentinel node could not be found.
i. Blue nodes
178 blue nodes were found in 74 patients.
A mean of 2.2 blue nodes were found in each patient.
A blue staining lymph node was found in 91.4 % of patients.
ii. Hot nodes
202 hot nodes were found in 72 patients.
A mean of 2.5 hot nodes were found in each patient.
A 'hot' lymph node was found in 88.9% of patients.
The detection rate was 97.5% with both blue dye and nanocoll in combination.
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iii. Node positivity
Positive lymph nodes were found in 26.6% (21 of 79) of patients and in 76% (16) of
these the sentinel lymph node(s) was/were the only positive node(s).
iv. False negative sentinel nodes
There were no falsely negative sentinel nodes found, i.e. false negative rate 0%.
A sentinel node(s) is defined as falsely negative when routine histology finds it to be
negative in the presence of one or more positive non-sentinel lymph nodes from the
same patient.
Figure 3.18 Sentinel node identification rate
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3.5.2 Scintigraphy
Scintiscans showed 'hot' lymph nodes in 77.8% (63 of 81) of patients with a mean of
1.47 'hot' nodes per scan. A range of 0 to 5 nodes was seen on scintiscans. More 'hot
nodes were found at surgery, which suggests either greater sensitivity of the
Navigator probe or obstruction of some 'hot' nodes by tumour radioactivity on scan
imaging. Figs 3.19-3.23 illustrate the different types of scan pattern, which can be
expected.
Figure 3.19 Scintiscan showing simultaneous hot internal mammary lymph node
Figure 3.20 Scintiscan showing multiple hot nodes demonstrating 'spill' of tracer
and hot axillary node





Figure 3.21 Negative Scintiscan
ANTERIOR LT ANTERIOR OBLIQUE .
•
Figure 3.22 Scintiscan of axillary lymph node with laterally sited tumour
ANTERIOR LT ANTERIOR OBLIQUE
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Figure 3.23 Scintiscan of a patient in whom nine sentinel nodes were identified at
surgery showing lateral position ofprimary tumour with axillary






3.5.3 Internal mammary nodes
Seven patients (8.6%) had internal mammary nodes as sentinel nodes on scintiscan.
In two of these the internal mammary node was the only sentinel node. None of the
internal mammary nodes was positive on histology.
Table 3.1 summarises these figures:
Table 3.1
Number of SNs 2.76 nodes (mean)
Positive nodes 26.6% (SN alone in 76%)
Blue nodes 91.4% of patients
Hot nodes 88.9% of patients
Scintiscans
77.8% (mean 1.47 nodes per
scan)
Internal Mammary 8.6% (8 nodes in 7 patients)
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3.5.4 Complications
A post-operative complication was encountered in 19 patients (24%). Of these, six
patients had more than one complication.
Seroma of the breast was the commonest complication affecting 11 women (13.6%).
Breast wound infection was the second commonest complication in 4 (5%) patients,
followed by axillary wound infection and breast haematoma requiring incision and
drainage in 3 (3.7%) patients each. Table 3.2 summarises these and the less common
complications with actual patient numbers in parentheses.
Table 3.2
Breast seroma 13.6%(11)
Breast wound infection 5%(4)
Axillary wound infection 3.7%(3)
Breast haematoma requiring incision and drainage 3.7%(3)
Axillary seroma 2.5%(2)
Pneumothorax 1.2%(1)
Breast infection requiring incision and drainage 1.2%( 1)
Blue dye sensitivity 1.2%(1)
Breast haematoma treated conservatively 1.2%( 1)
Axilla haematoma treated conservatively 1.2%(1)
i. Blue dye tattooing
A number of patients were left with blue discolouration on the skin of the breast from
the patent blue injections.
Twenty-five patients (30.9%) showed tattooing at 1 month post-op.
Nineteen patients (24.4%) still showed tattooing at 3 months post-op. See Table 3.3
below. Figs 3.24-3.27 illustrate some problems with blue dye tattooing.
Table 3.3
Number of patients with tattooing/
total number of patients
% of patients with
tattooing
1 month 25/81 30.9%
3 months 19/78 24.4%
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Figure 3.25 Tattooing of breast skin adjacent to scar in another patient
Both of the above patients had persistence of tattooing at three months.
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Figure 3.26 Gross blue staining of the breast immediately post-operatively in a
patient with a breast haematoma, which was drained.














Arm morbidity was documented according to the following criteria:
1. Any degree of sensory loss or altered sensation
2. Increase in arm volume of lOOmls or more independent of the
contralateral arm. This figure has been used before[122] and was chosen
as opposed to the 200ml cut-off used in some studies of lymphoedema
[116, 128] as it was felt necessary to detect more subtle changes in arm
volume than these previous studies which have generally included more
invasive procedures such as axillary clearance rather than the theoretically
less invasive procedure of sentinel node biopsy.




At 1 month 13.6% of patients demonstrated arm sensory loss and 17.3% axillary
sensory alteration. Two of these patients displayed both axillary and arm sensory
alteration. In total, 28.4% of patients displayed some degree of altered sensation of
the arm, axilla or both at one month post-operatively. The area of altered sensation
ranged from 1x3cm (3cm)2 to 12x40cm (480cm)2.
At 3 months these figures dropped to 9% and 11.5% for altered arm or axillary
sensation respectively. One patient displayed both axillary and arm sensory
alteration. In total, 19.2% of patients displayed some degree of altered sensation of
the arm, axilla or both three months post-operatively. The area of altered sensation
ranged from 2x7cm (14cm2) to 32x12cm (384cm2).
Of the twenty-three patients with sensory alteration at one month, eleven had
complete resolution of their symptoms at three months. Of the fifteen patients with
sensory alteration at three months, three had normal sensation at one month and three
had a smaller area of altered sensation at one month than at three months.
Sensory loss @ 1 month 13.6% (11 of 81 patients)
(arm) @ 3 months 9% (7 of 78 patients)
Sensory loss @ 1 month 17.3% (14 of 81 patients)
(axilla) @ 3 months 11.5% (9 of 78 patients)
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ii. Arm swelling
Arm swelling was encountered in 9 patients (11.1%) at 1 month post-operatively and
in 18 patients (23%) at 3 months post-op. These figures with ranges and percentages
are shown in table 3.4 below:
Table 3.4
1 month 3 months
Number ofpatients with swelling (% of total) 9(11.1%) 18(23%)
Mean % increase in arm volume 5.2% 6.4%
Range of increase in arm volume (mis) 103-196 101-388




One month post-operatively, 63% (51 of 81 patients) had shoulder stiffness.
Three months post-operatively, 35.9% (28 of 78 patients) had shoulder stiffness.
Table 3.5 below shows the movements affected and the percentage of patients
affected by each movement at one month and three months. The range of shoulder
restriction in degrees is shown in the far-right column of the table. Figs 3.28 and 3.29




Pt. Number % of total range
flexion
1 month 27/81 33.3 10-65
3 months 9/78 11.5 12-33
abduction
1 month 31/81 38.3 10-66
3 months 16/78 20.5 10-52
internal
rotation
1 month 17/81 21 11-48
3 months 5/78 6.4 14-39
external
rotation
1 month 14/81 17.3 10-25





























Average tumour size 16mm
Range 7-40mm
3.5.7 Sentinel node pathology





Hottest sentinel node alone was positive
Hottest sentinel node plus other sentinel nodes positive
Sentinel node other than the hottest was positive
Unclear from pathology which sentinel node was positive
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3.5.8 Admission Time
Average admission duration was 2 days for patients having a node sample plus SNB
and 4.7 days for patients having a node clearance plus SNB.
3.5.9 Recurrences
One patient developed a 1cm subcutaneous deposit beneath the axillary wound site
and simultaneously developed pulmonary metastases.
This patient had a 20mm grade 3 ductal carcinoma ofno special type with
lymphovascular invasion and had a single sentinel node positive. She received
adjuvant radiotherapy to the breast and axilla and was systemically treated with
tamoxifen and chemotherapy.
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Figure 3.28 Arm morbidity
■ 1 month ■ 3 months
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Figure 3.29 Shoulder stiffness
■ 1 MONTH ■ 3 MONTHS
40
flexion abduction I. Rotation E. rotation
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3.6 DISCUSSION
Sentinel node biopsy using the combined mapping technique was associated with a
97.5% sentinel node identification rate. These figures support the use of the
combined agents as opposed to the use of single mapping agents as the sentinel node
identification rates with either blue dye or nanocolloid alone were 91.4% and 88.9%
respectively.
Of the two patients in whom a sentinel node was not found, one had macroscopic
tumour visible in multiple axillary lymph nodes at operation suggesting that she had
been clinically understaged and would not have satisfied the entry criteria for the trial
had her node status been clinically detected pre-operatively. This highlights the
importance of a careful clinical assessment preoperatively in order to select patients
correctly for sentinel node biopsies. However, as clinical examination is notoriously
unreliable at detecting axillary metastases it will not always be possible to do this
until a more accurate non invasive method of examining lymph nodes is developed
for identifying metastases pre-operatively. Lymphatic obstruction by tumour renders
lymphatic drainage patterns abnormal. Mapping of sentinel nodes is thus inaccurate
in patients whose lymph nodes are completely replaced by tumour as the nodes will
not absorb mapping agents normally and blocked lymphatic vessels will divert
mapping agents away from true sentinel nodes to other lymph nodes increasing the
likelihood of a false negative result. The technique is thus more suitable only for
those who are clinically node negative. If grossly positive nodes are unexpectedly
encountered at surgery during a sentinel node procedure then the procedure is best
abandoned and converted to an axillary clearance. The other patient in whom a
sentinel node was not identified was clinically and histologically node-negative and
was therefore a suitable candidate for sentinel node biopsy. This particular patient
was overweight and this is a potential cause for the difficulty encountered when
trying to identify a sentinel node. In the next chapter, the association of sentinel node
identification with body mass index is shown in figure 4.2 'Body Mass Index'. It is
made apparent that fewer sentinel nodes are identified in patients with a higher body
mass index. This is possibly caused by fatty degeneration of lymph nodes leading to
a high fat component to the lymph node, a phenomenon that has been described in
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the literature and is occasionally observed at surgery [163, 191]. Should difficulty be
encountered in identification of a sentinel node during surgery in a case such as this
where the axilla is not obviously involved then the conventional operation should be
reverted back to according to the unit policy. It may be wise to impose a time limit
on the sentinel node procedure to avoid excessive dissection when it is clear that a
sentinel node cannot be found. These cases illustrate two potential pitfalls of the
technique.
The use of lymphoscintigraphy helped to detect internal mammary lymph nodes in 7
patients (8.6%). Internal mammary node biopsy resulted in one pneumothorax and
one severe breast infection at the internal mammary node biopsy site requiring
incision and drainage of pus in the follow-up clinic. Internal mammary node
dissection as an addition to axillary dissection is not reported to improve disease-free
recurrence or survival[31]. This questions the need to perform internal mammary
node biopsy as part of a sentinel node biopsy procedure. Results are now available
from the ALMANAC study phase 1 in the United Kingdom and revealed internal
mammary sentinel nodes in 8% of cases, in keeping with the results from Edinburgh.
Of these 14% were involved by tumour, which comprised 0.5% of patients overall.
Only 0.2% ofpatients had involved internal mammary nodes and negative axillary
nodes. Certainly, internal mammary node biopsy is not routinely practised in the
majority of breast cancer units. It is believed by some that adjuvant breast irradiation
will adequately treat internal mammary nodes involved by tumour in the majority of
patients. If only 2 patients per thousand operated upon will have positive internal
mammary nodes and negative axillary nodes it is difficult to justify using internal
mammary node biopsy as a routine on all patients. However, with the availability of
lymphoscintigraphy and sentinel node biopsy this may adequately select the small
group ofpatients in whom the technique may be of some benefit.
Lymphoscintigraphy detected sentinel nodes in only 77.8% of patients whereas the
gamma probe detected hot nodes in 88.9%. This may be explained by the fact that
tracer material has had a longer time-period to travel to lymph nodes but could also
be due to masking of some sentinel nodes from the view of the gamma camera by
radioactivity from the tumour site. The failure of scintigraphy to detect some axillary
nodes found at surgery and the questionable patient benefit in removal of internal
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mammary nodes suggest that lymphoscintigraphy may be an unnecessary component
of the mapping technique. Omission of these procedures would lead to a considerable
saving in time and labour and would also prevent the delay to surgery, which was
frequently encountered when patients were having their scintiscans. The logistics
involved in performing lymphoscintigraphy and the cost:benefit ratio in terms of
additional relevant patient information gleaned from scintigraphy needs to be
addressed.
Tumour histological type has not been shown to influence the ability to identify a
sentinel node in previous large studies [165] of sentinel node biopsy and as numbers
were small in this study a further analysis of this particular aspect of sentinel node
identification was not performed although tumour characteristics are presented in
section 3.5.6 showing the vast majority of tumours (81%) to be invasive ductal
carcinomas with the remaining 19% being the special types or mixed tumour
histology.
The procedure was associated with a relatively high complication rate although the
majority of complications were minor. Breast seroma was the commonest
complication affecting 13.9% of patients with breast infection as the second
commonest complication. The repeated puncturing of breast skin for peritumoural
injections, the massage of the breast to disperse mapping agents and the local effects
of injection to the breast tissue such as oedema and mild inflammation are almost
certainly the likely cause of these adverse effects. One way to minimise these side-
effects would be to perform fewer needle punctures to the skin injecting the skin in
two places instead of four and directing the needle around the tumour but underneath
the skin. Similarly, a gentle massage technique for a shorter time would further
reduce local trauma to the breast tissue. To minimise breast infection, a single
intravenous dose of a prophylactic antibiotic such as co-amoxiclav given on
induction of anaesthesia should also be considered.
In this study we have used a 5ml volume of diluted patent blue V. Other studies have
used smaller volumes with equal success by using the intradermal or subdermal
injection route [161, 166, 167]. Injection of a smaller volume of dye into the breast
or subdermal area would reduce local oedema from injection and possibly reduce
seroma formation. It has also been reported, however, that an increased volume of
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radioisotope leads to better detection of sentinel nodes [225]. Studies of tissue
adhesives in rat mastectomy models have reported a decrease in seroma formation
with the use of polyethylene oxide hydrogel[226] and this may have a future role in
seroma prevention should human studies mirror these results. Other measures to
reduce seroma formation have been tried in mastectomy and plastic surgery patients
such as pressure dressings and suction drainage but these are not ideal. A pressure
dressing in a patient undergoing breast conservation may produce a concave
deformity of the normal breast contour and suction drainage itself can further
contribute to inflammation or infection.
A significant number of patients (30.9%) showed blue tattooing of the skin adjacent
to their breast scar at one month post-operatively. Of these, approximately 20%
fewer were affected at 3 months than at 1 month post-op although a quarter of the
total number of patients remained affected. In the majority of cases the tattooing was
only a faint blue but in a handful of cases staining was deeper. The discolouration
appeared to become fainter over time and none of the patients affected was unduly
concerned or distressed about this. Once this side effect became apparent, patients
were warned about the risk of blue tattooing of the skin during their pre-operative
trial counselling session at the staging clinic.
Nearly one in three patients experienced altered sensation to the arm, axilla or both at
one month post-operatively. This fell to just under one in five after three months.
This reduction in incidence of altered sensation suggests that at least some of these
patients are suffering from a transient neuropraxia of the sensory nerves rather than a
permanent loss of function. Serious nerve damage in these patients is thus unlikely
and recovery of function suggests bruising or stretching of the nerves during surgery
may be to blame for the transient loss of function here.
Six (40%) of the patients with altered sensation at three months had progression of
sensory alteration from their one-month measurements and of these, half (three
patients) of them were measured as having normal sensation at one month. It is
possible for neuronal damage to progress over a period of time following an injury,
which would explain the cases of the three patients developing further sensory
alteration. It is not apparent, however, why three patients should develop new
symptoms of sensory alteration at three months after an absence of symptoms at one
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month. If nerve damage were present one would expect to see some signs of this
clinically during the first month rather than signs to develop de novo at three months.
Perhaps the best explanation would be one of operator error in that the initial one-
month measurement may have been performed less than accurately and failed to
detect small areas of sensory alteration, which later manifested themselves as larger
areas at three months. This phase of the trial did not follow patients beyond three
months so it is not possible to comment on the later progress of these patients' signs
of sensory nerve injury although it would be reasonable to expect continued
improvement in the majority of cases.
Arm swelling was recorded in twice as many patients (eighteen) at 3 months as at
one month (nine). The extent of swelling was not large with a mean increase in arm
volume of 5.2% and 6.4% at one and three months respectively. Without a suitable
control group in this phase of the trial, it is impossible to determine the exact reason
for the increase in incidence of arm swelling at three months. It is possible that the
increased incidence of objective arm swelling may be related to patients' breast and
axillary radiotherapy which was usually given at six weeks post operatively rather
than resulting directly in relation to axillary surgery. It is known that the
development of lymphoedema is related to the extent of axillary dissection, axillary
radiotherapy and to the number of involved axillary lymph nodes[l 16] so it is likely
that the administration of radiotherapy at 5-6 weeks post-surgery leads to a
synergistic effect with axillary surgery to increase incidence of arm swelling at three
months. The incidence of lymphoedema seen here lies within published figures of
lymphoedema incidence of between 9-28% [116, 227] despite the use of the lower
threshold of 1 OOmls increase in arm volume as a reference point for arm swelling in
this study. Only one patient had an increase in arm volume of greater than 10% of the
pre-operative arm volume, at 14.4%. Patients with swelling of less than 10% are
rarely referred for physiotherapy as is not usually troublesome. These figures are
encouraging and whilst only preliminary, suggest that sentinel node biopsy does not
have an adverse effect on the development of lymphoedema of the arm. If the figure
of 200mls had been used as a threshold figure for arm swelling, no patients would
have had swelling at 1 month and only four patients had swelling of greater than
200mls at 3 months of follow-up thus demonstrating lower rates of arm swelling than
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reported in other series which have included patients having axillary clearance. In the
next chapter this will be examined again comparing axillary sample with sentinel
node biopsy. As the majority ofpatients found to have arm swelling of greater than
lOOmls did not complain of problems it may be that the figure of 200mls is more
clinically useful in detection ofproblematic swelling.
Shoulder stiffness occurred in almost two-thirds of patients at one month and this fell
to just over a third at three months. Whilst these figures appear quite high, they may
be explained by the fact that a very subtle definition of ten degrees loss of movement
was recorded as shoulder stiffness. This inevitably results in the detection of more
patients with shoulder stiffness than had a less subtle definition been used as a
reference point. It is reassuring to see the incidence falling over time and it would be
expected that this would continue to fall over time although follow-up beyond three
months was not part of this initial phase of the trial. Abduction was the most
commonly affected movement at both one and three months with flexion and
external rotation being affected similarly and internal rotation least affected. These
findings have some similarities with other reports, which suggest external rotation
and abduction is affected by radiotherapy [121] although in others flexion was most
affected by radiotherapy and a node clearance with external rotation being affected
by radiotherapy [84],
In order to minimise shoulder stiffness patients were encouraged to mobilise their
shoulder joints early and were given instructions on simple arm exercises before they
were discharged.
In summary, it appears that sentinel node biopsy of axillary lymph nodes in breast
cancer is a relatively simple and reproducible method of sampling axillary nodes. It
is associated with a low false negative rate and a high degree of accuracy. Both
consultant surgeons performing the technique reported good results, which were
more than adequate to progress to the randomised phase of the trial. Potential pitfalls
of the technique include patients with gross tumour of the axillary lymph nodes
highlighting the importance of good patient selection and obese patients in whom
fatty degeneration of lymph nodes may occur making sentinel node identification
less straightforward. Complication rates were a little higher than expected and were
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more severe in patients undergoing internal mammary node biopsy. These issues will
be evaluated further in the next chapter within the randomised phase of the trial.
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Phase 2 - Randomised Phase
The primary objective of phase 2 is to compare sentinel node biopsy with
conventional axillary surgery. Three main outcome measures will be studied:
d) arm and axillary morbidity
e) resource costs
f) quality of life
Resource costs and quality of life are part of the national study and will not be
covered in this thesis.
The secondary objective is to record the incidence of local recurrence in the axilla for
the different axillary procedures.
In phase 2 patients will be randomised to either the control group who will have a
wide local excision or mastectomy plus axillary sampling or clearance according to
routine policy or the sentinel node biopsy group (study group) who will have a
wide local excision or mastectomy plus a sentinel node biopsy. Sentinel node
positive patients on routine histology will go on to have delayed treatment of the
axilla by surgery (axillary clearance) or radiotherapy. Sentinel node negative patients
will have no further axillary treatment. Patients who are node-positive after
conventional axillary surgery will go on to have adjuvant treatment according to unit
policies.
In Edinburgh we have selected patients being treated by axillary node sample as their
conventional axillary procedure as the control group in phase 2 to be compared with
sentinel node biopsy. It was felt that patients selected for axillary node clearance
generally had larger tumours, stage T2 and above and hence the risk of axillary
metastases and false negative procedures was greater than in those selected for
axillary sample, generally stage T1 or small T2 tumours.
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4.1 AIMS OF PHASE 2
The aims of this part of the trial were to:
1. Compare the success of axillary node sample with the new technique of
sentinel node biopsy as a method of staging the axilla in stage T1,N0,M0
invasive breast cancer.
2. Compare the outcomes of the two groups for post-operative complications.
3. Compare the outcomes of the two groups for post-operative arm morbidity.
4. Identify specific patient and tumour characteristics associated with improved
sentinel node detection.
4.2 PATIENTS
At the time of analysis, 70 patients with clinical stage Tl-2, NO, MO invasive breast
cancer had been enrolled into phase 2 of the trial.
Three patients had in-situ disease alone with no invasive cancer found in the
operative specimens histologically and these patients were excluded from the results.
As stated for similar cases in the previous chapter, all of these patients had been
diagnosed with malignancy based on the triple assessment of clinical, radiological
and cytological examination, as is the policy of Edinburgh Breast Unit.
Of the remaining patients, 58 patients were stage Tl, NO, MO and 8 patients were T2,
NO, MO. One patient was stage T3, NO, MO after being found to have a tumour
measuring 55mm on pathological examination. This patient was randomised to
receive an axillary node sample.
Tumour size ranged from 0-40mm clinically, 5-37mm radiologically and 5-55mm
histologically.
Patients' age ranged from 32-79 years.
35 cancers were screen detected
48 palpable tumours, 19 impalpable
19 patients had radiologically guided breast wide local excisions.
33 patients had sentinel node biopsy and 34 patients had an axillary node sample as
their axillary staging operation.
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4.3 METHODS
Patients were selected according to the inclusion criteria for Phase 1 of the trial and
were randomised to receive a sentinel node biopsy alone or an axillary node sample.
Inclusion criteria were: age 18-80 years, presence of invasive breast cancer proven
by cytology or histology, having an axillary procedure as part of the routine
treatment of the patient's disease, patient's informed consent in writing.
Exclusion criteria were in-situ breast cancer, clinically involved lymph nodes,
previous breast cancer in the same breast, multifocal disease, locally advanced
disease, pregnancy, previous axillary surgery, previous or existing limb swelling or
lymphoedema of the ipsilateral arm and history of allergy to human serum albumin
or patent blue V dye.
Patients details were sent to the central trials office in Cardiff and patients were
randomised to receive sentinel node biopsy or standard axillary surgery.
4.3.1 Patient recruitment
Patients were chosen by consultants at the multidisciplinary meeting. Patients who
were listed for axillary node sample according to the existing unit protocols were
considered for entry into the randomised trial. It was decided not to include patients
having an axillary clearance as their routine surgery until sentinel node biopsy has
been proven to be safe. It was felt that these patients were at higher risk of nodal
disease and that they were at risk of being understaged by a sentinel node biopsy
should the technique prove to be inadequate at staging the axilla in the future.
Suitable patients were counselled during a 20-30 minute consultation which included
a thorough explanation of an axillary node sample in addition to the technique of
sentinel node biopsy. Patients were given ample opportunity to ask questions during
and at the end of the consultation. A patient information sheet was given to any
patients who were interested in taking part following the consultation. Patients were
asked to return the signed consent form by mail if they agreed to take part in the trial.
Once consent was obtained, patients were randomised to receive sentinel node
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biopsy or axillary node sampling. Isotope was subsequently ordered from the nuclear
medicine department for preoperative injection of patients randomised to receive
sentinel node biopsy.
4.3.2 Preoperative assessment
The pre-operative assessment was identical to that in phase 1 of the study and pre¬
operative arm measurements were taken as before to assess post-operative arm
morbidity for the two surgical techniques. Quality of life questionnaires were
completed as before as part of a side study carried out by the CRC Psychosocial
Oncology Group, Department of Oncology, University College London Medical
School. Further questionnaires were mailed to patients at one, three, six, twelve and
eighteen months post-operatively and returned to University College London.
The quality of life study is not part of this thesis and its results will not be be
discussed here
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4.3.3 Sentinel node biopsy technique
An identical surgical technique to that described in phase one of the trial was used.
Injection of radioactive isotope, Patent blue V dye and scintiscans were all performed
as described in the previous chapter for phase one of the trial.
4.3.3 Axillary node sampling surgical technique
The axillary sampling technique was performed through a transverse incision
between the latissimus dorsi and the pectoralis major muscles. The axillary tail was
mobilized away from the serratus anterior muscle and nodes were identified by
palpation in the lower axilla. If no lower axillary nodes were palpated, palpable
nodes from level II or interpectoral regions were removed. At least 4 lymph nodes
were removed for histology.
4.3.4 Post operative care
Patients were informed of the risk that their urine may be discoloured by the blue dye
for 24 hours post-operatively.
Patients were seen on the ward and educated on arm exercises to reduce shoulder
stiffness following discharge.
Any immediate post-operative complications were documented recording in




Pathology results from the surgical specimens were followed up and recorded for
each patient including histological type, presence or absence of associated DCIS,
special features, grade, lymphovascular invasion, oestrogen receptor status and
presence or absence of metastatic disease in each lymph node specimen.
4.3.6 Follow up
Patients were seen at 1 month, 3 months, 6 months, 12 months and 18 months when
their breast and axilla was examined for recurrence and repeat measurements were
taken to assess arm morbidity as compared with pre-operative measurements.
Any further complications, surgical procedures or extra visits to their GP, practice
nurse or to the hospital were documented at this time.
A measured increase of greater than lOOmls from the pre-op measurement in the
ipsilateral arm volume compared with the contralateral arm was recorded as
objective arm swelling. Ifboth arms had swollen equally then a general increase in
patient's weight was presumed and the increase in volume was not recorded.
Patients were asked to describe any perceived arm swelling as mild, moderate or
severe and this was recorded as a subjective increase in arm volume.
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Failure to attend follow-up appointments for arm measurements
One patient did not attend (DNA) at 1 month, 2 patients DNA at 3 months, 6 DNA at
6 months, 11 DNA at 12 months and 16 DNA at 18 months (13 of these had yet to
attend their 18 month appointment).
One patient declined follow-up before her 1 month appointment, one patient declined
follow up after the 1-month appointment but before her 3-month appointment.
These patients were excluded from the figures when calculating percentages. These
patients were often required to attend extra appointments for follow-up arm
measurements to assess arm morbidity and these non-attendance statistics refer to






Ductal carcinoma no special type 44 24 20
Lobular carcinoma 9 5 4
Mixed ductal/lobular 2 2 0
Tubular 5 1 4
Mucinous 2 1 1
Medullary 1 0 1
Cribriform 1 0 1
Other mixed 3 1 2
Associated features
DCIS 33 15 18
LCIS 5 2 3
LCIS and DCIS 1 1 0
Cribriform in-situ 2 1 I
No associated features 26 15 11
Lymphovascular invasion
Present 9 5 4
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4.4.2 Lymph node characteristics
i. Node status
There were 55 node-negative and 12 node-positive patients (17.9%).
Eight patients (24.2%) had positive sentinel nodes.
Four patients (11.7%) had positive axillary node samples.
Chi-squared analysis x2=0.5, p«0.5.
ii. Node identification
119 sentinel nodes were found in 33 patients having a sentinel node biopsy.
The mean number of sentinel nodes identified was 3.6 per sentinel node biopsy.
163 nodes were found in 34 patients having an axillary sample.
The mean number of sampled nodes was 4.79 per axillary node sample.
iii. Hot nodes
A total of 101 hot nodes were found in 33 patients.
100% ofpatients had at least one hot sentinel node identified.
Of the 101 nodes, 63 nodes had a radioactivity count greater than 100 counts per 10
seconds and 38 nodes had a radioactivity count of less than 100 counts per 10
seconds.
A mean of 3.1 hot nodes were found in each patient.
iv. Blue nodes
85 blue nodes were found in 33 patients. A mean of 2.6 blue nodes were found in
each patient.
100% ofpatients had at least one blue node.
52 nodes were deeply stained with blue dye and 33 nodes were faintly stained with
blue dye.
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v. Hot and Blue nodes
67 nodes were both hot and blue.
A mean of 2 hot and blue nodes were found in each patient.
vi. Internal mammary nodes
Two patients (6.1%) had internal mammary nodes biopsied when their scintiscans
revealed drainage to the internal mammary nodes. In neither case was the internal
mammary node the only sentinel node. None of the internal mammary nodes was
positive.
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vii Sentinel node pathology
Sentinel nodes were positive in 8 patients:
Hottest sentinel node alone was positive
Hottest sentinel node plus other sentinel nodes positive




Of these patients, two (25%) had lymphovascular invasion on histology. Three
patients had grade 1 tumours, three were grade 2 and two were grade 3. Tumour
histology was ductal carcinoma no special type in five of these patients, lobular
carcinoma in one patient and mixed types in one patient.
viii Axillary node sample pathology
Four patients had a positive axillary sample. Of these, three had lymphovascular
invasion on histology. Two patients had grade 2 tumours and two had grade 3
tumours.
Three of these patients' histological tumour type was ductal carcinoma no special
type and one patient had a lobular carcinoma
ix Recurrences
At the time ofwriting there had been no axillary recurrences recorded with a median
follow-up period of 18 months.
4.4.3 Scintigraphy
Scintigraphy was positive in 75.8% ofpatients scanned.
48 nodes showed on scintigraphy in 25 patients.
8 patients had negative scintigraphy with no hot nodes showing.
Two patients (25%) with positive sentinel nodes had a negative scintiscan.
A mean of 1.45 nodes were found per scintiscan performed.
A mean of 1.92 nodes were found on each positive scintiscan.
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4.4.4 In-patient duration and operating time
i. In patient duration
Mean length of in-patient stay was 2.1 days for SNB and 2 days for ANS.
ii. Operating Time
Mean operating time was 21.3 minutes for SNB.
Mean operating time was 13.1 minutes for ANS.
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4.4.5 Factors affecting sentinel node identification
The number of sentinel nodes identified was not related to tumour size as shown in
figure 4.1. Pearson correlation coefficient P=0.141
As body mass index increased, the number of sentinel nodes identified decreased as
shown in figure 4.2. Pearson correlation coefficient P=0.009
There was no association between tumour grade and the number of sentinel nodes
identified, see figure 4.3. Pearson correlation coefficient P=0.903
The dose of isotope and the timing of injection of the isotope in relation to the time
of scintiscan did not affect the number of nodes identified by lymphoscintigraphy as
shown in figures 4.4 and 4.5 respectively. Pearson correlation coefficients P=0.761
(dose of isotope) and P=0.17 (timing of injection).*
A greater number of sentinel nodes was identified when tumours were sited in the
lateral half compared with the medial half of the breast. This is displayed in Table
4.1 Pearson correlation coefficient P=0.007
*It is important to note, when examining the scatter plots shown in figures 4.1-4.5
that the number of dots viewed does not always equal the number ofpatients and this
is because some dots are superimposed on one another when they have equal values.
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Figure 4.1 Tumour size
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Figure 4.2 Body mass index (BMI)
Pearson correlation coefficient P=0.009
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Figure 4.5 Timing of lymphoscintigraphy
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Table 4.1 Tumour site
Tumour site Number of patients Mean number of SNs
Lateral half 20 4.1
Medial half 13 2.8
Pearson correlation coefficient P=0.007
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4.4.6 Post-operative Complications
Complications were encountered more frequently in patients having a sentinel node
biopsy than in those having an axillary sample. Complications were encountered in
fifteen patients (45.5%) following a sentinel node biopsy and in six patients (17.6%)
following an axillary sample. In particular, more seromas of the axilla and breast and
more breast infections were seen following SNB.
Statistical analysis using the chi-squared test was performed to compare the risk of
breast seroma for the two procedures and was not significant ^2=2.19, p>0.1.
Fisher's exact test was performed comparing the risk of axillary seroma between the
two procedures and was approaching significance (p=0.092) but was not significant.
The higher incidence ofbreast infection in the sentinel node patients was not
statistically significant (p>0.1).
Potentially more serious complications were encountered in patients having a
sentinel node biopsy with one patient each having a pneumothorax, a pulmonary
embolism, and widespread cutaneous sensitivity to Patent Blue V dye.
The numbers of early post-operative complications found for each procedure are
shown in Table 4.2 overleaf with percentages in parentheses. Figure 4.6 displays the
main complications as a bar chart comparing the two procedures.
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Table 4.2 Early post-operative complications
COMPLICATION SNB ANS
Breast seroma 7(21.2%) 2(5.9%)
Axillary seroma 5(15.1%) 1(2.9%)
Breast wound infection 3(9.1%) 1(2.9%)
Axillary wound infection 0 2(5.9%)
Axillary wound dehiscence 1(3%) 0
Pneumothorax 1(3%) 0
PE 1(3%) 0
Blue dye sensitivity 1(3%) 0
Breast haematoma treated conservatively 1(3%) 0
Axilla haematoma treated conservatively 0 1(2.9%)
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4.4.7 Blue Dye Tattooing
Six patients (18.1%) had tattooing of the breast at one month, with three patients
(9.1%), two patients (6.5%) and 1 patient (3.7%) showing blue tattooing at 3, 6 and
12 months respectively. The only patient with persistence ofblue tattooing at twelve
months had not been followed up at 18 months.
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Figure 4.6 Immediate Complications
□ SNB HANS






There appeared to be little difference in arm swelling whether patients had a sentinel
node biopsy or an axillary sample as shown in the bar chart, figure 4.7 'objective arm
swelling'. The two procedures were compared using Fisher's exact test and there
were no significant differences between them, p>0.5.
There appeared to be an increase in arm swelling in both groups regardless of their
axillary procedure during the first 6 months post-operatively. The percentage of
patients with objective arm swelling fell slightly at 12 months and then increased
again at the 18-month follow-up appointment. Reasons for this are unclear.
The results for objective arm swelling are displayed separately for the two
procedures in table 4.3 overleaf.
The overall numbers of patients with objective arm swelling combined for both
procedures are described below:
7 patients (10.4%) had arm swelling at 1 month 3 had SNB and 4 had ANS.
10 patients (14.9%) had arm swelling at 3 months, 5 SNB and 5 ANS.
11 patients (18%) had arm swelling at 6 months, 4 SNB and 7 ANS.
6 patients (10.7%) had arm swelling at 12 months, 3 SNB and 3ANS.
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Of the patients who reported a perception of arm swelling, all reported the swelling
as 'mild' apart from two patients who reported swelling as 'moderate'. Reports of
'moderate' swelling were both in the first 3 months of follow-up and did not persist
beyond that time. Only one patient reported swelling of the arm at 18 months of
follow-up. These findings are shown in Table 4.4 overleaf.
There appeared to be a large difference in subjectively perceived arm swelling at 3
months and again at 6 months in favour of sentinel node biopsy as shown in the bar
chart figure 4.8 'subjective arm swelling'. Analysis of subjective arm swelling at 3
months almost reached statistical significance in favour of sentinel node biopsy,
p=0.053 using Fisher's exact test. Fisher's exact test revealed no other significant
differences in arm swelling between the two groups of patients whether they were
treated by axillary node sample or sentinel node biopsy, p>0.5.
Of all the patients who reported a subjective increase in arm volume, only four had a
simultaneously measured (objective) increase in arm volume.
Reports of subjective arm swelling declined over time with 7 patients reporting
swelling at 1 month post-operatively, 4 patients reporting swelling at both 3 and 6
months post-operatively and 2 patients and 1 patient respectively reporting swelling
at 12 and 18 months post-operatively.
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1 month # pts 3/33 2 mild,
1 moderate
4/33 4 mild 0
% pts 9.1 12.1




% pts 0% 12.5
6 months # pts 1/31 lmild 3/30 3 mild 2
% pts 3.2% 10%
12
months
# pts 1/27 1 mild 1 lmild 0
% pts 3.7% 3.4%
18
months
# pts 0/26 1 1 mild 0
% pts 0% 4%
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Altered sensation to pin-prick
A larger proportion ofpatients had altered sensation to pin-prick of the skin of the
upper arm and the axillary skin following an axillary node sample than following a
sentinel node biopsy. The difference was most marked at one month post¬
operatively to the axillary skin and three months post-operatively to the skin of the
upper arm. More than three times the number ofpatients affected by altered
sensation following a sentinel node biopsy were affected following an axillary
sample at one month but this difference did not reach statistical significance using
Fisher's exact test.
There was no significant difference in sensation to pin-prick between the two groups
at 3 months p>0.1 using Fisher's exact test.
Figures for patients affected by altered sensation to pin-prick of the upper arm and
axillary skin are displayed in table 4.5.
Altered pin-prick sensation appeared to decrease over time with fewer patients
reporting this problem as time progressed. This was more marked in the axillary
sample group of patients, a third ofwhom had altered axillary sensation at one month
falling to just 8% at 18 months. This factor is displayed graphically in figure 4.9 for
altered sensation to axillary skin and in figure 4.10 for altered sensation to the skin of
the upper arm.
One patient having a sentinel node biopsy had a large area of sensory loss of the
upper arm, which failed to reduce over 18 months of follow-up. This patient's results
distort the mean area of sensory loss to the arm in the sentinel node group to a higher
than expected value.
The majority of patients did not complain of sensory loss unless the area of loss was
large.
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Table 4.5 Patients reporting altered sensation to pin-prick
SNB ANS
AXILLA ARM AXILLA ARM
1 MONTH
# patients 3/33 4/33 11/33 10/33
%of
patients
9.1 12.2 33.3 30.3
Mean
area(cm2)
15 65.5 36.3 48
Range of
area(cm2)
9-24 14-119 6-88 1-108
3 months # patients 7/33 2/33 10/32 7/32
%of
patients
21.2 6.1 31.3 21.9
Mean area
(cm2)
19 96.5 32.9 47.6
Range of
area(cm2)
4-42 25-168 1-77 16.5-91
6 months # patients 3/31 2/31 7/30 5/30
%of
patients
9.7 6.5 23.3 16.7
Mean area
(cm2)
17 27 28.3 59.4
Range of
area(cm2) 6-36 4-50 4-50 36-98
12 months # patients 3/27 1/27 3/29 3/29
%of
patients
11.1 3.7 10.3 10.3
Mean area
(cm2)
22.8 147 12.3 34
Range of
area(cm2)
2.25-48 147 9-16 24-42
18 months # patients 2/26 1/26 2/25 2/25
%of
patients
7.7 3.8 8 8
Mean area
(cm2)
42 240 18.5 41
Range of
area(cm2)
36-48 240 2-35 30-52
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Figure 4.9 Altered pin-prick sensation axillary skin
ISNB BANS
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_i— 1 1 1 r-
3 months 6 months 12 months 18 months
Follow-up
Figure 4.10 Altered pin-prick sensation arm skin
□ SNB BANS
I —i —| ———r
1 month 3 months 6 months 12 months 18 months
Follow-up
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Altered sensation to light touch
Reduction in sensation to light-touch of the upper arm was encountered more
frequently in the ANS group of patients than in the SNB group p=0.011 as measured
at 3 months using Fisher's exact test.
Loss of light touch sensation appeared to reduce in frequency over the 18-month
follow-up period for both groups of patients. These findings are displayed
graphically in figure 4.11 for axillary sensation and figure 4.12 for arm sensation.
The frequency of alteration to light-touch sensation was lower than that for alteration
to pin-prick sensation with a maximum of 18.8% of axillary sampled patients
reporting an alteration to arm light-touch sensation at 3 months falling to only 4% at
18 months. No patients from the sentinel node biopsy group were shown to have
altered light-touch sensation of the arm after the 1-month follow-up visit or to the
axilla after the 6-month follow-up visit.
One axillary sample patient developed altered sensation to light-touch of the arm at
18 months after the 12-month follow-up visit had been normal. Reasons for this are
unclear but are unlikely to be related to her surgery.
Table 4.6 displays the numbers and percentages of patients affected by altered
sensation of the axillary skin and the skin of the upper arm to light-touch for both
groups ofpatients. The mean areas of altered sensation and the ranges of area loss for
both groups ofpatients are also displayed in the same table.
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Table 4.6 Light touch
SNB ANS
AXILLA ARM AXILLA ARM
1 MONTH
# patients 2/33 1/33 6/33 6/33
%of
patients
6.1 3 18.2 18.2
Mean area 18 119 40.5 56.2
Range of
area
12-24 119 6-88 1-108
3 months # patients 5/33 0/33 4/32 6/32
%of
patients
15.2 0 12.5 18.8
Mean area 23.2 0 52.6 54
Range of
area
5-42 0 7-77 28-91
6 months # patients 1/31 0/31 2/30 4/30
%of
patients
3.2 0 6.7 13.3
Mean area 36 0 47 63
Range of
area 36 0 4-90 50-98
12 months # patients 0/27 0/27 0/29 2/29
%of
patients
0 0 0 6.9




18 months # patients 0/26 0/26 1/25 1/25
%of
patients
0 0 4 4
Mean area 0 0 1 30
Range of
area
0 0 1 30
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Figure 4.11 Altered light-touch sensation axillary skin
■ SNB HANS
1 month 3 months 6 months 12 months 18 months
Follow-up
Figure 4.12 Altered light-touch sensation upper arm skin
■ SNB HANS




There was no significant difference in reduction in shoulder mobility between the
two groups, p>0.5.
More patients had a measured reduction in abduction, internal and external rotation
than in flexion, which was the least affected of the shoulder movements.
There was no clear trend towards a decrease in shoulder stiffness over the 18-month
follow-up period.
The numbers and percentages of patients with measured reduction in shoulder joint
mobility are presented in table 4.7 along with the ranges of reduction in shoulder
mobility.
Figures 4.13-4.16 display graphically the trends in shoulder stiffness for all four
measured movements separately and then in figure 4.17 for all four movements
combined.
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FLEXION 1 MONTH 2/33 6.1 18-41 3/33 9.1 15-18
3 MONTHS 2/33 6.1 15-19 4/32 12.5 12-24
6 MONTHS 3/31 9.7 10-19 1/30 3.3 17
12 MONTHS 1/27 3.7 29 2/29 6.9 23-33
18 MONTHS 2/26 7.7 10-12 3/25 12 15-34
ABDUCTION 1 MONTH 5/33 15.2 12-68 9/33 27.3 10-37
3 MONTHS 5/33 15.2 10-34 9/32 28.1 12-35
6 MONTHS 3/31 9.7 10-14 7/30 23.3 11-20
12 MONTHS 6/27 22.2 11-49 12/29 41.4 10-46
18 MONTHS 7/26 26.9 10-48 7/25 28 10-32
INTERNAL
ROTATION
1 MONTH 1/33 3 16 4/33 12.1 11-20
3 MONTHS 2/33 6.1 12-15 5/32 15.6 10-15
6 MONTHS 7/31 22.6 12-18 6/30 20 10-35
12 MONTHS 6/27 22.2 10-34 6/29 20.7 12-61
18 MONTHS 3/26 11.5 21-68 3/25 12 13-45
EXTERNAL
ROTATION
1 MONTH 3/33 9.1 15-25 5/33 15.2 10-26
3 MONTHS 5/33 15.2 10-14 2/32 6.3 13-18
6 MONTHS 4/31 12.9 12-19 2/30 6.7 10-20
12 MONTHS 5/27 18.5 11-59 6/29 20.7 14-82
18 MONTHS 5/26 19.2 10-94 1/25 4 20
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Follow-up
18 months
Figure 4.14 Shoulder stiffness-abduction
■ SNB ■ ANS
1 month 3 months 6 months 12 months 18 months
Follow-up
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Figure 4.15 Shoulder stiffness-internal rotation
■ SNB BANS
1 month 3 months 6 months 12 months 18 months
Follow-up
Figure 4.16 Shoulder stiffness-external rotation
BSNB BANS
1 month 3 months 6 months 12 months 18 months
Follow-up
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Figure 4.17 Shoulder stiffness all movements
HSNB ■ ANS




Axillary node sampling and sentinel node biopsy both involve the surgical removal
of a small number of axillary lymph nodes to stage the axilla. The mean number of
nodes removed in an axillary sample was 4.79 per patient with a mean of 3.6 nodes
removed during a sentinel node biopsy. Interestingly, only 11.7% ofpatients (4 of
34) having an axillary node sample had lymph node metastases in contrast to 24.2%
of patients (8 of 33) having lymph node metastases following a sentinel node biopsy.
These figures suggest that sentinel node biopsy may be a more exact method of
identifying lymph node metastases within the axillae ofpatients with Tl-2 breast
cancer. Although the sentinel node group had slightly more special types and grade 1
cancers than the axillary node sample group, tumours from the two groups were
otherwise well matched for histological type and presence or absence of
lymphovascular invasion. Lymphovascular invasion (LVI) was present in 25% of
tumours of positive sentinel node biopsies (2 of 8) compared with 8% (2 of 25) of
node-negative sentinel node biopsies. In contrast, 75% of node-positive axillary
samples (3 of 4) had tumours showing lymphovascular invasion compared with 6.7%
(2 of 30) of the node-negative primary tumours. These figures are in keeping with
other studies which correlate the presence of lymphovascular invasion with the
finding of lymph node metastases [24, 228, 229]. However, numbers are very small
and cannot be readily interpreted. The presence of lymphovascular invasion did not
affect the ability to identify a sentinel node and this is in agreement with Hill's large
study of 500 sentinel node biopsies [165]. The fact that sentinel node biopsy
involved removal of one fewer node per patient than an axillary node sample adds
strength to the theory that sentinel node biopsy is targeting those areas to which
disease spreads within the axilla more accurately. Although only small numbers have
been used here, the results are very promising and support further research using the
technique in larger numbers ofpatients. All patients who had positive axillary node
metastases received adjuvant axillary radiotherapy apart from one patient who was
treated by axillary clearance based on unit policy using prognostic criteria.
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All patients (100%) having a sentinel node biopsy had at least one lymph node,
which was stained with blue dye and at least one node with radioactivity. The
identification rate of 100% with each mapping agent is in contrast to phase one of the
trial in which the combination of agents led to a higher identification rate than with
the use of a single mapping agent alone. The mean number of sentinel nodes
identified per patient was higher in phase two of the trial suggesting that the surgeons
were perfecting the technique and were more successful at locating sentinel lymph
nodes than in phase one. Not all sentinel nodes were labelled with both mapping
agents simultaneously being frequently labelled by one or other agent alone. It is
important to emphasise here that both mapping agents must be used therefore, in
order to identify al|_sentinel nodes and that the use of a single mapping agent whilst
having the potential to identify at least one sentinel node in each patient, will not
identify all of the sentinel nodes in all of the patients.
The radioactivity count contained within a sentinel node does not appear to be a
proportionate indicator ofmetastatic disease. In 37.5% of patients with at least one
positive sentinel node, the node that contained the tumour was not the node with the
highest radioactivity count. This stresses the importance of continuing to search the
axilla for further radioactivity to identify such nodes after very hot nodes have been
removed. The original definition of the sentinel node described it as the first draining
lymph node of the primary tumour. Clearly there may be more than one node to
which the primary tumour can first drain as parallel lymphatics from a similar area of
the breast can cross directly to different lymph nodes within the regional lymph node
basin. That said, it is still possible for a single node alone to be the only sentinel
node.
A sentinel node biopsy should thus not be considered complete until all hot or blue
staining nodes have been removed for histology.
A similar incidence of internal mammary node drainage was seen in this phase of the
study as in phase one of the trial. Two patients (6.1%) had internal mammary node
biopsies and neither of them revealed a positive node. The incidence of internal
mammary drainage is lower than reported in some studies [230] although this
particular study used a much higher dosage of radioisotope than in our study.
Clearly, the drainage of radioisotope to the internal mammary basin is not related to
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node positivity in this area so the routine biopsy of internal mammary nodes purely
on the basis of a positive scintiscan does not guarantee additional staging
information. The procedure was associated with a high complication rate within this
study and as there is no currently agreed consensus recommending the routine
removal of internal mammary nodes for staging purposes, it cannot be justified for
use out with controlled randomised trials.
Lymphoscintigraphy results were almost identical to those found in phase one with a
75.8% identification rate. In keeping with the phase one findings, preoperative
lymphoscintigraphy of the axillary and internal mammary lymph nodes did not offer
much additional information for the operating surgeon other than to demonstrate the
small number of patients in whom drainage to the internal mammary nodes was
observed. The presence of a positive scan before surgery, however did reassure the
surgeon that sentinel nodes would be found at surgery whereas a negative scan was
associated with the feeling that sentinel nodes might be more difficult to find at
surgery. This would be in keeping with the finding of Hill et al [165], that a positive
result on lymphoscintigraphy was significantly associated with the successful
location of a sentinel node(P=0.0001).
The in-patient stay was the same for both groups ofpatients staying a mean of 2
nights in hospital. Sentinel node biopsy was, however, associated with a longer
operation time taking on average 8 minutes longer than an axillary node sample to
perform. When a sentinel node biopsy was performed, extra time was taken up
recording 10-second radioactivity counts for each sentinel node excised. Counts were
recorded both in-vivo and ex-vivo. The two consultant surgeons performing the
sentinel node biopsies were both very experienced in the technique of axillary node
sampling before this study began, whereas they had performed significantly fewer
sentinel node biopsies. This provides another reason for the longer operating time in
the case of sentinel node biopsy. It is reasonable to expect the operating time for
sentinel node biopsy to approach that of an axillary node sample as experience is
gained. Searching for lymph nodes under direct vision by following the course of
blue lymphatics is also likely to be a slightly slower process than reaching directly
into the axillary tissue and plucking out nodes by palpation, as it requires more exact
dissection than the latter. The small amount of extra time required to perform a
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sentinel node biopsy may be justified if larger trials prove the greater accuracy of this
technique over axillary node sampling.
Analysis of the relationship of patient and tumour characteristics with the number of
sentinel nodes identified revealed that high body mass index was significantly
associated with identification of fewer sentinel nodes. The reasons for this are
unclear and may either be related to differences in lymphatic dynamics between
overweight and slimmer patients or possibly to a greater degree of technical
difficulty in locating sentinel nodes surgically in overweight patients. It is perhaps
more likely that overweight patients have a less dynamic lymphatic system than
slimmer patients causing the migration of tracer agents to be slower and thus
reaching only one or two nodes as opposed to four or five. This finding may have
some relevance to the success of sentinel node biopsy in certain very obese patients
in whom the procedure may have to be abandoned in favour of a conventional
axillary node sample to stage the axilla should sentinel node identification fail.
Increasing tumour size was not significantly associated with identification of fewer
sentinel nodes although there was a weak correlation as shown by the trend line on
the scatter plot figure 4.1. Again reasons for this are unclear but possibly relate to the
relatively smaller volume of mapping agent injected per unit of breast volume in
patients with larger tumours as the volume of tracer is spread over a greater volume
of breast tissue. As has been mentioned in the previous chapter, one study reported
greater success in sentinel node identification when injecting a greater volume of
radiopharmaceutical [225] and this may be worth considering in patients with larger
tumours. Another explanation is that increasing tumour size is associated with an
increased incidence of lymphatic spread and this may lead to obstruction of some
lymphatics by tumour deposits, which may in turn reduce the number of sentinel
nodes to which the mapping agents will travel.
The location of the primary tumour in the lateral half of the breast was associated
with the identification of significantly more sentinel nodes than with tumours located
in the medial half of the breast. The relatively shorter distance for mapping agents to
travel to the axillary lymph nodes perhaps explains this finding. This is likely to
result in the spread ofmapping agents to a greater number of lymph nodes by the
time of surgery. This finding is in contrast to the findings of Krag and Hill who
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reported no significant association between tumour location and sentinel node
identification although Krag does note a non-significant relatively higher rate of
failure to identify a sentinel node in medial tumours [163, 165, 231]. Another
explanation given by Krag for this finding was the possibility that medial tumours
may mask internal mammary 'hot spots' by the interference of radioactivity from the
overlying tumour following injection of radioisotope. Certainly in our group of
patients we did not consider any particular tumour location to be a significant
hindrance to sentinel node identification although it was felt that upper outer
quadrant tumours occasionally caused interference from local radioactivity or
diffusion of blue dye from the primary injection site.
The dose of radioisotope injected was unrelated to the success at locating a 'hot spot'
on scintiscan but timing of injection did appear to have some bearing on this
although this was not a strong link and was not statistically significant. It is probably
wise to allow at least 3 hours after injection of isotope before performing a
scintiscan, as this is likely to maximise the chance of a positive scan. Krag et al
reported that the type of radiopharmaceutical, amount of technetium, volume
injected, tumour size and the time interval between injection and surgery were
significantly associated with success at finding a hot sentinel node [231], which is in
agreement with some of our findings mentioned above. In contrast to our results,
however, Krag did not find an association between tumour location and success at
identifying a hot sentinel node. Whilst these findings are relatively subtle and are
unlikely to significantly change the outcome of a sentinel node biopsy, they do
provide us with a little more information in helping us to understand the exact
dynamics of lymphatic mapping and sentinel node identification.
The rate of immediate post-operative complications was higher in the sentinel node
biopsy group ofpatients than in the group having an axillary sample. In particular,
breast seroma, axillary seroma and breast infection rates were all at least three times
more frequently encountered in patients having sentinel node biopsy than in those
having an axillary node sample. The numbers of patients in this phase of the study
are small and statistical analysis did not reach significance for these results. These
findings are closely associated to those found in phase one of the trial, however, and
are surely related to the repeated needle punctures of the breast and the localised
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oedema caused by injection of mapping agents. It was suggested in the previous
chapter that fewer needle punctures should be used when injecting mapping agents,
for example two punctures should suffice for each agent, as the clinician can direct
the injection subcutaneously around the full 360° circumference of the tumour using
this method without the need for multiple skin punctures. In addition, as mentioned
in the last chapter it may be sensible to administer a prophylactic dose of antibiotic,
such as co-amoxiclav 1,2g intravenously, at induction of anaesthesia in an attempt to
reduce the post-operative infection rate.
One of the two patients having an internal mammary node biopsy developed a
moderate post-operative pneumothorax requiring a single aspiration on the ward.
This patient's discharge was delayed by one day but she made a complete recovery.
Another patient in phase one of the study also developed a pneumothorax following
an internal mammary node biopsy, which resulted in a significant delay to her
discharge. As mentioned earlier in this discussion and in the previous chapter,
internal mammary node biopsy did not add any staging information to any of the
patients in this study and was associated with a very high complication rate with
some potentially serious complications. It is not routinely practised out with trials in
Edinburgh and it is likely to be proved to be of little value when adequate numbers of
patients have been investigated.
The single patient who developed a widespread cutaneous hypersensitivity reaction
to Patent blue V dye recovered within 12 hours requiring supportive management
and observation only. A single patient in phase one also developed a cutaneous
hypersensitivity reaction to blue Patent blue V dye and followed a similar course of
recovery. The incidence of such a hypersensitivity to blue dye in this study is similar
to that reported in other studies of 2.2% [194]. Any patient developing such a
reaction should be informed of the product to which they are sensitive, advised to
avoid further contact with that particular product, a report should be sent to the
Committee for Safety of Medicines (CSM) detailing the adverse effect(s) witnessed
and a further report should also be sent to the patient's general practitioner. Clear
documentation of the incident must be made in the patient's medical notes with an
allergy-warning message written preferably on the front of these notes. It is also wise
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to inform any patient who is considering undergoing lymphatic mapping of the small
risk of a hypersensitivity reaction.
Blue dye tattooing of breast skin was less frequently encountered than in phase one
and appeared to decrease over time with only one patient having persistent tattooing
at 12 months. None of the patients with tattooing considered this to be a problem as
the discolouration faded with time in the majority. It is not clear why so many
patients were left with blue tattooing after phase one but from the results in phase
two it could be expected that the persistence of blue tattooing in phase one patients at
3 months would fade and disappear in the majority of cases.
Arm swelling was not a major problem in the majority of patients. Although a
record has been made of any patient who was observed as having an increase of over
lOOmls in arm volume when compared to their pre-operative measurement,
independently of the contralateral arm, few patients had an increase of greater than
10% of their pre-operative arm volume. A 10% increase in arm volume is the level at
which lymphoedema therapists would usually begin to commence treatment regimes
for patients starting with simple massage and skin care programmes. One patient in
the axillary sample group was measured as having a 20% increase in arm volume at
18 months but interestingly she did not report any subjective awareness of an
increase. It is possible that this particular measurement may be spurious and a result
of a measurement error. The technique used to measure arm volume in this study is
particularly prone to error particularly if not performed by the same operator on each
occasion. The author of this thesis and one research nurse who had been instructed
on the measuring technique by the author made the majority of arm measurements
although on one or two occasions towards the end of the follow-up period, a research
fellow in breast surgery made the measurements due to unavailability of the other
two staff members. It is worth considering a more foolhardy technique for measuring
subtle arm volume changes such as a water displacement tank in which the arm is
submerged up to a constant mark and the volume of water displaced is recorded. This
method is likely to be more readily reproducible than the tape measure method
employed here. An alternative option would be only to record cases of arm swelling
which the patient perceives to be troublesome as this is a more realistic indicator of
morbidity.
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Patients having axillary node sample were more frequently likely to have altered
sensation of the skin of the axilla and upper medial arm than those having a sentinel
node biopsy. The difference between the two groups was statistically significant for
light touch sensation of the upper arm at 3 months post-operatively in favour of
sentinel node biopsy. More patients had altered pin-prick sensation to the skin of the
axilla and upper arm at one and three months after an axillary sample than after a
sentinel node biopsy although figures did not reach statistical significance because of
small numbers. It would appear from these results that sentinel node biopsy is less
invasive than axillary sample in terms of damage to the intercostobrachial nerve.
This is possibly explained by the more exact dissection under direct vision required
for this procedure as opposed to the blind and blunt dissection used to extract lymph
nodes during axillary sampling. Having stated this, it is clear from the results that the
majority ofpatients will only have a transient loss of sensation, which will most
likely return completely within 6 months of surgery. Fewer patients suffered loss of
light touch sensation than pin-prick sensation regardless of the procedure performed.
This suggests that the A5 (or 'fast pain') nerve fibres of the intercostobrachial nerve
are more susceptible to trauma than those which conduct light-touch sensation.
Recovery ofpin-prick sensation was similar to that for light touch over the 18
months with less than 10% of patients in either group being affected at 18 months.
Abduction was the most commonly affected movement at the shoulder joint followed
by rotational movement. Other studies of arm morbidity have reported shoulder
flexion and rotation as the most commonly affected [84, 128] but related the shoulder
stiffness to axillary radiotherapy or an axillary node clearance. Rotational shoulder
stiffness and abduction appeared to be slightly more frequently measured from the 6-
month follow-up visit onwards. The effects of radiotherapy on the shoulder joint
rather than the axillary surgery may possibly explain this. There was no significant
difference between the two groups in terms of shoulder joint stiffness suggesting
neither procedure is more damaging than the other to the shoulder's mobility. The
fact that shoulder mobility did not improve considerably over the 18-month follow-
up period seems disappointing. The rather minimal surgical invasion of the axilla
might suggest that the surgery is an unlikely cause of this persistent stiffness in some
patients and that radiotherapy might be a more likely cause. Certainly, a greater
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proportion of patients having axillary radiotherapy were found to have persisting
shoulder stiffness than those who had no radiotherapy to the axilla.
There were no axillary recurrences in either group ofpatients during the median 18-
month follow-up period. These are encouraging preliminary results although a longer
period of follow-up is required before sentinel node biopsy can be confirmed as
being safe.
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5. IMPRINT CYTOLOGY OF AXILLARY LYMPH
NODES AS AN INTRAOPERATIVE DIAGNOSTIC TOOL
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5.1 BACKGROUND
Imprint cytology is a special variation of applied cytology. It can be used as an
adjunct to frozen and paraffin section as a diagnostic tool. Imprints can reveal very
subtle diagnostic changes and also make it possible to make a diagnosis in a shorter
time than with paraffin section [232],
Sentinel node biopsy is being validated as an alternative to axillary node clearance in
staging the axilla in breast cancer. This will inevitably lead to the development of a
group ofpatients with positive sentinel nodes either requiring a second operation to
clear the axilla of its remaining lymph nodes or being treated by axillary
radiotherapy. Currently, some centres use an axillary sampling technique to stage the
axilla by removing a small number of selected lymph nodes, those with positive
nodes likewise requiring further axillary treatment. A reliable and accurate
intraoperative technique of examining lymph nodes would mean that a second
operation could be avoided because patients with positive nodes could have an
axillary clearance during the same sitting. This would avoid the considerable anxiety
and emotional upset associated with a second operative procedure.
It is also possible that a significant number of sampled patients with stage Tl-2
breast cancer could avoid an axillary clearance if nodes were negative following
intraoperative examination [206]. This would lead to a shorter time in hospital than is
usual following complete axillary dissection and would reduce the rates of arm
morbidity, particularly lymphoedema, which is more commonly associated with
lymph node clearance.
Frozen section histological examination of lymph nodes is known to have a high
false negative rate of up to 27% in some studies[197]. Imprint cytology has been
reported to have a lower false negative rate with the sensitivity reaching one hundred
per cent in some studies[207].
It is important to realise that when performing a frozen section procedure, 25-50% of
the material may be lost[200], A potentially serious consequence of this could be the
failed detection of a small area of micrometastasis within part of a lymph node.
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Imprint cytology does not lead to any loss ofmaterial and the entire specimen is
available for histological and immunohistochemical examination if necessary.
The aim of the current study was to assess the reliability of imprint cytology as an
intraoperative diagnostic tool in patients having an axillary sampling procedure as
part ofbreast cancer surgery.
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5.2 PATIENTS AND METHODS
We examined 238 lymph nodes in 53 patients having an axillary node sample of at
least four lymph nodes for Tl-2 breast cancer. There was no age restriction and
patient age ranged from 32 to 82 years. All but three patients had a breast conserving
wide local excision to remove their primary breast cancer with the remaining three
patients having a mastectomy.
Axillary node samples were performed through a transverse curvilinear incision just
inferior to the hair-bearing area in the axillary skin crease. At least four lymph nodes
were removed from the lower axilla using a standard technique of digital palpation.
Each fresh lymph node was processed immediately. Lymph nodes were sliced every
3-4mm and imprints were taken from each cut surface. Two identical sets of imprints
were prepared on two separate slides for each lymph node. All slides were
immediately fixed in a methanol and acetone 50:50 mix. One set of slides was
stained with toluidine blue before drying and mounting cover slips. The second set
was stained with anti-pancytokeratin (Pan-CK) immunoglobulin as an
immunohistochemical marker to determine whether this improved the sensitivity of
the test. Immunohistochemistry was performed using a standard technique of antigen
retrieval, buffer washes and incubation with primary and secondary antibodies using
a streptavidin-biotin complex and immunoperoxidase with the labelling antigen
diaminobenzidine. Cells were then counterstained with haematoxylin to show up the
nuclei before undergoing fixation and mounting.
A single consultant histopathologist (Dr. M. A. Mclntyre) examined all of the slides.
A non-pathologist (the author, PAL) also examined all of the slides to determine
whether using a technician to screen slides could decrease a pathologist's workload.
The non-pathologist received regular feedback on imprint examination from the
consultant histopathologist during the study. Both examiners were blinded to the
routine histology results prior to examining the nodes.
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Lymph node metastases were defined as those measuring greater than 2mm in size
(i.e macrometastases not micrometastases) and were compared against the currently
accepted standard ofhaematoxylin and eosin (H & E) histology.
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5.3 RESULTS
Of the 53 patients in the study, six patients were found to have in-situ disease only on
H & E histology. These patients were excluded from the analysis. This left 217
lymph nodes from 47 patients with invasive Tl-2 cancer. Imprints were not possible
in five of these lymph nodes as they were too small leaving 212 nodes available for
analysis. None of the five lymph nodes excluded were subsequently shown to have
metastases on H & E histology.
Ten positive lymph nodes in six patients were found using H & E histology of the
217 lymph nodes examined. Imprint cytology and toluidine blue staining detected
metastases in eight of these. One further positive node was identified by imprint
cytology, which was reported as negative on routine histology. The H&E histology
was reviewed by the consultant histopathologist and thought to be equivocal rather
than definitely negative or positive. Immunohistochemical marking using Pan-CK
(antipancytokeratin immunoglobulin) was performed on this lymph node and this
confirmed the presence ofmetastatic deposits measuring greater than 2mm in
diameter (i.e macrometastasis not micrometastasis) within this lymph node.
Consequently there were 11 positive lymph nodes identified in six patients. Imprint
cytology detected 9/11 of these giving a sensitivity of 82% and a false negative rate
of 18%. There were no false positive results amongst the cases analysed giving a
specificity of 100% and a positive predictive value of 100% (9 of 9). The negative
predictive value was 99% (201 of 203). Routine H&E detected 10/11 of the positive
nodes giving a sensitivity of 91% and a false negative rate of 9%.
Six of 47 patients had positive lymph nodes. All six patients had lymph nodes
identified as positive by the consultant histopathologist on imprint cytology
preparation. Analysis of data according to the lymph node sample as a whole rather
than for single lymph nodes eliminates the false negatives as all patients with
positive samples were detected by imprint cytology and would thus have gone on to
have a lymph node clearance or axillary radiotherapy in clinical practice. Using this
analysis the sensitivity is 100% with a false negative rate of 0%.
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Using anti-pancytokeratin antibody (Pan-CK), seven positive lymph nodes were
detected by the consultant histopathologist. Four of these were positive on routine H
& E histology. The sensitivity was thus only 36.4% with a false negative rate of
63.6% using immunohistochemistry. Three lymph nodes were found to be positive
with Pan-CK but were negative on routine H & E histology. The original H & E
histology for these three lymph nodes was re-examined but malignant cells were not
seen. The positive predictive value was thus 57% (4 of 7). The false positive rate was
1.5% with a specificity of 98.5% for immunohistochemistry. The negative predictive
value was 98% (201 of 205).
A non-pathologist (surgical research fellow, PAL) also examined all lymph nodes to
determine whether an untrained technician could help in screening for positive cases.
Only five of the eleven positive lymph nodes were detected on examination of the
toluidine blue imprints giving a sensitivity of 45% and a false negative rate of 55%.
There were also 12 false positive cases giving a false positive rate of 6% and a
specificity of 94%. The positive predictive value was thus 29.4% (5 of 17), negative
predictive value was 97% (189 of 195). A diagnosis could not be made from ten of
the slides and these were checked by the histopathologist and found to be negative.
Examination of the Pan-CK slides revealed 6 of the 11 to be positive giving a
sensitivity of 54.5% and a false negative rate of 45.5%. There were 2 false positives
giving a specificity of 99% and a false positive rate of 1%. Positive predictive value
was 75% (6 of 8). Negative predictive value was 98.5% (201 of 204). There were
two slides in which a diagnosis was unclear and these were checked by the
histopathologist and found to be negative.
All metastatic deposits identified and used in the results were defined as those
measuring greater than 2mm in size.
Table 5.1 shows the figures for each staining method and for each examiner for
sensitivity, specificity, positive and negative predictive values.
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Table 5.1 Values of each staining method as examined by a consultant
histopathologist and a non-pathologist
Consultant Histopathologist Non-Pat lologist
Toluidine Blue Pan-CK Toluidine Blue Pan-CK
Sensitivity 82% 36.4% 45% 54.5%








99% 98% 97% 98.5%
Legends to Figures 5.1-5.6 (Imprint photomicrographs)
Figure 5.1 Negative Toluidine Blue Imprint with a typical mixed picture of
lymphoid cells predominantly lymphocytes.
Figure 5.2 Positive Toluidine Blue Imprint showing a cluster of cells with large
nuclei and nuclear pleomorphism against a background of
lymphocytes.
Figure 5.3 Positive Toluidine Blue Imprint. Abnormal cells appear in loose
clusters with poor cell-cell adhesion, high nucleancytoplasmic ratio
and nuclear pleomorphism.
Figure 5.4 Strongly positive brown staining ofmalignant cells with Pan CK
against a background of non-malignant, unstained lymphocytes.
Figure 5.5 Weakly positive Pan CK staining of a group of malignant cells.
Figure 5.6 Strong positive Pan CK staining of malignant cells detected initially
on Toluidine blue imprint of a lymph node, which was reported as
being negative on routine H&E histology
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Figure 5.1- Negative Toluidine Blue Imprint
Figure 5.2-Positive Toluidine Blue Imprint
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Figure 5.4- Pan CK positively staining malignant cells x40
n
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Our results show a similar false negative rate to frozen section histology when
imprints are stained with toluidine blue dye and examined by a consultant
histopathologist. This is in contrast to several studies which report a higher
sensitivity of imprint cytology than frozen section histology[207, 209, 233]. The
addition of an immunohistochemical staining with Pan-CK did not increase yield in
our series and was actually associated with a higher false negative rate than that with
toluidine blue. In some of the positive lymph nodes, malignant cells could be clearly
seen but were not staining positively with Pan-CK. This suggests a failure of the
antibody marker and it is possible that the use of a different antibody may improve
these disappointing results.
Examination of lymph node cytology by an untrained non-pathologist does not
appear to be a reliable option for reducing pathologists' workload. Cytology is a
specialised subspecialty ofpathology and requires considerable expertise to make an
accurate diagnosis. However, when immunohistochemistry is used the yield of a non-
pathologist is improved. This is of potential value should a more reliable
immunohistochemical marker become available, as detection rates were much closer
to those of the histopathologist when using this technique. Some centres have used
the monoclonal antibodies AE-1 and CAM 5.2 with reasonable success in lymph
nodes and these may prove useful in imprint cytology[48].
The positive and negative predictive values of the test using toluidine blue and a
consultant histopathologist were very high. This suggests that the technique could be
applied as an intra-operative diagnostic tool with the reassurance that a positive
result can be wholly relied upon. This is obviously of great importance when
performing axillary node clearance on the basis of such results. Patients would need
to be warned of the risk of a false negative result in a minority of cases along with
the possible need for further surgery later. Despite this failure rate, a second
operation is potentially avoidable in at least 4 out of 5 cases with positive lymph
nodes. In our series we would have avoided a second operation in six of 53 patients
(11.3%) and there were no patients who would have required re-operation to the
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axilla. The additional cost to the pathology department in materials by using
toluidine blue imprint cytology is certainly lower than that for frozen section
histology as it uses a single inexpensive staining agent only as opposed to the use of
complex equipment such as that required for frozen section. Imprint cytology is
likely to be faster to perform than frozen section thus requiring less technician time
and further reducing costs. The cost of re-admission and a second axillary operation
in six patients is a potentially greater expense than the imprint cytology of lymph
nodes in 53 patients although a detailed cost-analysis has not been carried out in this
study. Should sentinel node biopsy become a standard method of axillary staging in
early breast cancer in the future, fewer lymph nodes would require examination than
with an axillary sample. This would further reduce the pathology costs and workload
involved with imprint cytology.
The two positive lymph nodes which were not picked up on imprint cytology by the
consultant histopathologist were reviewed and a positive diagnosis could not be
made as malignant cells were not present even in retrospect on these slides. Both
these nodes were from patients in whom multiple nodes were involved and other
involved nodes were identified on imprint cytology with Toluidine blue. The most
likely explanation for this discrepancy between histology and cytology is that
different levels of lymph nodes were sectioned for histology compared to those
levels taken for imprints and unless the node is entirely replaced by tumour it is quite
logical for some levels to be involved whilst others are not. Similar discrepancies
have been reported in rates of detection ofmicro-metastases when serial sections of a
lymph node are sampled as opposed to a single section. The presence of such
micrometastases has been reported to adversely affect five year and overall
survival[55] although the importance of micrometastases is not clear and remains a
subject of considerable debate.
In conclusion, intra-operative imprint cytology has a similar sensitivity to frozen
section when used as a diagnostic aid for axillary lymph node metastases. Imprint
cytology does have one technical advantage over frozen section histology resulting in
little interference with nodal material leaving the whole specimen available for
routine and/or special analysis. Staining of imprints with antibody to pancytokeratin
does not appear to be of added value. Further studies are required to assess whether
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alternative immunohistochemical markers will improve the sensitivity ofplain (non-
immunohistochemical) imprint cytology. A non-pathologist (e.g MLSO/surgical
trainee) without specific training is not acceptable to screen slides but whether or not
such an individual would be more accurate at detecting involved nodes stained by a
better immunohistochemical marker, should be assessed.
Imprint cytology may have a role in reducing the re-operation rate on the axilla in
patients undergoing axillary sampling or sentinel node biopsy. The cost implications
of performing imprint cytology on all patients having such axillary surgery as
opposed to the cost of a second axillary operation in a small number ofpatients
requires further study.
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5.5 IMMUNOHISTOCHEMICAL STAINING OF IMPRINTS
After fixing slides in methanol and acetone, they were stained by the
immunohistochemical technique. This involves a complex series of events as
follows:
5.5.1 Prepara tion
1. Wash in xylene to dissolve any wax ( not necessary in the case of imprint
cytology).
2. Two changes of 100% ethanol to eliminate excess xylene.
3. One change of industrial methylated spirits (IMS)
4. Into water
5. Blocking of endogenous peroxidase from red blood cells with 0.5%
hydrogen peroxide plus 0.1% sodium azide (10 minutes).
6. Antigen retrieval (histology only) - any cross-links in the protein chains
need breaking to expose any hidden antigen lying within a loop of the
protein chain. This may be done by two methods:
1. Using an enzyme e.g. trypsin
2. Heat specimen to boiling point or higher (specimens must be kept
moist whilst heating).
Incubation - slides then irrigated in buffer bath of phosphate buffered saline (PBS) at
pH 7.6. This keeps specimens damp.
5.5.2 Blocking stage
Before addition of antibody, the slides are treated with egg-white protein. This
neutralises any positively charged proteins, which would otherwise be attracted
indiscriminately by the antibodies' negative charges.
Wash in PBS for five minutes to remove excess egg-white from the specimens.
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5.5.3 Antibody staining
Slides are processed using the "Shandon Sequenza" which is a sequenced set of
containers for holding slides whilst they are treated with antibody.
1. Antibody diluted in PBS with biotin and bovine serum albumin (same
function as egg-white) is added to the specimens
2. Incubation for thirty minutes with primary antibody
3. Rinse in PBS to wash off any unbound primary antibody
4. Incubate with secondary antibody (goat anti-mouse antibody) for thirty
minutes
5. Incubate with Streptavidin ABC complex (streptavidin-biotin complex with
peroxidase attached) for thirty minutes
6. Add peroxidase-labelling antigen
i peroxidase '





Cells were then counter-stained with haematoxylin to show up the nuclei.
5.5.3 Fixation
Slides then undergo reverse sequence through alcohols:
IMS xl, two changes in ethanol 100% and xylene xl before adding coverslip and
mountant.
216
6. OCCULT LYMPH NODE METASTASES
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Occult lymph node metastases in patients with node negative
breast carcinoma following axillary node sample
6.1 AIMS
1. To compare the incidence of occult metastatic disease in the axillary
lymph nodes of node-negative patients who subsequently developed
axillary recurrence with those without axillary recurrence when treated by
an axillary node sample and breast conserving wide local excision.
2. To examine the clinical significance of occult metastatic disease in the
axillary lymph nodes of node-negative patients following a lymph node
sample.
3. To assess the reliability of a non-pathologist after a limited training
period, in the detection of lymph node micrometastases in slides stained
immunohistochemically.
6.2 PATIENTS AND METHODS
6.2.1 Patients
Lymph nodes from 26 patients with node-negative Tl-3 breast cancer who
subsequently developed axillary recurrence after treatment by breast-conserving
wide local excision and axillary node sample between 1987 and 1995 were re¬
examined for metastases. Lymph nodes from a further 26 patients with node-negative
Tl-3 breast cancer who did not develop any axillary recurrence after a breast
conserving wide local excision and axillary node sample were examined similarly
and used as control cases. Patients were matched for tumour size, grade, and type,
menopausal status and number of lymph nodes sampled.
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6.2.2 Methods
Each paraffin-embedded lymph node from the study and control groups was re¬
examined at two additional levels 100 microns apart. Three sections were taken from
each level and one was stained with haematoxylin and eosin (H & E). The remaining
two sections from each level were stained with antibodies to pancytokeratin
(MNF116, Dako, UK) and MUC1 protein (HMFG2, Prof J Taylor-Papadimitrou,
ICRF, London). Each immunocytochemically-stained slide was examined for
metastases by a senior histopathology registrar (KLM) and by a non-pathologist
(PAL) with no post-graduate experience ofhistopathology. The senior
histopathology registrar also examined each H & E-stained slide in addition to the
immunocytochemically-stained slides. Lymph node sections were examined using
standard light microscopy. Both the histopathologist and the non-pathologist were
blinded to the patients' clinical outcome whilst examining the nodes. Positive cases
were noted and the incidence of micrometastases compared between the two groups.
Statistical analysis using the chi-squared test compared the results from the axillary
recurrence group of patients with the control cases with regard to the number of
micrometastases identified.
6.2.3 Staining methods
Sections were dewaxed and rehydrated. Antigen retrieval was necessary for
cytokeratin staining and was carried out by microwaving sections in Vector Retrieval
Solution 3 for five minutes and then washing in water. The HMFG2 antibody did not
require antigen retrieval. All sections were then immersed in a solution of 1.5%
hydrogen peroxide in methanol for ten minutes and subsequently loaded into a
Biogenax Optimax staining machine and incubated with 1:5 normal rabbit serum
(NRS) diluted in Optimax buffer for thirty minutes. The MNF116 and HMFG2
primary antibodies were applied for sixty minutes at dilutions of 1:500 and 1:4
respectively. Sections were then further incubated following a buffer wash for thirty
minutes in a 1:400 dilution ofbiotinylated rabbit anti-mouse antiserum (DAKO).




133 lymph nodes were examined from each of the axillary recurrence and the control
groups with a mean of 5.1 lymph nodes per patient. A total of 596 slides were
examined, two for each of two levels sectioned from each lymph node. There were
micrometastases present in four patients with known axillary recurrence and in three
patients with no axillary recurrence as detected by the histopathologist. The non-
pathologist detected micrometastases in six (85.7%) of these patients but in one
patient who had a subcapsular metastatic deposit present in one of the nodes, the
metastasis was missed. This gave a false negative rate of 14.3%. The sensitivity of
the non-pathologist in detecting metastases in lymph nodes was thus 85.7%.
The results analysed as number of slides examined gives a different picture. Eighteen
slides demonstrated micrometastatic deposits and 10 (55.6%) of these were identified
by the non-pathologist. Eight slides (44.4%) were consequently falsely diagnosed as
negative. Sensitivity in detection ofpositive slides was thus 55.6%.
Of the pancytokeratin slides showing metastases, six of nine slides (66.7%) were
detected but only four of nine slides (44.4%) showing metastases with HMFG2 were
detected. Sensitivity is thus greater with pancytokeratin at 66.7% than with HMFG2
at 44.4%. In terms of levels identified, metastatic disease was seen in nine levels of
the sectioned nodes of which the non-pathologist identified seven levels (77.8%).
False positive cases were found by the non-pathologist in 16 slides. This translates to
a false positive rate of 2.8% and a specificity of 97.2%. Nine false positives (3.1 %)
were from CK stained slides and seven (2.4%) from HMFG2 slides. Positive
predictive value of the non pathologist was thus only 38.5% (10 of 26). The negative
predictive value was 97.3% (570 of 586). Positive predictive values for Pan CK and
HMFG2 were 40% and 36.4% respectively. Negative predictive values were 96.9%
and 97.6% for Pan CK and HMFG2 respectively.
Nine slides were referred to the pathologist for checking but these slides were not
thought to be positive by the non-pathologist.
The results as defined by the histopathologist revealed that in two patients from the
study group (those who developed axillary recurrence) macrometastases had been
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overlooked on routine H & E histology. This suggested that the pathologist had
originally understaged these two patients. Of the remaining patients, two patients
from the study group (7.7%) and three patients from the control group (11.5%) were
found to have micrometastases on immunohistochemistry. All of these
micrometastases measured less than 1mm in diameter and were either
intraparenchymal, subcapsular or both. Statistical analysis using the chi-squared test
revealed no significant difference in the rate of micrometastases between the two
groups (P=l) whether or not they developed axillary recurrence. Both the antibodies
to pancytokeratin and to MUC1 protein showed similar intensity of staining.
Table 6.1 overleaf displays the numbers of metastases identified by the pathologist.
Table 6.2 overleaf displays the sensitivity, specificity and predictive values of each
antibody separately and in total as examined by the non-pathologist.
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Pan CK 298 66.7% 96.9% 40% 96.9%
HMFG2 298 44.4% 97.6% 36.4% 97.6%
(MUC1)
Total 596 55.6% 97.2% 38.5% 97.3%
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6.2 DISCUSSION
The results of this study have shown that in this relatively small group of patients,
micrometastases do not have clinical relevance in relation to the development of
axillary recurrence. These findings are in contrast to those of the Ludwig
international study group who reported a significantly poorer disease-free and overall
survival in postmenopausal patients with occult lymph node metastases
(micrometastases) [48].
The same study also reported that the presence of lymph node micrometastases was
an independent and highly significant predictor of recurrence in post-menopausal
women. The study performed in Edinburgh, however did not stratify patients to
separate groups ofpre and postmenopausal women, as numbers were small. It is
possible that a study of larger numbers of patients could produce different findings
particularly if specific patient groups are studied. Other studies have reported no
clinical significance to the presence of lymph node micrometastases[46, 60] in terms
of overall survival. It should be mentioned here that these two studies were carried
out during the 1970s and were studies of serial sectioning using standard H & E
histology rather than modem immunohistochemistry techniques. In addition, both
studies were of smaller numbers of patients (227 patients and 78 patients) than the
Ludwig study (736 patients). It becomes apparent from the findings of these different
studies that lymph node micrometastases may have more significance in certain
patient groups than in others. Subsequent studies which examine their clinical
significance would perhaps be better set up prospectively to study separate patient
groups in large numbers. For example, patients with a particular histological type of
tumour or patient groups according to menopausal status or age. Until this issue has
been clarified, it will continue to be a subject of some debate.
The introduction of sentinel node biopsy allows a small number of lymph nodes to be
subjected to a more detailed histological analysis and one study reports a high
incidence of lymph node micrometastases in sentinel nodes examined by
immunohistochemistry, which were negative for metastases on conventional
histology [234], If such detailed analysis is to be carried out on sentinel lymph nodes,
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then it is essential that the true significance of occult metastases be understood before
patients are subjected to highly toxic and potentially harmful chemotherapy.
Pressures on pathologists to perform a greater number of sections on each lymph
node examined and to examine further slides stained by immunohistochemistry are
likely to impose a considerable workload on an already stretched specialty with staff
recruitment problems. The ability of a laboratory technician such as an MLSO
(medical laboratory scientific officer) to examine and screen slides for pathologists
could greatly reduce this burden. In this study the non-pathologist was able to
identify over half of the positive slides stained using antibody to pan-CK after only a
very limited period of training. The use of the microscope to screen slides is a
potential area for error as by scanning too fast or too far at each sweep of the lens, it
is easily possible to miss a small area of micrometastasis. In addition, the detection
of sixteen false positive slides suggests that extra training in the distinction between
true positive staining and background staining would be useful. Although some
positive slides were missed, it is possible that with a longer period of training and
with closer supervision early on in the training, these figures could be improved.
The figures achieved with the HMFG2 antibody were significantly lower than with
the antibody to pan-CK. Reasons for this are unclear as the pathologist stated that the
intensity of staining was similar with each antibody. The non-pathologist disagreed
with this and felt that the pan-CK staining was easier to see than the staining with
HMFG2 and this is worth consideration if the technique is to be tried with a non-
trained member of staff in the future. Other antibodies may prove to be more specific
in the detection of occult metastases without leading to background staining of
normal tissue and this would allow an untrained person to identify abnormalities
more easily. The antibodies AE-1, AE-2, AE-3, CAM 5.2, MCA (mucous-like
carcinoma antigen) and EMA (epithelial membrane antigen) amongst others have all
been used to detect lymph node micrometastases of the axilla in a number of
different studies [235].
On the basis of this study however, an untrained technician should not attempt to
screen histology slides outside the confines of a controlled clinical trial.
In summary, this study did not associate the presence of axillary lymph node
micrometastases with axillary recurrence. Further studies on larger numbers of
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specific patient subgroups need to be performed to clarify the debate on the
significance of lymph node micrometastases in breast cancer. All micrometastases
identified in this study measured less than 1mm in diameter and this may be an
important threshold point in the clinical significance of micrometastases as found a
previous report [61]. It may be possible to train a pathology technician to screen
large numbers of slides stained immunohistochemically if a longer period of training
is provided with close supervision from a trained pathologist. Some antibodies may
allow easier detection of lymph node micrometastases than others. It is vital that an
international consensus is reached giving clear guidelines to pathologists, surgeons
and oncologists on how best to process and manage lymph node micrometastases
before clinical decisions are made on their presence. Until a decision has been
reached, studies into this must be confined to clinical trials.
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227
7.1 GENERAL DISCUSSION
7.1.1 Purpose of these studies
These studies were set up in an attempt to discover the most suitable approach to the
management of the axillary lymph nodes in operable breast cancer both surgically
and histologically. The following pages will bring together all the information
provided by the previous chapters and analyse it critically against today's up to date
research, which has been published since this thesis started. The result of this it is
hoped, will offer some guidance as to the current preferred management of the axilla
in this complicated disease. The fight against breast cancer is an ongoing process and
the suggestions drawn from this thesis only offer a further drop in the ocean of
knowledge, which is being diligently gathered by medical researchers around the
globe. Each piece of medical research goes some way however, in directing new
research towards the next stepping-stone in the journey towards a cure for this
terrible disease as the pioneering work of Halsted, McWhirter, Patey and Forrest and
many others has done in bringing us to the point where we lie today.
7.1.2 Current research and views for the future
Early results of randomised studies comparing sentinel node biopsy with standard
axillary dissection are now being published. A Multicentre trial of 965 patients based
at the Moffitt Cancer Centre, Tampa, Florida, reports that there have been no
recurrences to date in node-negative patients treated by sentinel node biopsy to stage
the axilla after a median follow-up of 16 months [236]. These results are in keeping
with ours found in Edinburgh. No recurrences have yet been reported in our small
group of 33 patients whose axillae were staged with sentinel node biopsy for node-
negative disease after a median follow-up of 18 months. These reports are very
encouraging. It is too early however, to draw final conclusions from these findings as
the mean time to axillary recurrence in patients treated by axillary clearance or
axillary node sample is 4.5 years (see chapter 2) suggesting that a follow-up period
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of at least 5 years is required to confirm the safety of this technique. Our figures are
for patients with stage Tl-2 breast cancer although it has now been reported that
sentinel node biopsy is no less accurate when T3 tumours are staged using this
technique following a large Multicentre study of over 2000 patients with stage Tl-3
breast cancer based at the University of Louisville, USA [237]. Patients enrolled into
this trial were initially staged as having Tl-2 cancers clinically but some were
subsequently found to have T3 tumours on pathological examination. It is likely that
these were small T3 tumours and other reports have found that sentinel node biopsy
is less accurate in T2-3 tumours than in T1 tumours [238]. It is probably wise to
reserve the technique of sentinel node biopsy for use in patients with clinical stage
Tl-2 NO MO until further information on the subject of T3 tumours becomes
available, l he increasing risk ofnodal metastases with increasing tumour size makes
sentinel node biopsy less suitable for patients with T3 tumours as their risk of
requiring further surgery to clear the axilla is higher.
The original aim of the sentinel node biopsy was to reduce the extent of axillary
surgery required in breast cancer patients with the hope of reducing post-operative
morbidity without sacrificing staging information. Reports now suggest that
morbidity is found to be lower following a sentinel node biopsy than following a
standard axillary dissection or clearance [239, 240]. In particular the number of
symptoms, tenderness, soreness, tightness, pain, limited range of motion of the
operated upper extremity, numbness, paraesthesias, and arm swelling as well as
perceived disability in activities of daily living were significantly less common in
patients having sentinel node biopsy than in those having an axillary dissection to
level II. These results are in agreement in part with our preliminary results, which
suggest that less sensory alteration of the axilla and upper medial arm is encountered
following a sentinel node biopsy than following an axillary node sample.
A recent report on the arm morbidity of patients receiving a level I-III axillary
dissection reported that shoulder stiffness, pain and loss of arm strength were
frequent complications with pain and loss of arm strength occurring in half the
patients and a reduction of 20 degrees of abduction, dorsal or ventral elevation of the
arm occurring in 12%. The arm morbidity appeared to persist rather than to improve
with time with no difference in morbidity between patients treated 6-12 months ago
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and those treated 5 years ago [145]. These findings would agree with the findings of
phase 2 of the ALMANAC trial, which showed persistence of shoulder stiffness
rather than improvement over the 18-month follow-up period (see figures 4.14 to
4.18).
Another report suggests that there is less arm swelling and that patients returned to
their normal activities sooner after surgery following a sentinel node biopsy than
following axillary node dissection [241], These findings add further support to the
validation of sentinel node biopsy as a non-radical method of staging the axilla.
Certain patient and tumour characteristics have been associated with a higher risk of
failed lymphatic mapping such as patient age, body mass index and lower inner
quadrant tumours [242, 243], These findings are in agreement with the findings
reported in this thesis (see chapter 4 figs 4.1 - 4.3).
Axillary node sample of at least four lymph nodes has been shown to be safe in terms
of long-term overall patient survival when compared with a level III axillary node
clearance as part of randomised clinical trials (see chapter 2). It is however,
associated with a false negative rate of 9.75% that does adversely affect a small
group ofpatients who will develop axillary recurrence. It is because of this that some
breast surgeons have been sceptical of the technique, as they have found it difficult to
perform and have felt that there is a risk of leaving positive disease behind in the
axilla. Sentinel node biopsy may offer some benefit over axillary node sample in
terms of its accuracy and reproducibility. Sentinel node biopsy has been shown to be
easy to perform and reproduce by two consultant surgeons who achieved an
identification rate of close to 100% after performing 40 cases each (see chapter 3). In
phase 2 of the ALMANAC trial (chapter 4) the sentinel node identification rate was
100%. Surgeons sceptical of axillary node sample may find sentinel node biopsy
easier to perform and reproduce as it offers a more definite and precise way of
targeting specific lymph nodes as opposed to the less defined method of'cherry-
picking' of lymph nodes as in a sample.
It is important to remember that should the sentinel node biopsy procedure fail to
identify a lymph node then conventional axillary surgery should be reverted back to
as an alternative. Similarly, it is essential not to forget that sentinel node biopsy is not
suitable for all groups of patients and it should not be seen as a substitute for patients
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with large or multifocal tumours or with palpable axillary nodes who are better
treated with an axillary node clearance when they have their primary tumour excised
because of the high risk ofnodal metastases in these patients.
Two recent papers have reported that intraoperative imprint cytology of sentinel
lymph nodes is helpful in determining which patients should go on to have a
completion axillary node clearance [244, 245]. Both papers reported a specificity of
100% with no false positive results and an accuracy of over 80% in keeping with the
findings of chapter 5 of this thesis. A false positive lymph node imprint thus does not
appear to be a likely problem with this technique and this should reassure the
surgeon that a positive imprint is likely to be a true positive.
7.1.3 Cost implications of sentinel node biopsy
After the initial expensive outlay of purchasing a gamma probe for between £10,000
and £15,000 the cost of sentinel node biopsy is relatively inexpensive. A single dose
ofNanocoll costs £35 and a single vial of Patent blue V costs £4.80 in the United
Kingdom. If scintiscan is avoided, the extra cost over that of an axillary sample is
likely to be less than £50 per patient. If sentinel node biopsy proves to be more
accurate at staging the axilla, it has the potential to recoup these costs in prevention
of axillary recurrence and the additional healthcare costs associated with it.
An American study profiling the cumulative treatment costs of 555 patients treated
by sentinel node biopsy reported inconclusive results regarding the cost-effectiveness
of sentinel node biopsy in the average breast cancer patient and recommended
measurement of longer term costs and outcomes before conclusions could be reached
on this subject [246].
7.1.4 Problems of sentinel node biopsy
The various pitfalls and side effects of sentinel node biopsy have been discussed in
the introduction so do not need to be repeated here. The problem of a false negative
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sentinel node biopsy however, needs addressing. A meta-analysis of eleven studies of
sentinel node biopsy followed by axillary node dissection concluded that the false
negative rate for the technique was 5% and that sentinel node reflected the status of
the axilla in 97% of patients [247]. This figure of a 5% false negative rate is likely to
be realistic with the majority of studies reporting false negative rates at between 0%
and 11.9% [150, 157, 160, 161, 163, 164, 168]. As demonstrated in chapter 2 of this
thesis, axillary node sample was associated with a false negative rate of 9.75%,
which assumes that all axillary recurrences were a result of missed disease present at
the time of surgery. Level III axillary clearance was also associated with a false
negative rate of 2.9% in that five patients who were node-negative subsequently
developed axillary recurrence. Perhaps the axillary relapse rate is not a true reflection
of false negatives but this representation may help to bring into context the small
number of false negatives associated with an axillary node sample and with sentinel
node biopsy.
It is clear that some patients will always develop axillary recurrence despite
apparently adequate surgery and this may not necessarily be fairly blamed on the
surgical technique but rather blamed on the nature of aggressive disease. A figure of
a 5% false negative rate may thus be considered an acceptable compromise against
the unnecessary indiscriminate clearance of all patients' axillae. This figure may be
minimised by the careful selection of patients for sentinel node biopsy, by the use of
a combined mapping procedure, by the careful attention to detail during surgery
which should result in removal of all lymph nodes taking up mapping agents not
only the hottest or most deeply stained and by the intraoperative palpation of the
surgically opened axilla to check for and remove clinically suspicious lymph nodes
in addition to sentinel nodes. This coupled with careful follow-up should help to
reduce the false negatives to a minimum whilst detecting any recurrent axillary
disease early on when salvage axillary clearance still remains an option.
The other problem of sentinel node biopsy highlighted by this research thesis is that
of post-operative breast and axillary seroma formation and ofbreast infection. These
complications whilst minor, can be upsetting for the patient but are easier to deal
with ifpatients are warned of the risk before surgery. Prophylactic antibiotics and
wound drainage have been discussed earlier and most seromas resolved rapidly with
232
one or two aspirations in the outpatient clinic. If clinicians are aware of the slightly
higher risk of these complications they can be easily detected and managed with
minimal disturbance to the patient.
7.1.5 Findings of thesis and conclusions
A retrospective review of 855 patients with Tl-3 NO-1 MO breast cancer has revealed
the survival for node-negative breast cancer to be over 70% after a median follow-up
of 8.2 years. The treatment received to the axilla by these patients was either a
surgical clearance of all axillary lymph nodes up to and including level III nodes or
an axillary node sample of at least four lower axillary nodes. Neither group of
patients had axillary radiotherapy. The survival was similar regardless of the axillary
procedure carried out. The suggestion here is that a complete clearance of axillary
lymph nodes to level III is an unnecessarily invasive operation in node-negative
patients, as it does not improve long-term survival. Conversely, axillary recurrences
were significantly more common in patients who received a four-node axillary
sample rather than an axillary clearance. The logical assumption was to conclude that
some of these patients were understaged by a four-node axillary sample and that
positive axillary disease was missed by this operation.
The survival for node-positive breast cancer patients was approximately 20% lower
than for node-negative patients at around 55% after a median follow-up of 8.2 years.
Treatment received to the axilla was either an axillary clearance of all axillary lymph
nodes up to and including level III nodes or a four-node axillary sample of lower
axillary nodes followed by post-operative axillary radiotherapy. Survival figures
were similar regardless of the axillary treatment received. The suggestion here is that
axillary radiotherapy following an axillary sample is equivalent treatment to a level
III axillary clearance of the involved axilla. As in the case of node-negative patients
however, axillary recurrences were significantly more common in patients who
received a four-node axillary sample plus axillary radiotherapy rather than an axillary
clearance. The conclusion here was that axillary clearance provides better local
control of the involved axilla than axillary radiotherapy. Further analysis revealed
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that patients with four or more involved nodes following an axillary sample were
significantly more likely to develop axillary recurrence than those with three or
fewer nodes involved. It was concluded that patients with four or more involved
axillary lymph nodes after an axillary sample should have a second operation to clear
the remaining lymph nodes but that patients with three or fewer involved nodes are
adequately treated by axillary radiotherapy.
The clear difference in survival between node-positive and node-negative patients
demonstrates the importance of accurate axillary staging. Axillary recurrence is
infrequent occurring in less than 10% of patients overall during a 10-year period of
follow-up but the effects of it are devastating to the patient both physically and
psychologically. Although axillary recurrence does not affect overall patient survival,
it does affect the individual survival of patients who develop it. Survival following
axillary recurrence is less than 50%. The mean time to axillary recurrence is 4.5
years in this study. Close observation of the axilla is thus mandatory for all patients
post-operatively. Node-positive patients treated by axillary node sample followed by
axillary radiotherapy had the highest rate of axillary recurrence with a rate of 10.7%
over a 10-year follow-up period. It is hoped that this rate of recurrence will fall if all
patients return for an axillary clearance if found to have four or more positive lymph
nodes after an axillary sample. Complete control of the axilla in all patients is not
possible using present management as a few patients continue to return with axillary
recurrence after an axillary clearance even if they were node-negative. In these
patients aggressive primary disease may be responsible and this is another subject
outside the scope of this thesis.
Axillary sampling thus potentially misses axillary disease in a small number of
patients. The technique of sentinel node biopsy and lymphatic mapping aims to
improve on this problem associated with axillary sampling without the need for
radical surgery and the logic behind this has already been explained in the
introduction. Phase one of the ALMANAC trial in Edinburgh has proved that
sentinel node biopsy is not difficult to perform and is easily reproducible. Using a
combined mapping technique with the use of blue dye and a radiopharmaceutical it
can identify a sentinel node in close to 100% of patients. Patients with obvious nodal
disease should not have sentinel node biopsy and should be treated by axillary
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clearance and systemic therapy if they have operable disease and are clinically fit.
Patients in whom a sentinel node is not easily found (i.e. a failed mapping procedure)
should be treated by a conventional axillary procedure according to their clinical
disease stage (i.e axillary sample or clearance).
Sentinel node biopsy in clinically node-negative patients with Tl-2 breast cancer
detects twice as many axillary metastases than axillary node sample as demonstrated
in chapter 4. Although numbers are too small to reach statistical significance the
figures are encouraging. It may prove necessary to remove fewer lymph nodes during
a sentinel node biopsy than during an axillary node sample in order to acquire this
information but the longer-term results must be awaited before we can assume this. If
this proves true, sentinel node biopsy has the potential to provide the breast surgeon
and breast oncologist with more accurate information regarding the status of the
axillary lymph nodes with a non-radical operation and in turn allow better decisions
to be made on subsequent regional and systemic therapy. Sentinel node biopsy has
not been associated with any axillary recurrences after a median follow-up of 18
months. Sentinel node biopsy was associated with more immediate post-operative
complications such as breast seroma and infection but caused less post-operative
sensory alteration than an axillary sample.
Imprint cytology of axillary lymph nodes can rapidly provide accurate intraoperative
information on the axillary status of over 99% of lymph nodes when using toluidine
blue to stain lymph nodes. It has the advantage over frozen section of allowing all
lymph node tissue to be retained for further histological analysis. It is easy to
perform and nodes can be processed very rapidly without the need for expensive
equipment such as that required for frozen section histology. Immunohistochemistry
of imprints using antibody to pancytokeratin does not improve on the results with
toluidine blue.
Intraoperative imprint cytology is worth considering as an option to avoid two
operations in a small group of node-positive patients (up to 15-20% in T1 breast
cancer). It is not associated with false positive results when using toluidine blue so a
positive result allows the surgeon to proceed to immediate axillary clearance whilst
the patient is on the operating table.
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The clinical significance of occult lymph node micrometastases remains a subject of
considerable debate. The findings of the study detailed in chapter 6 are not in
agreement with the majority of larger studies published during the last 10 years,
which have reported negative effects on disease-free and overall survival from lymph
node micrometastases [48, 58, 64, 235]. Other studies have however, reported similar
to results to those reported in chapter 6 of no clinical correlation between lymph
node micrometastases and axillary recurrence or overall survival [248, 249]. Clearly,
as breast cancer is a heterogeneous entity with multiple possible confounding factors,
it is vital that all factors are taken into consideration including patient characteristics,
tumour characteristics, the number of levels of each node examined by the
pathologist, whether or not to perform immunohistochemistry, and so on, to allow a
structured and critical analysis of the many different clinical and histological
possibilities that face us in our every day work. It is essential that a clear definition
ofwhat constitutes a micrometastasis is agreed upon based on its clinical relevance
otherwise continued poorly structured study merely becomes an academic exercise.
Until a consensus has been reached on the best way to manage lymph node
micrometastases, it cannot be advised to base therapy decisions on their presence.
Patients with lymph node micrometastases who are otherwise lymph node negative
should have their progress followed carefully.
236
8. Bibliography
1. Haagensen, C., Diseases ofthe breast. 3rd ed. 1986, Philadelphia: Saunders.
2. Halsted, W., The results ofradical operations for the cure ofcarcinoma of
the breast. Annals of surgery, 1907. 46: p. 1-19.
3. Patey, D.H. and W.H. Dyson, The prognosis ofcarcinoma of the breast in
relation to the type ofoperation performed. British Journal of Cancer, 1948.
2: p. 7-13.
4. McWhirter, R., Radiotherapy. Lancet, 1947. 2: p. 873.
5. McWhirter, R., The role ofsimple mastectomy and radiotherapy in the
treatment ofcancer ofthe breast. Br J Radiol, 1948. 21: p. 599-610.
6. Forrest, A.P.M. and P.B. Kunkler, Breast cancer management of the early
case. Br J Hosp Med, 1968. 1: p. 398-407.
7. Forrest, A.P.M., M.M. Roberts, P. Preece, J.M. Henk, H. Campbell, L.E.
Hughes, et al., The Cardiff-St. Mary's trial. Br J Surg, 1974. 61: p. 766-9.
8. Roberts, M.M., A.P.M. Forrest, L.H. Blumgart, H. Campbell, M. Davies,
E.N. Gleave, et ah, Simple versus radical mastectomy. Lancet, 1973. 1(1973):
p. 1073-1076.
9. Gray, H., Mammary Lymphatic Drainage, in Gray's Anatomy, P. Williams,
Editor. 1999, Churchill-Livingstone, p. 1431-4, 1605-6, 1615.
10. Turner-Warwick, R.T., The Lymphatics of the breast. Br J Surg, 1959. 46: p.
574-582.
11. Ganong, W.F., Review ofmedical physiology. 16 ed. 1993: Appleton and
Lange. 398-413.
12. Dixon, J.M., J.R.C. Sainsbury, N.J. Bundred, R.E. Mansel, R.W. Blarney,
W.R. Miller, and e. ah, ABC ofbreast diseases. 2nd ed, ed. J.M. Dixon. 2000:
BMJ Books. Ch2 pi 1.
13. Cotran, R.S., V. Kumar, and S.L. Robbins, Robbins'pathologic basis of
disease. 5th ed. 1994: W.B. Saunders Co. 1099-1108.
14. Lambah, P.A. and J.M. Dixon, Breast cancer: detection and management.
The Practitioner, 2000. 244: p. 884-898.
15. Chadha, M., A.B. Chabon, P. Friedmann, and B. Vikram, Predictors of
axillary lymph node metastases in patients with T1 breast cancer. A
multivariate analysis. Cancer, 1994. 73(2): p. 350-3.
16. Rivadeneira, D.E., R.M. Simmons, P.J. Christos, K. Hanna, J.M. Daly, and
M.P. Osborne, Predictivefactors associated with axillary lymph node
metastases in Tla and Tib breast carcinomas: analysis in more than 900
patients. J Am Coll Surg, 2000. 191(1): p. 1-6; discussion 6-8.
17. Olivotto, I.A., J.S.H. Jackson, D. Mates, S. Andersen, W. Davidson, C.J.
Bryce, and J. Ragaz, Prediction ofaxillary lymph node involvement ofwomen
with invasive breast carcinoma. Cancer, 1998. 83(5): p. 948-955.
18. Mittra, I., A.A. Redkar, and R.A. Badwe, Prognosis ofbreast cancer:
evidencefor interaction between c-erbB-2 overexpression and number of
involved axillary lymph nodes. J Surg Oncol, 1995. 60(2): p. 106-11.
237
19. Sonnenschein, E., P. Toniolo, M.B. Terry, P.F. Bruning, I. Kato, K.L.
Koenig, and R.E. Shore, Bodyfat distribution and obesity in pre- and
postmenopausal breast cancer. Int J Epidemiol, 1999. 28(6): p. 1026-31.
20. den Tonkelaar, I., J.C. Seidell, H.J. Collette, and F. de Waard, Obesity and
subcutaneous fatpatterning in relation to breast cancer in postmenopausal
women participating in the Diagnostic Investigation ofMammary Cancer
Project. Cancer, 1992. 69(11): p. 2663-7.
21. Tartter, P.I., A.E. Papatestas, J. Ioannovich, M.N. Mulvihill, G. Lesnick, and
A.H. Aufses, Jr., Cholesterol and obesity as prognostic factors in breast
cancer. Cancer, 1981. 47(9): p. 2222-1.
22. Schapira, D.V., N.B. Kumar, G.H. Lyman, and C.E. Cox, Obesity and body
fat distribution and breast cancer prognosis. Cancer, 1991. 67(2): p. 523-8.
23. Sohrabi, A., J. Sandoz, J.S. Spratt, and H.C. Polk, Jr., Recurrence ofbreast
cancer. Obesity, tumor size, and axillary lymph node metastases. Jama, 1980.
244(3): p. 264-5.
24. Chua, B., O. Ung, R. Taylor, and J. Boyages, Frequency andpredictors of
axillary lymph node metastases in invasive breast cancer. ANZ J Surg, 2001.
71(12): p. 723-8.
25. Choong, P.L., C.J. deSilva, H.J. Dawkins, G.F. Sterrett, P. Robbins, J.M.
Harvey, et al., Predicting axillary lymph node metastases in breast carcinoma
patients. Breast Cancer Res Treat, 1996. 37(2): p. 135-49.
26. Gonzalez-Vela, M.C., M.F. Garijo, F.A. Fernandez, L. Buelta, and J.F. Val-
Bernal, Predictors ofaxillary lymph node metastases in patients with invasive
breast carcinoma by a combination ofclassical and biological prognostic
factors. Pathol Res Pract, 1999.195(9): p. 611-8.
27. Mitsuyama, S., K. Anan, S. Toyoshima, K. Nishihara, Y. Abe, T. Iwashita, et
al., Histopathological Predictors ofAxillary Lymph Node Metastases in
Patients with Breast Cancer. Breast Cancer, 1999. 6(3): p. 237-241.
28. Caldarola, L., P. Calderini, P. Volterrani, F. Di Carlo, and P. Gaglia, The
correlation between estrogen receptor status, axillary-node metastases and
disease-free interval after surgery in primary breast cancer. Ital J Surg Sci,
1983.13(3): p. 179-85.
29. Horst, H.A., H.P. Horny, H.J. Gent, C. Sellschopp, and J. Hedderich,
[Biological significance ofestrogen receptor status in axillary lymph node
metastases of invasive ductal breast cancers]. Klin Wochenschr, 1988.
66(23): p. 1160-6.
30. Kambouris, A.A., Axillary node metastases in relation to size and location of
breast cancers: analysis of147patients. Am Surg, 1996. 62(7): p. 519-24.
31. Veronesi, U. and P. Valagussa, Inefficacy ofinternal mammary nodes
dissection in breast cancer surgery. Cancer, 1981. 47(1): p. 170-5.
32. Lacour, J., P. Bucalossi, E. Cacers, G. Jacobelli, T. Koszarowski, M. Le, et
al., Radical mastectomy versus radical mastectomy plus internal mammary
dissection. Five-year results ofan international cooperative study. Cancer,
1976. 37(1): p. 206-14.
33. Chu, J.S., W.J. Lee, T.C. Chang, K.J. Chang, and H.C. Hsu, Correlation
between tumor angiogenesis and metastasis in breast cancer. J Formos Med
Assoc, 1995. 94(7): p. 373-8.
238
34. Gasparini, G., M. Barbareschi, P. Boracchi, P. Verderio, O. Caffo, S. Meli, et
al., Tumor Angiogenesis Predicts Clinical Outcome ofNode-Positive Breast
Cancer Patients Treated With Adjuvant Hormone Therapy or Chemotherapy.
Cancer J Sci Am, 1995. 1(2): p. 131.
35. Kato, T., S. Kameoka, T. Kimura, T. Nishikawa, and T. Kasajima,
Angiogenesis and blood vessel invasion as prognostic indicators for node-
negative breast cancer. Breast Cancer Res Treat, 2001. 65(3): p. 203-15.
36. Guidi, A.J., D.A. Berry, G. Broadwater, M. Perloff, L. Norton, M.P. Barcos,
and D.F. Hayes, Association ofangiogenesis in lymph node metastases with
outcome ofbreast cancer. J Natl Cancer Inst, 2000. 92(6): p. 486-92.
37. Heimann, R., D. Ferguson, C. Powers, W.M. Recant, R.R. Weichselbaum,
and S. Hellman, Angiogenesis as a predictor of long-term survivalfor
patients with node-negative breast cancer. J Natl Cancer Inst, 1996. 88(23):
p. 1764-9.
38. Aranda, F.I. and J.B. Laforga, Microvessel quantitation in breast ductal
invasive carcinoma. Correlation with proliferative activity, hormonal
receptors and lymph node metastases. Pathol Res Pract, 1996. 192(2): p. 124-
9.
39. Marinho, A., R. Soares, J. Ferro, M. Lacerda, and F.C. Schmitt, Angiogenesis
in breast cancer is related to age but not to other prognostic parameters.
Pathol Res Pract, 1997. 193(4): p. 267-73.
40. Magennis, D.P., Angiogenesis: a new prognostic markerfor breast cancer.
Br J Biomed Sci, 1998. 55(3): p. 214-20.
41. Recht, A. and M.J. Houlihan, Axillary lymph nodes and breast cancer: a
review. Cancer, 1995. 76(9): p. 1491-512.
42. Papadatos, G., A.M. Rangan, T. Psarianos, O. Ung, R. Taylor, and J.
Boyages, Probability ofaxillary node involvement in patients with tubular
carcinoma ofthe breast. British Journal of Surgery, 2001. 88(6): p. 860-864.
43. Cascinelli, N., M. Greco, R. Bufalino, C. Clemente, D. Galluzzo, V. delle
Donne, et al., Prognosis ofbreast cancer with axillary node metastases after
surgical treatment only. Eur J Cancer Clin Oncol, 1987. 23(6): p. 795-9.
44. Canavese, G., A. Catturich, C. Vecchio, D. Tomei, M. Gipponi, P. Bruzzi,
and F. Badellino, Prognostic role of lymph-node level involvement in patients
undergoing axillary dissection for breast cancer. Eur J Surg Oncol, 1998.
24(2): p. 104-9.
45. Fisher, B., M. Bauer, D.L. Wickerham, C.K. Redmond, E.R. Fisher, A.B.
Cruz, et al., Relation ofnumber ofpositive axillary nodes to the prognosis of
patients with primary breast cancer. An NSABP update. Cancer, 1983. 52(9):
p. 1551-7.
46. Huvos, A.G., R.V.P. Hutter, and J.W. Berg, Significance ofaxillary
macrometastases and micrometastases in mammary cancer. Annals of
surgery, 1971. 173(1): p. 44-46.
47. Nasser, I.A., A.K. Lee, S. Bosari, R. Saganich, G. Heatley, and M.L.
Silverman, Occult axillary lymph node metastases in "node-negative" breast
carcinoma. Hum Pathol, 1993. 24(9): p. 950-7.
239
48. Cote, R.J., H.F. Peterson, B. Chaiwun, R.D. Gelber, A. Goldhirsch, M.
Castiglione-Gertsch, et al., Role of immunohistochemical detection oflymph-
node metastases in management ofbreast cancer. International Breast
Cancer Study Group. Lancet, 1999. 354(9182): p. 896-900.
49. Karalak, A. and P. Homcha-Em, Occult axillary lymph node metastases
discovered by serial section in node-negative breast cancer. J Med Assoc
Thai, 1999. 82(10): p. 1017-9.
50. Kohlberger, P., M. Gantert, T. Volk-Orlowska, D.G. Kieback, and G. Gitsch,
Immunohistochemical detection oflymph node metastases in node-negative
breast cancer patients. Anticancer Res, 2001. 21(1B): p. 697-9.
51. Wu, J., Z. Yu, and G. Li, [Detection ofmicrometastases in axillary lymph
nodes ofnode-negative breast cancer patients and its clinical significance].
Zhonghua Zhong Liu Za Zhi, 1996. 18(4): p. 289-91.
52. Schoenfeld, A., Y. Luqmani, D. Smith, S. O'Reilly, S. Shousha, H.D. Sinnett,
and R.C. Coombes, Detection ofbreast cancer micrometastases in axillary
lymph nodes by using polymerase chain reaction. Cancer Res, 1994. 54(11):
p. 2986-90.
53. Aihara, T., Y. Fujiwara, M. Ooka, I. Sakita, Y. Tamaki, and M. Monden,
Mammaglobin B as a novel markerfor detection ofbreast cancer
micrometastases in axillary lymph nodes by reverse transcription-polymerase
chain reaction. Breast Cancer Res Treat, 1999. 58(2): p. 137-40.
54. Anderson, T.J., The challenge ofsentinel lymph node biopsy. Flistopathology,
1999. 35(1): p. 82-4.
55. Group, I.L.B.C.S., Prognostic importance ofoccult axillary lymph node
micrometastasesfrom breast cancers. International (Ludwig) Breast Cancer
Study Group. Lancet, 1990. 335(8705): p. 1565-8.
56. Gusterson, B.A. and R. Ott, Occult axillary lymph node micrometastases in
breast cancer. Lancet, 1990. 336: p. 434-435.
57. Prognostic importance ofoccult axillary lymph node micrometastases from
breast cancers. International (Ludwig) Breast Cancer Study Group. Lancet,
1990. 335(8705): p. 1565-8.
58. Masuda, N., Y. Tamaki, I. Sakita, M. Ooka, T. Ohnishi, M. Kadota, et al.,
Clinical significance ofmicrometastases in axillary lymph nodes assessed by
reverse transcription-polymerase chain reaction in breast cancer patients.
Clin Cancer Res, 2000. 6(11): p. 4176-85.
59. McGuckin, M.A., M.C. Cummings, M.D. Walsh, B.G. Hohn, I.C. Bennett,
and R.G. Wright, Occult axillary node metastases in breast cancer: their
detection and prognostic significance. Br J Cancer, 1996. 73(1): p. 88-95.
60. Fisher, E.R., S. Swamidoss, C.H. Lee, H. Rockette, C. Redmond, and B.
Fisher, Detection and significance ofoccult axillary node metastases in
patients with invasive breast cancer. Cancer, 1978. 42(4): p. 2025-31.
61. Viale, G., E. Maiorano, G. Mazzarol, S. Zurrida, V. Galimberti, A. Luini, et
al., Histologic detection and clinical implications ofmicrometastases in
axillary sentinel lymph nodes forpatients with breast carcinoma. Cancer,
2001. 92(6): p. 1378-84.
240
62. Kamath, V.J., R. Giuliano, E.L. Dauway, A. Cantor, C. Berman, N.N. Ku, et
al., Characteristics of the sentinel lymph node in breast cancer predict further
involvement ofhigher-echelon nodes in the axilla: a study to evaluate the
needfor complete axillary lymph node dissection. Arch Surg, 2001. 136(6): p.
688-92.
63. Tjan-Heijnen, V.C., P. Buit, L.M. de Widt-Evert, T.J. Ruers, and L.V. Beex,
Micro-metastases in axillary lymph nodes: an increasing classification and
treatment dilemma in breast cancer due to the introduction of the sentinel
lymph node procedure. Breast Cancer Res Treat, 2001. 70(2): p. 81-8.
64. Yeatman, T.J. and C.E. Cox, The significance ofbreast cancer lymph node
micrometastases. Surg Oncol Clin N Am, 1999. 8(3): p. 481-96, ix.
65. Trojani, M., I. de Mascarel, F. Bonichon, J.M. Coindre, and G. Delsol,
Micrometastases to axillary lymph nodes from carcinoma ofbreast: detection
by immunohistochemistry andprognostic significance. Br J Cancer, 1987.
55(3): p. 303-6.
66. de Mascarel, I., F. Bonichon, J.M. Coindre, and M. Trojani, Prognostic
significance ofbreast cancer axillary lymph node micrometastases assessed
by two special techniques: reevaluation with longerfollow-up. Br J Cancer,
1992. 66(3): p. 523-7.
67. Klauber-DeMore, N., K.J. Van Zee, I. Linkov, P.I. Borgen, and W.L. Gerald,
Biological behavior ofhuman breast cancer micrometastases. Clin Cancer
Res, 2001. 7(8): p. 2434-9.
68. Veronesi, U., F. Rilke, A. Luini, V. Sacchini, V. Galimberti, T. Campa, et al.,
Distribution ofaxillary node metastases by level of invasion. An analysis of
539 cases. Cancer, 1987. 59(4): p. 682-7.
69. Danforth, D.N., Jr., P.A. Findlay, H.D. McDonald, M.E. Lippman, C.M.
Reichert, T. d'Angelo, et al., Complete axillary lymph node dissection for
stage I-II carcinoma ofthe breast. J Clin Oncol, 1986. 4(5): p. 655-62.
70. Barth, R.J., Jr., D.N. Danforth, Jr., D.J. Venzon, K.L. Straus, T. d'Angelo,
M.J. Merino, and L. Gerber, Level ofaxillary involvement by lymph node
metastases from breast cancer is not an independent predictor ofsurvival.
Arch Surg, 1991. 126(5): p. 574-7.
71. Sosa, J.A., M. Diener-West, Y. Gusev, M.A. Choti, J.R. Lange, W.C. Dooley,
and M.A. Zeiger, Association between extent ofaxillary lymph node
dissection and survival in patients with stage I breast cancer. Ann Surg
Oncol, 1998. 5(2): p. 140-9.
72. Sun, A., F.F. Liu, M. Pintilie, and G. Rawlings, Outcome in breast cancer
managed without an initial axillary lymph node dissection. Radiother Oncol,
1998. 48(2): p. 191-6.
73. Lagares-Garcia, J.A., G. Garguilo, S. Kurek, G. LeBlond, and F. Diaz,
Axillary lymph node dissection in breast cancer: an evolving question? Am
Surg, 2000. 66(1): p. 66-72.
74. Feigelson, B., J. Acosta, H. Feigelson, A. Findley, and E. Saunders, T1 Breast
carcinoma in women 70 years ofage and older may not require axillary
















Jackson, J.S., I.A. Olivotto, M.D.E. Wai, C. Grau, D. Mates, and J. Ragaz, A
decision analysis ofthe effect ofavoiding axillary lymph node dissection in
low risk women with invasive breast carcinoma. Cancer, 2000. 88(8): p.
1852-62.
Moore, M.P. and D.W. Kinne, Is axillary lymph node dissection necessary in
the routine management ofbreast cancer? Yes. Important Adv Oncol, 1996:
p. 245-50.
Schwartz, G.F., A.L. Rosenberg, B.F. Danoff, C.M. Mansfield, and S.A.
Feig, Lumpectomy and level I axillary dissection prior to irradiation for
"operable" breast cancer. Ann Surg, 1984. 200(4): p. 554-60.
Siegel, B.M., K.A. Mayzel, and S.M. Love, Level I and II axillary dissection
in the treatment ofearly-stage breast cancer. An analysis of259 consecutive
patients. Arch Surg, 1990. 125(9): p. 1144-7.
Forrest, A.P.M., D. Everington, C. McDonald, R.J.C. Steele, U. Chetty, and
H.J. Stewart, The Edinburgh randomised trial ofaxillary sampling or
clearance after mastectomy. Br J Surg, 1995. 82: p. 1504-1508.
Axelsson, C.K., II.T. Mouridscn, and K. Zedeler, Axillary dissection of level I
and II lymph nodes is important in breast cancer classification. The Danish
Breast Cancer Cooperative Group (DBCG). Eur J Cancer, 1992. 28A(8-9): p.
1415-8.
Boova, R.S., R. Bonanni, and F.E. Rosato, Patterns ofaxillary nodal
involvement in breast cancer. Predictability of level one dissection. Ann
Surg, 1982. 196(6): p. 642-4.
Lloyd, L.R., R.K. Waits, Jr., D. Schroder, A. Hawasli, P. Rizzo, and J. Rizzo,
Axillary dissection for breast carcinoma. The myth ofskip metastasis. Am
Surg, 1989. 55(6): p. 381-4.
Tocchi, A., G. Mazzoni, E. Bettelli, M. Miccini, A. Giuliani, and D. Cassini,
Impact ofaxillary level I and II lymphnode dissection on the therapy ofstage
I and II breast cancer. Panminerva Med, 2001. 43(2): p. 103-7.
Chetty, U., W. Jack, R.J. Prescott, C. Tyler, and A. Rodger, Management of
the axilla in operable breast cancer treated by breast conservation: a
randomized clinical trial. Edinburgh Breast Unit. Br J Surg, 2000. 87(2): p.
163-9.
Dufour, P., J.C. Laurent, G. Depadt, and A. Demaille, [Breast cancer: can
axillary dissection be restricted to Berg stages 1 and 2? Study of895 cases].
J Gynecol Obstet Biol Reprod (Paris), 1991. 20(2): p. 171-7.
Du, X., J.L. Freeman, and J.S. Goodwin, The declining use ofaxillary
dissection in patients with early stage breast cancer. Breast Cancer Res
Treat, 1999. 53(2): p. 137-44.
Gervasoni, J.E., Jr., C. Taneja, M.A. Chung, and B. Cady, Axillary dissection
in the context ofthe biology of lymph node metastases. Am J Surg, 2000.
180(4): p. 278-83.
Orr, R.K., The impact ofprophylactic axillary node dissection on breast
cancer survival—a Bayesian meta-analysis. Ann Surg Oncol, 1999. 6(1): p.
109-16.
242
89. Fisher, B., C. Redmond, E.R. Fisher, M. Bauer, N. Wolmark, D.L.
Wickerham, et al., Ten-year results ofa randomized clinical trial comparing
radical mastectomy and total mastectomy with or without radiation. N Engl J
Med, 1985. 312(11): p. 674-81.
90. Forrest, A.P., H.J. Stewart, M.M. Roberts, and R.J. Steele, Simple
mastectomy and axillary node sampling (pectoral node biopsy) in the
management ofprimary breast cancer. Ann Surg, 1982. 196(3): p. 371-8.
91. Port, E.R., L.K. Tan, P.I. Borgen, and K.J. Van Zee, Incidence ofaxillary
lymph node metastases in Tla and Tib breast carcinoma. Ann Surg Oncol,
1998. 5(1): p. 23-7.
92. Steele, R.J., A.P. Forrest, T. Gibson, H.J. Stewart, and U. Chetty, The efficacy
oflower axillary sampling in obtaining lymph node status in breast cancer: a
controlled randomized trial. Br J Surg, 1985. 72(5): p. 368-9.
93. Ahlgren, J., L. Holmberg, J. Bergh, and G. Liljegren, Five-node biopsy ofthe
axilla: an alternative to axillary dissection oflevels I—II in operable breast
cancer. Eur J Surg Oncol, 2001. 28(2): p. 97-102.
94. Dent, D.M., C.A. Gudgeon, and E.M. Murray, Mastectomy with axillary
clearance versus mastectomy without it. Late results ofa trial in which
patients had no adjuvant chemo-, radio- or endocrine therapy. S Afr Med J,
1996. 86(6): p. 670-1.
95. Kjaergaard, J., M. Blichert-Toft, J.A. Andersen, F. Rank, and B.V. Pedersen,
Probability offalse negative nodal staging in conjunction with partial
axillary dissection in breast cancer. Br J Surg, 1985. 72(5): p. 365-7.
96. Graversen, H.P., M. Blichert-Toft, J.A. Andersen, and K. Zedeler, Breast
cancer: risk ofaxillary recurrence in node-negative patients followingpartial
dissection ofthe axilla. Eur J Surg Oncol, 1988. 14(5): p. 407-12.
97. Haffty, B.G., B. Ward, P. Pathare, R. Salem, C. McKhann, M. Beinfield, et
al., Reappraisal ofthe role ofaxillary lymph node dissection in the
conservative treatment ofbreast cancer. J Clin Oncol, 1997. 15(2): p. 691-
700.
98. Kuznetsova, M., J.C. Graybill, T.W. Zusag, W.F. Hartsell, and K.L. Griem,
Omission ofaxillary lymph node dissection in early-stage breast cancer:
effect on treatment outcome. Radiology, 1995. 197(2): p. 507-10.
99. Moffat, F.L., G.M. Senofsky, K. Davis, K.C. Clark, D.S. Robinson, and A.S.
Ketcham, Axillary node dissection for early breast cancer: some is good, but
all is better. J Surg Oncol, 1992. 51(1): p. 8-13.
100. Velanovich, V., Axillary lymph node dissection for breast cancer: a decision
analysis ofTl lesions. Ann Surg Oncol, 1998. 5(2): p. 131-9.
101. Van Lancker, M., C. Goor, R. Sacre, J. Lamote, S. Van Belle, N. De Coene,
et al., Patterns ofaxillary lymph node metastasis in breast cancer. Am J Clin
Oncol, 1995. 18(3): p. 267-72.
102. de Freitas, R., Jr., M.V. Costa, S.V. Schneider, M.A. Nicolau, and E.
Marussi, Accuracy ofultrasound and clinical examination in the diagnosis of
axillary lymph node metastases in breast cancer. Eur J Surg Oncol, 1991.
17(3): p. 240-4.
103. Tate, J.J., V. Lewis, T. Archer, P.G. Guyer, G.T. Royle, and I. Taylor,
Ultrasound detection ofaxillary lymph node metastases in breast cancer. Eur
J Surg Oncol, 1989. 15(2): p. 139-41.
243
104. Pamilo, M., M. Soiva, and E.M. Lavast, Real-time ultrasound, axillary
mammography, and clinical examination in the detection ofaxillary lymph
node metastases in breast cancer patients. J Ultrasound Med, 1989. 8(3): p.
115-20.
105. Walsh, J.S., J.M. Dixon, U. Chetty, and D. Paterson, Colour Doppler studies
ofaxillary node metastases in breast carcinoma. Clin Radiol, 1994. 49(3): p.
189-91.
106. Kvistad, K.A., J. Rydland, H.B. Smethurst, S. Lundgren, H.E. Fjosne, and O.
Haraldseth, Axillary lymph node metastases in breast cancer: preoperative
detection with dynamic contrast-enhanced MRI. Eur Radiol, 2000. 10(9): p.
1464-71.
107. Bonnema, J., A.N. van Geel, B. van Ooijen, S.P. Mali, S.L. Tjiam, S.C.
Henzen-Logmans, et al., Ultrasound-guided aspiration biopsyfor detection of
nonpalpable axillary node metastases in breast cancer patients: new
diagnostic method. World J Surg, 1997. 21(3): p. 270-4.
108. Lindfors, K.K., J.E. Meyer, P.M. Busse, D.B. Kopans, J.E. Munzenrider, and
J.M. Sawicka, CT evaluation oflocal and regional breast cancer recurrence.
AJR Am J Roentgenol, 1985. 145(4): p. 833-7.
109. March, D.E., R.J. Wechsler, A.B. Kurtz, A.L. Rosenberg, and L. Needleman,
CT-pathologic correlation ofaxillary lymph nodes in breast carcinoma. J
Comput Assist Tomogr, 1991. 15(3): p. 440-4.
110. Hata, Y., Y. Ogawa, A. Nishioka, T. Inomata, and S. Yoshida, Thin section
computed tomography in the prone position for detection ofaxillary lymph
node metastases in breast cancer. Oncol Rep, 1998. 5(6): p. 1403-6.
111. Acland, K.M., C. Healy, E. Calonje, M. O'Doherty, T. Nunan, C. Page, et al.,
Comparison ofpositron emission tomography scanning and sentinel node
biopsy in the detection ofmicrometastases ofprimary cutaneous malignant
melanoma. J Clin Oncol, 2001. 19(10): p. 2674-8.
112. Ohta, M., Y. Tokuda, Y. Saitoh, Y. Suzuki, A. Okumura, M. Kubota, et al.,
Comparative efficacy ofpositron emission tomography and ultrasonography
in preoperative evaluation ofaxillary lymph node metastases in breast
cancer. Breast Cancer, 2000. 7(1): p. 99-103.
113. Wagner, J.D., D. Schauwecker, D. Davidson, J.J. Coleman, 3rd, S. Saxman,
G. Hutchins, et al., Prospective study offluorodeoxyglucose-positron
emission tomography imaging of lymph node basins in melanoma patients
undergoing sentinel node biopsy. J Clin Oncol, 1999. 17(5): p. 1508-15.
114. Yang, J.H., S.J. Nam, T.S. Lee, H.K. Lee, S.H. Jung, and B.T. Kim,
Comparison of intraoperative frozen section analysis ofsentinel node with
preoperative positron emission tomography in the diagnosis ofaxillary lymph
node status in breast cancer patients. Jpn J Clin Oncol, 2001. 31(1): p. 1-6.
115. Avril, N., J. Dose, F. Janicke, S. Ziegler, W. Romer, W. Weber, et al.,
Assessment ofaxillary lymph node involvement in breast cancer patients with
positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-
deoxy-D-glucose. J Natl Cancer Inst, 1996. 88(17): p. 1204-9.
116. Kissin, M.W., G. Querci della Rovere, D. Easton, and G. Westbury, Risk of
lymphoedemafollowing the treatment ofbreast cancer. Br J Surg, 1986.
73(7): p. 580-4.
244
117. Zurrida, S., R. Orecchia, V. Galimberti, A. Luini, I. Giannetti, B. Ballardini,
et al., Axillary radiotherapy instead ofaxillary dissection: a randomized trial.
Italian Oncological Senology Group. Ann Surg Oncol, 2002. 9(2): p. 156-60.
118. Hoebers, F.J., J.H. Borger, A.A. Hart, J.L. Peterse, E.J. Th, and J.V.
Lebesque, Primary axillary radiotherapy as axillary treatment in breast-
conserving therapyforpatients with breast carcinoma and clinically negative
axillary lymph nodes. Cancer, 2000. 88(7): p. 1633-42.
119. Recht, B.A.E., Stephen B.; Solin, Lawrence J.; Robinson, David S.;, A.F.
Estabrook, Richard E.; Fleming, Gini F.; Formenti, Silvia; Hudis,, J.J.K.
Clifford; Kirshner, David A.; Kuske, Robert R.; Langer, Amy, G.W.J. S.;
Sledge,; Whelan, Timothy J.; Pfister, David G.; for the, and A.S.o.C.
Oncology,
Postmastectomy Radiotherapy; Clinical Practice Guidelines ofthe American
Society ofClinical Oncology. Journal of Clinical Oncology, 2001. 19(5): p.
1539-69.
120. Pierce, L.J., H.A. Oberman, M.H. Strawderman, and A.S. Lichter,
Microscopic extracapsular extension in the axilla: is this an indication for
axillary radiotherapy? Int J Radiat Oncol Biol Phys, 1995. 33(2): p. 253-9.
121. Aitken, R.J., M.N. Gaze, A. Rodger, U. Chetty, and A.P. Forrest, Arm
morbidity within a trial ofmastectomy and either nodal sample with selective
radiotherapy or axillary clearance. Br J Surg, 1989. 76(6): p. 568-71.
122. Liljegren, G. and L. Holmberg, Arm morbidity after sector resection and
axillary dissection with or without postoperative radiotherapy in breast
cancer stage I. Results from a randomised trial. Uppsala-Orebro Breast
Cancer Study Group. Eur J Cancer, 1997. 33(2): p. 193-9.
123. Keramopoulos, A., C. Tsionou, D. Minaretzis, S. Michalas, and D.
Aravantinos, Arm morbidityfollowing treatment ofbreast cancer with total
axillary dissection: a multivariated approach. Oncology, 1993. 50(6): p. 445-
9.
124. Tengrup, I., L. Tennvall-Nittby, I. Christiansson, and M. Laurin, Arm
morbidity after breast-conserving therapyfor breast cancer. Acta Oncol,
2000. 39(3): p. 393-7.
125. McMinn, R., Last's Anatomy. 9th ed. 1994: Churchill Livingstone.
126. Tobin, M.B., H.J. Lacey, L. Meyer, and P.S. Mortimer, The psychological
morbidity ofbreast cancer-related arm swelling. Psychological morbidity of
lymphoedema. Cancer, 1993. 72(11): p. 3248-52.
127. Champagne, L.P. and J.W. Futrell, Lymphedema, in Plastic Surgery Secrets,
J. Weinzweig, Editor. 1999, Hanley and Belfus Inc.: Philadelphia, p. 371.
128. Thompson, A.M., M. Air, W.J.L. Jack, G.R. Kerr, A. Rodger, and U. Chetty,
Arm morbidity after breast conservation and axillary therapy. The Breast,
1995. 4: p. 273-276.
129. Pain, S.J. and A.D. Purushotham, Lymphoedema following surgeryfor breast
cancer. Br J Surg, 2000. 87(9): p. 1128-41.
130. Pani, S.P., P. Vanamail, and J. Yuvaraj, Limb circumference measurementfor
recording edema volume in patients with fdarial lymphedema. Lymphology,
1995. 28: p. 57-63.
245
131. Stranden, E., A Comparison between surface measurements and water
displacement volumetryfor the quantification of leg oedema. Journal of Oslo
City Hospital, 1981. 31: p. 153-5.
132. Casley-Smith, J.R., Measuring and representing peripheral oedema and its
alterations. Lymphology, 1994. 27: p. 56-70.
133. Edwards, T.L., Prevalence and aetiology of lymphoedema after breast cancer
treatment in southern Tasmania. Aust N Z J Surg, 2000. 70(6): p. 412-8.
134. Brismar, B. and I. Ljungdahl, Postoperative lymphoedema after treatment of
breast cancer. Acta Chir Scand, 1983. 149(7): p. 687-9.
135. Jungi, W.F., The prevention and management oflymphoedema after
treatmentfor breast cancer. Int Rehabil Med, 1981. 3(3): p. 129-34.
136. Clark, R., T. Wasilewska, and J. Carter, Lymphoedema: a study ofOtago
women treatedfor breast cancer. Nurs Prax N Z, 1997. 12(2): p. 4-15.
137. Brorson, H. and H. Svensson, Complete reduction oflymphoedema of the arm
by liposuction after breast cancer. Scand J Plast Reconstr Surg Hand Surg,
1997. 31(2): p. 137-43.
138. Ridings, P. and T.E. Bucknall, Modern trends in breast cancer therapy:
towards less lymphoedema? Eur J Surg Oncol, 1998. 24(1): p. 21-2.
139. Maycock, L.A., P. Dillon, and J.M. Dixon, Morbidity related to
intercostobrachial nerve damagefollowing axillary surgeryfor breast
cancer. The Breast, 1998. 7: p. 209-212.
140. Ivens, D., A.L. Hoe, T.J. Podd, C.R. Hamilton, I. Taylor, and G.T. Royle,
Assessment ofmorbidity from complete axillary dissection. Br J Cancer,
1992. 66: p. 136-8.
141. Warmuth, M.A., G. Bowen, L.R. Prosnitz, L. Chu, G. Broadwater, B.
Peterson, et al., Complications ofaxillary node dissection for carcinoma of
the breast. Cancer, 1998. 83(7): p. 1362-8.
142. Maunsell, E., J. Brisson, and L. Deschenes, Arm problems andpsychological
distress after surgeryfor breast cancer. Can J Surg, 1993. 36(4): p. 315-20.
143. Bundred, N.J., D.A. Morgan, and J.M. Dixon, ABC ofbreast diseases.
Management ofregional nodes in breast cancer. Bmj, 1994. 309(6963): p.
1222-5.
144. Kakuda, J.T., M. Stuntz, V. Trivedi, S.R. Klein, and H.I. Vargas, Objective
assessment ofaxillary morbidity in breast cancer treatment. Am Surg, 1999.
65(10): p. 995-8.
145. Ernst, M.F., A.C. Voogd, W. Balder, J.H. Klinkenbijl, and J.A. Roukema,
Early and late morbidity associated with axillary levels I-III dissection in
breast cancer. J Surg Oncol, 2002. 79(3): p. 151-5; discussion 156.
146. Gould, E.A., T. Winship, P.H. Philbin, and H.H. Kerr, Observations on a
"sentinel node" in cancer ofthe parotid. Cancer, 1960. 13: p. 77-78.
147. Cabanas, R.M., An approach for the treatment ofpenile carcinoma. Cancer,
1977. 39: p. 456-466.
148. Wespes, E., J. Simon, and C.C. Schulman, Cabanas approach: is sentinel
node biopsy reliablefor staging penile carcinoma? Urology, 1986. 28(4): p.
278-9.
149. Morton, D.L., D.R. Wen, J.H. Wong, J.S. Economou, L.A. Cagle, F.K.
Storm, et ah, Technical details of intraoperative lymphatic mappingfor early
stage melanoma. Arch Surg, 1992. 127: p. 392-399.
246
150. Guenther, J.M., M. Krishnamoorthy, and L.R. Tan, Sentinel
lymphadenectomyfor breast cancer in a community managed care setting.
Cancer J Sci Am, 1997. 3(6): p. 336-40.
151. Giuliano, A.E., R.C. Jones, M. Brennan, and R. Statman, Sentinel
lymphadenectomy in breast cancer. J Clin Oncol, 1997. 15(6): p. 2345-50.
152. Giuliano, A.E., P.S. Dale, R.R. Turner, D.L. Morton, S.W. Evans, and D.L.
Krasne, Improved axillary staging ofbreast cancer with sentinel
lymphadenectomy. Ann Surg, 1995. 222(3): p. 394-9; discussion 399-401.
153. Alex, J.C. and D.N. Krag, Gamma-probe guided localization oflymph nodes.
Surg Oncol, 1993. 2(3): p. 137-43.
154. Alex, J.C., D.L. Weaver, J.T. Fairbank, B.S. Rankin, and D.N. Krag, Gamma-
probe-guided lymph node localization in malignant melanoma. Surg Oncol,
1993. 2(5): p. 303-8.
155. Krag, D.N., D.L. Weaver, J.C. Alex, and J.T. Fairbank, Surgical resection
and radiolocalization ofthe sentinel lymph node in breast cancer using a
gamma probe. Surg Oncol, 1993. 2(6): p. 335-9; discussion 340.
156. Reynolds, C., R. Mick, J.H. Donohue, C.S. Grant, D.R. Farley, L.S. Callans,
et al., Sentinel lymph node biopsy with metastasis: can axillary dissection be
avoided in some patients with breast cancer? J Clin Oncol, 1999. 17(6): p.
1720-6.
157. Giuliano, A.E., D.M. Kirgan, J.M. Guenther, and D.L. Morton, Lymphatic
mapping and sentinel lymphadenectomyfor breast cancer. Ann Surg, 1994.
220(3): p. 391-8; discussion 398-401.
158. van der Veen, H., O.S. Hoekstra, M.A. Paul, M.A. Cuesta, and S. Meijer,
Gamma probe-guided sentinel node biopsy to select patients with melanoma
for lymphadenectomy. Br J Surg, 1994. 81(12): p. 1769-70.
159. Pijpers, R., G.J. Collet, S. Meijer, and O.S. Hoekstra, The impact ofdynamic
lymphoscintigraphy and gamma probe guidance on sentinel node biopsy in
melanoma. Eur JNucl Med, 1995. 22(11): p. 1238-41.
160. Albertini, J.J., G.H. Lyman, C. Cox, T. Yeatman, L. Balducci, N. Ku, et al.,
Lymphatic mapping and sentinel node biopsy in the patient with breast
cancer. Jama, 1996. 276(22): p. 1818-22.
161. Veronesi, U., G. Paganelli, V. Galimberti, G. Viale, S. Zurrida, M. Bedoni, et
al., Sentinel-node biopsy to avoid axillary dissection in breast cancer with
clinically negative lymph-nodes. Lancet, 1997. 349(9069): p. 1864-7.
162. Meijer, S., G.J. Collet, H.J. Pijpers, L. van Hattum, and O.S. Hoekstra, [Less
axillary dissection necessary due to sentinel node biopsy in patients with
breast carcinoma]. Ned Tijdschr Geneeskd, 1996. 140(45): p. 2239-43.
163. Krag, D., D. Weaver, T. Ashikaga, F. Moffat, V.S. Klimberg, C. Shriver, et
al., The sentinel node in breast cancer—a multicenter validation study. N
Engl J Med, 1998. 339(14): p. 941-6.
164. Cox, C.E., S. Pendas, J.M. Cox, E. Joseph, A.R. Shons, T. Yeatman, et al.,
Guidelines for sentinel node biopsy and lymphatic mapping ofpatients with
breast cancer. Ann Surg, 1998. 227(5): p. 645-51; discussion 651-3.
165. Hill, A.D., K.N. Tran, T. Akhurst, H. Yeung, S.D. Yeh, P.P. Rosen, et al.,
Lessons learnedfrom 500 cases oflymphatic mappingfor breast cancer. Ann
Surg, 1999. 229(4): p. 528-35.
247
166. De Cicco, C., M. Cremonesi, A. Luini, M. Bartolomei, C. Grana, G. Prisco, et
al., Lymphoscintigraphy and radioguided biopsy of the sentinel axillary node
in breast cancer. J Nucl Med, 1998. 39(12): p. 2080-4.
167. van der Ent, F.W., R.A. Kengen, H.A. van der Pol, and A.G. Hoofwijk,
Sentinel node biopsy in 70 unselectedpatients with breast cancer: increased
feasibility by using 10 md radiocolloid in combination with a blue dye
tracer. Eur J Surg Oncol, 1999. 25(1): p. 24-9.
168. Giuliano, A.E., Lymphatic mapping and sentinel node biopsy in breast
cancer. Jama, 1997. 277(10): p. 791-2.
169. Shimazu, K., Y. Tamaki, T. Taguchi, Y. Takamura, and S. Noguchi,
Comparison between periareolar andperitumoral injection ofradiotracerfor
sentinel lymph node biopsy in patients with breast cancer. Surgery, 2002.
131(3): p. 277-86.
170. Borgstein, P.J., S. Meijer, R.J. Pijpers, and P.J. van Diest, Functional
lymphatic anatomyfor sentinel node biopsy in breast cancer: echoesfrom the
past and the periareolar blue method. Ann Surg, 2000. 232(1): p. 81-9.
171. Agwunobi, T.C. and J.L. Boak, Diagnosis ofmalignant breast disease by
axillary lymphoscintigraphy: a preliminary report. Br J Surg, 1978. 65(6): p.
379-83.
172. Ege, G.N., Internal mammary lymphoscintigraphy: a rational adjunct to the
staging and management ofbreast carcinoma. Clinical Radiology, 1978. 29:
p. 453-456.
173. Wilhelm, A.J., G.S. Mijnhout, and E.J. Franssen, Radiopharmaceuticals in
sentinel lymph-node detection - an overview. Eur J Nucl Med, 1999. 26(4
Suppl): p. S36-42.
174. Pijpers, R., S. Meijer, O.S. Hoekstra, G.J. Collet, E.F. Comans, R.P. Boom, et
al., Impact of lymphoscintigraphy on sentinel node identification with
technetium-99m-colloidal albumin in breast cancer. The Journal of Nuclear
Medicine, 1997. 38(3): p. 366-368.
175. Kaplan, W.D., M.A. Davis, and C.M. Rose, A comparison of two technetium-
99m-labeled radiopharmaceuticalsfor lymphoscintigraphy: concise
communication. J Nucl Med, 1979. 20(9): p. 933-7.
176. Offodile, R., C. Floh, S.H. Barsky, S.D. Nelson, R. Elashoff, F.R. Eilber, et
al., Minimally invasive breast carcinoma staging using lymphatic mapping
with radiolabeled dextran. Cancer, 1998. 82(9): p. 1704-8.
177. Paganelli, G., C. Chicco, M. Cremonesi, G. Prisco, P. Calza, A. Luini, et al.,
Optimised sentinel node scintigraphy in breast cancer. Q J Nucl Med, 1998.
42: p. 49-53.
178. Keshtgar, M.R.S., W.A. Waddington, S.R. Lakhani, and P.J. Ell, The sentinel
node in surgical oncology. 1st ed, ed. M.R.S. Keshtgar. 1999, London:
Springer-Verlag. 193.
179. Black, R.B., M.V. Merrick, T.V. Taylor, and A.P. Forrest, Prediction of
axillary metastases in breast cancer by lymphoscintigraphy. Lancet, 1980.
2(8184): p. 15-17.
180. Mazzeo, F., A. Accurso, G. Petrella, S. Capuano, L. Maurelli, L. Celentano,
et al., Pre-operative axillary lymphoscintigraphy in breast cancer: experience
with sub-areolar injection of99Tcm-nanocolloidal albumin. Nucl Med
Commun, 1986. 7(1): p. 5-16.
248
181. McLean, R.G. and G.N. Ege, Prognostic value ofaxillary
lymphoscintigraphy in breast carcinoma patients. J Nucl Med, 1986. 27(7):
p. 1116-24.
182. Gasparini, M., C. Andreoli, A. Rodari, A. Costa, and G.L. Buraggi, Lack of
efficacy oflymphoscintigraphy in detecting axillary lymph node metastases
from breast cancer. Eur J Cancer Clin Oncol, 1987. 23(5): p. 475-80.
183. Serin, D., J.M. Vinot, P. Martin, F. Reboul, M. Robin, and J. Chevallier, [The
value ofbreast lymphoscintigraphy in the definition ofaxillary staging in
cancer ofthe breast]. Bull Cancer, 1986. 73(3): p. 299-304.
184. Uren, R.F., R. Howman-Giles, J.F. Thompson, D. Malouf, G. Ramsey-
Stewart, F.W. Niesche, and S.B. Renwick, Mammary lymphoscintigraphy in
breast cancer. J Nucl Med, 1995. 36: p. 1775-1780.
185. Schneebaum, S., J. Stadler, M. Cohen, D. Yaniv, J. Baron, and Y. Skornick,
Gamma probe-guided sentinel node biopsy—optimal timingfor injection. Eur
J Surg Oncol, 1998. 24(6): p. 515-9.
186. Tiourina, T., B. Arends, D. Huysmans, H. Rutten, B. Lemaire, and S. Muller,
Evaluation ofsurgical gamma probesfor radioguided sentinel node
localisation. Eur J Nucl Med, 1998. 25(9): p. 1224-1231.
187. Kollias, J., P.G. Gill, B. Chatterton, W. Raymond, and P.J. Collins, Sentinel
node biopsy in breast cancer: recommendations for surgeons, pathologists,
nuclear physicians and radiologists in Australia and New Zealand. Aust N Z
J Surg, 2000. 70(2): p. 132-6.
188. Stratmann, S.L., T.M. McCarty, and J.A. Kuhn, Radiation safety with breast
sentinel node biopsy. Am J Surg, 1999. 178(6): p. 454-7.
189. Nugent, N., A.D. Hill, M. Casey, L. Kelly, B. Dijkstra, C.D. Collins, et al.,
Safety guidelinesfor radiolocalised sentinel node resection. Ir J Med Sci,
2001. 170(4): p. 236-8.
190. Borgstein, P.J., R. Pijpers, E.F. Comans, P.J. van Diest, R.P. Boom, and S.
Meijer, Sentinel lymph node biopsy in breast cancer: guidelines andpitfalls
oflymphoscintigraphy and gamma probe detection. J Am Coll Surg, 1998.
186(3): p. 275-83.
191. Keshtgar, M.R.S., W.A. Waddington, S.R. Lakhani, and P.J. Ell, The sentinel
node in surgical oncology, M.R.S. Keshtgar, Editor. 1999, Springer-Verlag:
London, p. 144.
192. Cody, H.S., 3rd, A.D. Hill, K.N. Tran, M.F. Brennan, and P.I. Borgen,
Credentialingfor breast lymphatic mapping: how many cases are enough?
Ann Surg, 1999. 229(5): p. 723-6; discussion 726-8.
193. Khonji, N.I., D. Clarke, S. Goyal, Z. Mukhtar, K. Al-Rawi, H.M. Sweetland,
and R.E. Mansel, Effect ofblue dye on pulse oximetry during sentinel node
biopsy. Breast Cancer Research and Treatment, 2000. 64(1): p. 38 Abstract
112.
194. Kalimo, K., C.T. Jansen, and M. Kormano, Sensitivity to patent blue dye
during skin-prick testing and lymphography. Radiology, 1981. 141: p. 365-
367.
195. Albo, D., J.D. Wayne, K.K. Hunt, T.F. Rahlfs, S.E. Singletary, F.C. Ames, et
ah, Anaphylactic reactions to isosulfan blue dye during sentinel lymph node
biopsyfor breast cancer. Am J Surg, 2001. 182(4): p. 393-8.
249
196. Kaufman, Z., S. Lew, B. Griffel, and A. Dinbar, Frozen-section diagnosis in
surgical pathology. A prospective analysis of526frozen sections. Cancer,
1986. 57(2): p. 377-9.
197. Dixon, J.M., U. Mamman, and J. Thomas, Accuracy of intraoperative frozen-
section analysis ofaxillary nodes. Edinburgh Breast Unit team. Br J Sure,
1999. 86(3): p. 392-5.
198. Tanis, P.J., R.P. Boom, H.S. Koops, I.F. Faneyte, J.L. Peterse, O.E. Nieweg,
et al., Frozen section investigation ofthe sentinel node in malignant
melanoma and breast cancer. Ann Surg Oncol, 2001. 8(3): p. 222-6.
199. Chao, C., S.L. Wong, D. Ackermann, D. Simpson, M.B. Carter, C.M. Brown,
et al., Utility of intraoperativefrozen section analysis ofsentinel lymph nodes
in breast cancer. Am J Surg, 2001. 182(6): p. 609-15.
200. Van Diest, P.J., H. Torrenga, P.J. Borgstein, R. Pijpers, R.P. Bleichrodt, F.D.
Rahusen, and S. Meijer, Reliability of intraoperative frozen section and
imprint cytological investigation ofsentinel lymph nodes in breast cancer.
Histopathology, 1999. 35(1): p. 14-8.
201. van der Loo, E.M., S.H. Sastrowijoto, H. Bril, C. van Krimpen, P.W. de
Graaf, and F. Eulderink, [Less operations required due to perioperative
frozen section examination ofsentinel nodes in 275 breast cancer patients].
Ned Tijdschr Geneeskd, 2001.145(41): p. 1986-91.
202. Weiser, M.R., L.L. Montgomery, B. Susnik, L.K. Tan, P.I. Borgen, and H.S.
Cody, Is routine intraoperative frozen-section examination ofsentinel lymph
nodes in breast cancer worthwhile? Ann Surg Oncol, 2000. 7(9): p. 651-5.
203. Gulec, S.A., J. Su, J.P. O'Leary, and A. Stolier, Clinical utility offrozen
section in sentinel node biopsy in breast cancer. Am Surg, 2001. 67(6): p.
529-32.
204. Turner, R.R., N.M. Hansen, S.L. Stern, and A.E. Giuliano, Intraoperative
examination ofthe sentinel lymph nodefor breast carcinoma staging. Am J
Clin Pathol, 1999. 112: p. 627-634.
205. Veronesi, U., S. Zurrida, G. Mazzarol, and G. Viale, Extensivefrozen section
examination ofaxillary sentinel nodes to determine selective axillary
dissection. World J Surg, 2001. 25(6): p. 806-8.
206. Hadjiminas, D.J. and M. Burke, Intraoperative assessment ofnodal status in
the selection ofpatients with breast cancerfor axillary clearance. Br J Surg,
1994. 81(11): p. 1615-6.
207. Usman, T., D. Rowlands, and D. England, Rapidperoperative assessment of
axillary node status using imprint cytology. The Breast, 1999. 8: p. 101-103.
208. Fisher, C.J., S. Boyle, M. Burke, and A.B. Price, Intraoperative assessment of
nodal status in the selection ofpatients with breast cancerfor axillary
clearance. Br J Surg, 1993. 80(4): p. 457-8.
209. Motomura, K., H. Inaji, Y. Komoike, T. Kasugai, S. Nagumo, S. Noguchi,
and H. Koyama, Intraoperative sentinel lymph node examination by imprint
cytology andfrozen sectioning during breast surgery. Br J Surg, 2000. 87(5):
p. 597-601.
210. Ghandur-Mnaymneh, L. and J. Paz, The use oftouch preparations (tissue
imprints) in the rapid intraoperative diagnosis ofmetastatic lymph node
disease in cancer stagingprocedures. Cancer, 1985. 56(2): p. 339-44.
250
211. Rubio, I.T., S. Korourian, C. Cowan, D.N. Krag, M. Colvert, and V.S.
Klimberg, Use of touch preps for intraoperative diagnosis ofsentinel lymph
node metastases in breast cancer. Ann Surg Oncol, 1998. 5(8): p. 689-94.
212. Ratanawichitrasin, A., C.V. Biscotti, L. Levy, and J.P. Crowe, Touch imprint
cytological analysis ofsentinel lymph nodes for detecting axillary metastases
in patients with breast cancer. British Journal of Surgery, 1999. 86: p. 1346-
1349.
213. Chonmaitri, I.S., Imprint cytologic examination as an adjunct to frozen
section. J Med Assoc Thai, 1993. 76(8): p. 458-64.
214. Forrest, A.P., D. Everington, C.C. McDonald, R.J. Steele, U. Chetty, and H.J.
Stewart, The Edinburgh randomized trial ofaxillary sampling or clearance
after mastectomy. Br J Surg, 1995. 82(11): p. 1504-8.
215. Forrest, A.P.M., H.J. Stewart, D. Everington, R.J. Prescott, C.S. McArdle,
A.N. Harnett, et al., Randomised controlled trial ofconservation therapyfor
breast cancer: 6-year analysis ofthe Scottish trial. Lancet, 1996. 348: p. 708-
713.
216. Murray, K.L., P.A. Lambah, T.J. Anderson, and J.M. Dixon, Patients Who
Are Node Negative On Axillary Sampling: Do They Recur Because ofOccult
Lymph Node Metastases Missed By The Pathologist? Eur J Cancer, 2001. 37
Suppl. 5: p. 20 Abstract 0-58.
217. Gray, R.J., C.E. Cox, and D.S. Reintgen, Importance ofmissed axillary
micrometastases in breast cancerpatients. Breast J, 2001. 7(5): p. 303-7.
218. Veronesi, U., F. Rilke, R. Luini, V. Sacchini, V. Galimberit, and T.e.a.
Campa, Distribution ofaxillary node metastases by level of invasion: an
analysis of539 cases. Cancer, 1987. 59: p. 682-7.
219. Chevinsky, A., J. Ferrara, A. James, J. Minton, D. Young, and W. Farrar,
Prospective evaluation ofaxillary metastases in patients with carcinoma of
the breast. Surgery, 1990.108: p. 612-8.
220. Ciatto, S., P. Pacini, M. Rosselli Del Turco, L. Cataliotti, G. Cardona, and
M.L. Carcangiu, Patterns ofaxillary metastases in breast cancer. Radiother
Oncol, 1986. 5(2): p. 91-4.
221. Reynolds, J.V., P. Mercer, E.W. McDermott, S. Cross, M. Stokes, D.
Murphy, and N.J. O'Higgins, Audit ofcomplete axillary dissection in early
breast cancer. Eur J Cancer, 1994. 30A(2): p. 148-9.
222. Dixon, J., V. Dobie, and U. Chetty, The Importance ofInterpectoral Nodes In
Breast Cancer. Eur J Cancer, 1993. 29A(3): p. 334-336.
223. Cabanes, P., R. Salmon, J. Vilcoq, J. Durand, A. Fourquet, and C.e.a. Gautier,
Value ofaxillary dissection in addition to lumpectomy and radiotherapy in
early breast cancer. Lancet, 1992. 339: p. 1245-8.
224. Clarke, D., N.I. Khonji, and R.E. Mansel, Sentinel node biopsy in breast
cancer: ALMANAC trial. World J Surg, 2001. 25(6): p. 819-22.
225. Krag, D.N., S. Harlow, D. Weaver, and T. Ashikaga, Radiolabeled sentinel
node biopsy: collaborative trial with the National Cancer Institute. World J
Surg, 2001. 25(6): p. 823-8.
226. Silverman, R.P., J. Elisseeff, D. Passaretti, W. Huang, M.A. Randolph, and
M.J. Yaremchuk, Transdermalphotopolymerised adhesivefor seroma
prevention. Plastic and Reconstructive Surgery, 1999. 103(2): p. 531-535.
251
227. Logan, V., Incidence andprevalence of lymphoedema: a literature review. J
ClinNurs, 1995. 4(4): p. 213-9.
228. Abdessalam, S.F., E.E. Zervos, M. Prasad, W.B. Farrar, L.D. Yee, M.J.
Walker, et al., Predictors ofpositive axillary lymph nodes after sentinel
lymph node biopsy in breast cancer. Am J Surg, 2001. 182(4): p. 316-20.
229. Chen, M., S. Palleschi, A. Khoynezhad, G. Gecelter, C.P. Marini, and H.H.
Simms, Role ofprimary breast cancer characteristics in predicting positive
sentinel lymph node biopsy results: a multivariate analysis. Arch Surg, 2002.
137(5): p. 606-9; discussion 609-10.
230. van der Ent, F.W., R.A. Kengen, H.A. van der Pol, J.A. Povel, H.J. Stroeken,
and A.G. Hoofwijk, Halsted revisited: internal mammary sentinel lymph
node biopsy in breast cancer. Ann Surg, 2001. 234(1): p. 79-84.
231. Krag, D., T. Ashikaga, S.P. Harlow, and D.L. Weaver, Development of
sentinel node targeting technique in breast cancer patients. The Breast
Journal, 1998. 4(2): p. 67-74.
232. Muller, H.A., [Imprint cytology. Advantages andpossibilities]. Fortschr Med,
1976. 94(1): p. 7-10.
233. Quill, D.S., A.L. Leahy, R.G. Lawler, and R.D. Finney, Lymph node imprint
cytologyfor the rapid assessment ofaxillary node metastases in breast
cancer. Br J Surg, 1984. 71(6): p. 454-5.
234. Mann, B.G., M. Buchanan, P.J. Collins, and M. Lichtenstein, High incidence
ofmicrometastases in breast cancer sentinel nodes. Aust N Z J Surg, 2000.
70(11): p. 786-90.
235. Siziopikou, K.P., S. Schnitt, J.L. Connolly, and D.F. Hayes, Detection and
significance ofoccult axillary metastatic disease in breast cancer patients.
The Breast Journal, 1999. 5(4): p. 221-229.
236. Shivers, S., C. Cox, G. Leight, D. Beauchamp, P. Blumencranz, M. Ross, and
D. Reintgen, Final results ofthe department ofdefense multicenter breast
lymphatic mapping trial. Ann Surg Oncol, 2002. 9(3): p. 248-55.
237. Wong, S.L., C. Chao, M.J. Edwards, T.M. Tuttle, R.D. Noyes, D.J. Carlson,
et al., Accuracy ofsentinel lymph node biopsyfor patients with T2 and T3
breast cancers. Am Surg, 2001. 67(6): p. 522-6; discussion 527-8.
238. O'Hea, B.J., A.D. Hill, A.M. El-Shirbiny, S.D. Yeh, P.P. Rosen, D.G. Coit, et
al., Sentinel lymph node biopsy in breast cancer: initial experience at
Memorial Sloan-Kettering Cancer Center. J Am Coll Surg, 1998. 186(4): p.
423-7.
239. Baron, R.H., J.V. Fey, S. Raboy, H.T. Thaler, P.I. Borgen, L.K. Temple, and
K.J. Van Zee, Eighteen sensations after breast cancer surgery: a comparison
ofsentinel lymph node biopsy and axillary lymph node dissection. Oncol
Nurs Forum, 2002. 29(4): p. 651-9.
240. Haid, A., R. Koberle-Wuhrer, M. Rnauer, J. Burtscher, H. Fritzsche, W.
Peschina, et al., Morbidity ofbreast cancer patients following complete
axillary dissection or sentinel node biopsy only: a comparative evaluation.
Breast Cancer Res Treat, 2002. 73(1): p. 31-6.
241. Burak, W.E., S.T. Hollenbeck, E.E. Zervos, K.L. Hock, L.C. Kemp, and D.C.
Young, Sentinel lymph node biopsy results in less postoperative morbidity
compared with axillary lymph node dissection for breast cancer. Am J Surg,
2002. 183(1): p. 23-7.
252
242. Cox, C.E., E. Dupont, G.F. Whitehead, M.D. Ebert, K. Nguyen, E.S. Peltz, et
ah, Age and body mass index may increase the chance offailure in sentinel
lymph node biopsyfor women with breast cancer. Breast J, 2002. 8(2): p. 88-
91.
243. Ahrendt, G.M., P. Laud, J. Tjoe, D. Eastwood, A.P. Walker, M.F. Otterson,
and P.N. Redlich, Does breast tumor location influence success ofsentinel
lymph node biopsy? J Am Coll Surg, 2002. 194(3): p. 278-84.
244. Baitchev, G., G. Gortchev, and A. Todorova, Intraoperative sentinel lymph
node examination by imprint cytology during breast surgery. Curr Med Res
Opin, 2002.18(4): p. 185-7.
245. Llatjos, M., E. Castella, M. Fraile, M. Rull, F.J. Julian, F. Fuste, et ah,
Intraoperative assessment ofsentinel lymph nodes in patients with breast
carcinoma: accuracy ofrapid imprint cytology compared with definitive
histologic workup. Cancer, 2002. 96(3): p. 150-6.
246. Chirikos, T.N., C.G. Berman, S.L. Luther, and R.A. Clark, Cost
consequences ofsentinel lymph node biopsy in the treatment ofbreast cancer.
A preliminary analysis. Int J Technol Assess Health Care, 2001. 17(4): p.
626-31.
247. Miltenburg, D.M., C. Miller, T.B. Karamlou, and F.C. Brunicardi, Meta¬
analysis ofsentinel lymph node biopsy in breast cancer. J Surg Res, 1999.
84(2): p. 138-42.
248. Wilkinson, E.J., L.L. Hause, R.G. Hoffman, J.F. Kuzma, D.J. Rothwell, W.L.
Donegan, et ah, Occult axillary lymph node metastases in invasive breast
carcinoma: characteristics ofthe primary tumor and significance ofthe
metastases. Pathol Annu, 1982. 17 Pt 2: p. 67-91.
249. Millis, R.R., R. Springall, A.H. Lee, K. Ryder, E.R. Rytina, and I.S.
Fentiman, Occult axillary lymph node metastases are ofno prognostic
significance in breast cancer. Br J Cancer, 2002. 86(3): p. 396-401.
253
Publications and Abstracts
Lambah PA, Dixon JM, Prescott R, Jack W, Forrest P, Chetty U.
Long term Results of Randomised Studies of Axillary clearance vs Non-targeted
Axillary Sampling.
Abstract published in Breast Cancer Research And Treatment Vol 64, 1, Page 38,
Nov 2000.
Abstract published in the British Journal of Surgery Vol 88, Suppl. 1:40, May 2001.
Abstract presented at the International San Antonio Breast Cancer Conference,
Texas, USA. December 6 - 9th 2000.
Paper submitted for publication.
Lambah PA, Dixon JM, Jack W, Forrest APM, Rodger A, Chetty U.
Randomised study of axillary clearance versus 4 node sampling.
Presented at Nottingham International Breast Cancer Conference September 2001.
Abstract published in The European Journal of Cancer 2001; 37 (suppl 5): 2.
Lambah PA, Mclntyre MA, Dixon JM, Chetty U.
Imprint Cytology As An Intraoperative Diagnostic Tool In Breast Cancer.
Paper published in European Journal of Surgical Oncology Vol 29:224-228, April
2003.
Murray KM, Lambah PA, Dixon JM, Anderson TJ.
Patients who are node negative on axillary node sampling: do they recur because of
occult lymph node metastases missed by the pathologist? The Breast Vol 11: 3, 249-
251 June 2002.
Abstract presented at European Pathology Conference, Brussels, Belgium. January
2001.
Presented at Nottingham International Breast Cancer Conference September 2001.
Abstract published in The European Journal of Cancer 2001; 37 (suppl 5): 20.
254
